var title_f17_19_17712="Rejection drug withdrawal CT";
var content_f17_19_17712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Allograft rejection after immunosuppression withdrawal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abdominal and pelvic CT scan shows ill-defined margins and heterogenous enhancement of renal allograft (arrow), findings that represent rejection. The surrounding mesenteric fat and abdominal wall musculature have inflammatory changes. This patient, in whom immunosuppression had been completely withdrawn, eventually required a transplant nephrectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Brent Miller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17712=[""].join("\n");
var outline_f17_19_17712=null;
var title_f17_19_17713="Periph blood Tregs";
var content_f17_19_17713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F63330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F63330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Detection of human T regulatory cells in peripheral blood",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 234px; height: 466px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal expression of CD4+ CD25+ CD127dim regulatory T (T",
"    <sub>",
"     reg",
"    </sub>",
"    ) cells in peripheral blood. Foxp3 staining in the CD25+ CD127dim CD4+ cells is shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17713=[""].join("\n");
var outline_f17_19_17713=null;
var title_f17_19_17714="Severe dry eye";
var content_f17_19_17714=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dry eye disease with conjunctival injection, associated neovascularization of the cornea, and a central corneal opacity/scarring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17714=[""].join("\n");
var outline_f17_19_17714=null;
var title_f17_19_17715="Head thrust test";
var content_f17_19_17715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Head thrust test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 494px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHuAfkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoprSIp+ZlB9zQrq33WB+hoAdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFI7qiFnYKoGSScACgBaK5e98RzTytFo0HmKDg3EgOz8B3/Ssy5l1BwWn1SdW9ImCgflj+tYyrxRoqbe51WrazYaSga+uFjYjITqx/D+tYMnjIyDdZ2D+Wekk7hP0/8Ar151rkVz/aAmluHuCTgGQ5J9Mk1pQ3NtDtVt13NnGdxC59BXPLEyltojZUYpa6nTt4s1MnKR2WP9xz/JqfB4v1BT++soZB/sbk/nmqNtFcyIHMEEIPZm5q4IHCnKI3+41T7SpvcOWPY1bTxfYyELdRzWzdyw3L+Y5/St+1uoLuISW00cqeqMCK4KSNGyrqG9Qw5FUzavbSefp80kEnqjY/A1ccTJfFqS6UXsen0Vx+h+LAHFrrJEUnRZ+it9fT69K68EEAg5B6GuqE1NXRjKLi7MWiiirJCiiigAooooAKKKKACiiigAoJAHNQXt3BZWzz3MgjiXqT/L3PtXn2saze6zI8aFrey6bAcFh/tHv9OlZVKqp7lwpuR0ureLtOsXMcLG6mHBWL7o+rdPyzWFcePrhMslhHt/u+YSfzxWAII+kSgJ3cjO76Viaw0bApH87dM5J/XpXJKvNnRGlE9C074h2d0WiktJo7gDhQQyn6njH5VVvvEd1dkhHITuIzsUfU9TXN+HtA+yWTXWqZVpOVi747Z/wqTVGSONXMYjUn5VB5PvmlKrNrVjVON9DXt/Mmy7+X/vbT/MmrKOsTAiaJT/ALPBri7C7vbq5a0to5WUDO/BOPqatSLPayAXGwKT/fBY1leRfLfQ72z1G7U/ubgyAdm+Yfr/AI1rWmsn7t5FtP8Afj5H5dR+teZnWIbbCk3EgHZW2L/9er1j4hsJnCSxzRH+95hOK2hWlHqZypX6HqkUscqB4nV1PdTkU+uGjmmtgLi2mLwnnzEPI/3h3FdFpGsJdkRT7Ul7EdH/APr+1dUKyk7PcwlTa1Rr0UUVsZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABOK5LWLwarI0Qcrp8Zw2DgzMP8A2X/PpWj4qvTBaLbxttefIJB5CDqf1A/GsOzi8wKCNqL0HoK5q8/sI2pxt7xNGrSqEiURxDgAccUy6eztUP2hwfxpL26KjyLfAYjr6D1NcnfOZrrZAxkYdXYZ/KuZuxtCLk9CDxTcWd3FizEgcHqBxWPpE8ttMZJExtHyM3T/APXXUWukBhulG5v9rmr405AoG0Y+lTyN6m/KkrXOXutQmkfIEjn33YH61PpmuvDKEcEZPQnH5VvS2YHQVnXdojqRIgYe4o5Gh8iaN5ZluoBIvJHfuKiVwJAj8FunoazNClaO4Nu2Sp4GfStK6iDqyE49D6GkzBqzsU9UtRKhBH09RWj4L1+S1uU0u/YtGx2wuf4T2H0/lUFsxubUiT/WodrfUVkajbc5HyuvKkdjRGbpyugcVJWZ6/RWT4W1I6po8M8n+uX93KP9of48H8a1q9RNNXRxtWdmFFFFMQUUUUAFFFFABTZHWNGdyFVRkk9hTq5nxdeltmnxN98b5sf3ew/E/wAqic+SNyox5nYxdYvH1q+VhuFsnEKHv/tEev8An1qtdRJHEYxjavMjevtV6JPIjXA/evwB6CsrVZy0yWdsN7ZGcdzXnyd3d7nUuyM64kDLulyIzwqDq34f0qbQ9P8Atepb5owkEIDlO5PYH/ParZtEsU82U+dckYUdgfb296u+H18rTZJpDl5XLE/p+XWlFa6jb00DUmDyF5DiKPk57muVZ59X1MRWYGWOPMYcIvtV/VGk1Gdo1Yi1Q/Nj+KtHSrePTbN7qXCvJ8qKOw9vrR8TGtENvfL020EFqM9iT1kf1PtWda6RJOxluGLO3JJrWtLdrubzplx2VfQVsiIIgAFWo31NIvkVupydzpAC8LWTPpSgk7Np9V4rvpIwRjFZt1bjnir5S1K+5keHNRexnWCclomO3mt26QWU42n/AEeTlMdvaufu7cZyBWvBKbzw+4k5ltz1+n/1qiUdNDKcUndHbaFqH2uDy5GzKg6/3h61qV5x4c1B4ZVzzJEen95e4r0ZGDqGU5UjIPrXXQqc8ddzjqR5WLRRRWxmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFI7KilmICgZJPYUtYHjS9+y6O0K/6y5PlAe38X6cfjUylypscVzOxzk14dV1Ka6OfJztjB/ujp/j+NXZ5ltbVnY4wOf8KpadAUiQngdvc+tQ6mWublLdPujlq8/me7Oq3Qikd00ua5k/1s3AB9PSo9ItQqhiMsepp+sOHeG2j+6nB98df6frV2yTCCqitTaGi9S2igDGKeQKRaUmtCSJ1BFUrqIYq+ar3A+U0mikzM0uHdqZIH3R/hU1/IWvEgU99zY/SrWixhWu5SOQcD8qy7dt+pXEh9/04/pWMtERLWTLNs2zUJ1HRgr/AKc0t3FvWRcfMvIqFW26kT7bPyX/AOtV65O26z2IBrNiHeALzyNVntGYhZ1yAf7y/wD1s/kK9BryO6d9O1SG6i/hcOP8K9XtZ0ubeKeM5SRQw+hrtws7x5X0MK0deYlooorqMQooooAKKKKAIrmZLe3kmlOI41LMfYVwtmXvLiW8uPvSMZGz2HYfgOK2PGt4RBDYRn57htz47IP8T/Ws5Y9sCRDjdy3sK468ry5exvTVo37kF3c+VC8/8bHbGP8ACoNPtvs6s2A90/33PRB6VZVFluBOfuplIh6erf0qBpmvHaC1+SFPvyGsHoaIz9VkZY5Ftsy3DD5m9B/Srk4ZbaCyhJWOKMCV+hzjp9aLgRwwiO3XgsASerH3okcRREM3A+Z39TUooppcQIQiru/uxj+L6+gq3FFLdSiS4O4joOy/SodLsmmne5mGC54HoO1bqIEHArSMbmtlH1FtYggHFTyDimxVLIOK1M29SsarzplTVimSDihlowrqPBNS6Qu221AN90R5/Q1Jdr1qtM/k6Ncgf6y5bYP90Dn+tQOprEpLJ9nvbaQcblBavTtDl87ToyTkrlfy6fpivKdUJRrUjr9lVv516L4Jn8/Ry5/v/wDsop4Z2m0c1Ze7c6Ciiiu45gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAridXYatrrOx/0Ozyi/7T/xH+n4V199P9ms5pupjQsB6nHAriZn8iFYQegy59T3rnxErKxrSWtx9zcqiF+irworLNylpE80rKsh5Jb+Eev/ANas/WdTS2x5jZYfwj19K5+O6fUrtWuGxEp3bew9/rXHe7OqML6HTWG65czsCAeFB7D/ABret1wlULIFoF8lQq9ialnmmij+WRA3uK2irFsv0VzjatdwPl9jr9MVu6bexXsO5OGHDD0NVcTViU1HIhZatrGCeTUGqXEVhaPO4yq44+pxQTcrWTeVPJEeBMOD/tVlKPKuZQRghyG+hOf61QGrXV3IdmxAWyCOw/xq/cyyTxK7YFyBguBw/wBRWUlcbjrcrQzGWVZDwfMOR6ZBrXuz88LeqCuYu5LiBxJIuOhyBjPfmuhaQTafDKpyY+D9KzktAnGzRS1VfNsW/vxH9K7L4eXhudAETnLW8hj/AA6j+f6VyTsGlKn7sikVpfDiYw6ld2pOA6bvxU/4Gqw8rVF5mdVXgehUUUV6ZxhRRRQAUGiquq3P2PTbm47xxkj3Pb9cUm7K4LXQ4m7m/tDX7mc/cRvKT/dX/wCvzUt3IVAC/fk4H0qnpa7Ylyck8kmnROZtWjA+7uwPoOf515vNd3fU7GibUQVK28HUKEH1NPlSGxtRG0ixQqMszHGTWbqmqLZahNIRudR8gPqe9c7axXXiK+kEtxhVBbLDI+gFK93puNRNS98Q2cRItt07D+IDC/maZo7y6q/nTYWIH5EHT61gX2nywXMUGPlfBUgdeldjo8S2lsoxgAcVUYu+ppGNtTZjVY0ApRKmfmYD8ahiTzB5kjEL6DvWfqetWliQv7tXPQAcmtb2Bam5HPbqMmaMeuWFTebDIPklRvo2a8/udYSVwXjdR2ZoyAPxxTVmUv5mTyPvZ7fWlzB7O/U7txg0xqr2NybiBGY5bHJ9akuZBFEWPAHNUK1tCtOgIOTisuYQrBt84MxX5ckZNYU+qy6pdsqv5dkhwTnG/wCvtWlDJZKgUheucnPWs2zVLQw9Yvw2okIwaIReUmDnpxXqvw+jKeG4WP8Ay0ZmH06f0rzHX7cXkkSWyhp2ZVjA7knGK9p0y1Wx0+3tU+7DGE+uB1rWhH3uY5K+isWaKKK6zlCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMnxNL5enon/PWVV/L5v/Za4PULnEkhzwo3Guu8XyhXsYz/ABF2/LA/rXA6kwbUooDnbOyqcemea4MQ7zsdVFaDUsLeWy865QSTSjfkruwDyPp6fhWJo8BN40ecqHKj6Cu3SMGZ1RQsMYCAD/PvWHFbj+3ZtgAUKp/Hn/AUnGx2wkrGteXjWsaRQRlpCOOwH1Nc9f3iIc6hq8UJP/LOLHH4mtfXIbieAJC6RKV+ZjncfYVwPjzSkurWGHRbcLviCMZEYyK4bJOR3PHPPGa1hHmdmznnPkV7XN35bm3Mmnag07D+FiCDU/h/VjBdKsmVDHafY1j+CNHn07R7g3cc3m/KI2ZShLDOW57cge+KW9AWYsGUyMcYWpn7srF03zx5tj1RJfkD54xmvP8Axh4g+0XLW8bHyI/vY/iPpXX6QzT6JGWOXMfJ/CvMFQJe3KSDMwkOC3Sh7DjHUtWzTSgPcXBtoOyq20/ia17cwlQbHUi0o/hMm8H61leINJeTRIpbe2aa6ViW8xS6EY46dq5/4daBLDcOupOPKVWLsScAYwoBPfPNaKmnHmMZ1Wp8lj0Ca8F1aNDcIFnXrjofcU3RNSMaGFwWIGwp/eHbHvWKsNxHeBN5eJchWb72KsS7ba9tZTwqyqT+YrGUbm1uaOp1t5pNxa20c7yqWB3eWF6Dr1+ntUfg+bb4lgYdDIyn3yuK2Li6F9FG2yRIyMBiPXj6965vw8TbeKraEnkXO36/dqJRUZxa7mVrxdz2CiiivSOEKKKKACue8cS7NFEY/wCW0qp/7N/SuhrlPHbf8eEfYl2/ID/GsqztBl01eSMKORYLZ5HOAq1V0S4aTU4d0UiKQcMykAnBpqS+bcOmA3lFdoPQsemfYYJrUS0MM8EzTyuQ4yGPHPHTt1rijDS52cujbMaS0t73X7kXTlURCQM4zz/9eptL0+3gu5XjDRxiNS4ViB0zip7COI6nf3EoX92AAT265/kKtuhXS7uYjDSqx/MYFXBaFRehl6zZeZBFcrI/n/fXnheOgHpU9hL9qsYpwMbhyPerBsli00tliSnBJJwKp+G2DaTCvsf50W1NG04lzVLo2+nOwYJ8v3sZxXAX2tQeHYIb2Sxmup7tsJNcOI1PIGcnoOevSvRZVV4ijqCpGMVy2v8Ah+21WJILueTyUztRgGAB7fSrha/vGU+bl93coeEfFdz4nurq3+xWkYjRmVclw4VgrfMPqMYFTTBrGV12nyGbgHrGfQ+3vS6FpNn4YMslpMWd08sAIPlXOSB9Tj8qS8vxIv71GwM7QWJNOfLf3RUlK3vm74auC0Tpn7h4+lbWrQPdaPdRwnErxsq/XFc94WhljRpJQV39AewrqbSUMSlSi5d0eN/2pZ6cUW9kldwpYW8A+bCgk5PbgH8q39KvtN1nRJL60tLmFEOC4bcw4yCRnkVneMPCtjea7dQXhdA5EsbDpz/9fNa3h+2OjaTLZwGP98RucdlAwAq/T1NVywUfMm9Ry8i/4Ij/ALT8RWZRlZIHMjMvT5eR+uK9kryHT7qTRykliqxu/wC7LEZPPf68CvRvC17LfaUJLht0iuULY6/5zWlGS2MsRCVufobFFFFbnIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAch46lEd7peemJT+RSuZsbQ3XiZHIzFADIT79BXRfEeM+Xp8w/gZ1/MD/CqOloLLRmuJDmSYbifRccD8q4akb1WddP4EPt8fZ7hx3lbH54rn9MbzL25k9ZCB+HFdBEnl6VHn7xXJ+prmdGcKZM9d7fzpvc6KWqZ0yhXj2yKGU9iKrPY2vJRCp9jU1vKCBmpwqnmmTsc3qFk8uVjQn61jHS1ti0kxyw6k9q7qdQEOBXEazcPc3v2OBSQGG8+gzWcjSnqdhoRB02Pb93FcXqdkra5cquBJkMPevQtLtNllGqYAVa5DxBEF1pZE5ZV+bHcZqnohQacmaOjxtHEu7chx26VdltUbJ3sM+hxUemyh4lI5BGQatyFQOlApbmNJYRIxKLz6ms28tknvrOHA+eVQf51tXkwUGuekuxHrNixzgTDp+VK9mapPlZ3mrgQ2aogA2rn8q5m0TPj/TwOjTeZ/wCO/wD1q6nUCJoVbqGWsfRbUyeM9InxlfIc59wpH9RVNXa9TlXws9LooortOEKKKKACuS8cHNzYj0SQ/wDoNdbXKeNEzPbN6Rv/ADWscR/DZpS+JHDw3Ih1Z0bjcwYfhkf1rpJJN1pNIDwoyPw5rj9dUxOJ1+8pzXRaPJ9pstjnIbn6iuSm7qx6CV4kdoDc6jNboCUZxI5Hcdh+f8q3NYIS3jhXq7quPxrN8JLhZ3cZcNtz9Ktzt5+twIekalz9T/8Aqq47GS39C1fx7dPZf9g/yrkfC0mLEqT912H612WqnFq4/wBk1594bmxHKB08xv502XS1R2KMGFR3FrvU8VBby8itCOQMMUFSVjDexG/5hgUwafbRyeZtDP2J7Vu3CKVJrAv5vJJJ6DmjYatI0ElEcR6CrGjs0rMwBwD1rk9Ghk1UtcXMrBeoXOAorqtB1OxZzbW0u9l74xn6HvSTuwmuWNupB4x01bqKK5UYkiPJH92s2zsiq/OwP4Vb8W+ILWBXskbfcy/JtXnbn1p0R2qBTYqd7amVqjeWqj0df/QhXovgkg6S6jqJTn8QK801l91xBH/ekH+P9K9C8GSBJbq3J5IWQD9D/Sqo6SIxKvA6miiius84KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAxPGNk17oU3ljMsJ85AO+Ov6ZrkZnLaNaKOjhV/A16SRkc15/fIkdraoowokUAenNYVI63OijLSxLdMFtNo6AYribKbbeXEY6h8/nXd6lGBbnHpXnkSFfEkgH8SD+ZrnludtBqx1NrISBWhE5qlaw4UGr0SfNzVIUrFgrmIk1xulFWl1XywhutzGNX7+n4V1l6xaLy0OM9SKzF0i3kkDGMbh/EODSluKLstSHTdavreB4r4RBwOCgx/U1kWb3Vzqs13eSItsQQFPb3ropbGOBokiTgnknkmo7rRbKWTe8bc9V3HafwpNNlpxWxF4XIl08P2DsF+meP0rTuBhahgi8h8wgKnQoOB+FS3LApmqI6nPajIQSKwrVTP4isIj08wMfwrc1AZY1kaGy/wDCXW24gBQTzUJam8naB6bfqFgAHpTPCKhri2Yj5ljYZ9OlPvnSSMbGDDHUHNN8Hf8AH64/uq+P++hW8d0cD+BnYUUUV0nIFFFFABXO+Lk3JCfRX/8AZa6KsbxKoMEB9ZCn5qT/AEFZ1leDRcHaR5xrUIdWU/xJVuBf7Psre6bIt5EUuf7jY6/Q96drMZECOByoIP4Vr2irP4dh4BUxgEfhXDS3Z2xlZEXhplIutpDKZSQR055p6ZXXJMdSi/zNQeFLdbZLmNBhRIcAVbthu16c/wB1VFbdAe7LOrg/ZmHqDXnvhtT/AKQP7sjD9a9K1VM2zfSuE8MxAyXoHac0nuVSfumpCpBq9ATSrD7VMkeKC2xtw+ErAngN9drCv3T976Vt3iMy/L1p2mWYgUuw+dqLXJTsYMOjXtnG8FtLE1u4IIdTkA/SrVppcVuYoV3faEUuHUYC9v8AGuhkdIxmRlUepOKgV4TI8nmR8jGcjiklYHJs80hsLiR5LyVlZRN5jcfMRu7n0rsLaQSw7x6VJb2iRvMmAY26elUpF+xFgv8Aqz29KVzRMzJs3Ov28S9F+Y13uh5g12DHSRGQ/ln+lcV4Yj+063PMRkKdortIT5esWR/6agfnxVR0aM6jvdeR2lFFFdp5gUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV55qz/vbZPScj8ia9CYhVJPAHNeakm5vLQd8eYfxrKr0NqPU1tTlQW/zMAMdScV5/MVXxNEykEMuMg+9dVczWseueXqP+q8oGPPTOTmq2vW2mzqklntWdeVZe1c0lfU7aenumtbKCgqbbWboV39ogw/EicMPetWmthS0ZVm2xgtKwVR3JxWTceIrOElYnD479qv6jp9rqDhLoO2OwYis/8A4RizjJKJuHv1o1Kjy/aM9vFUQzmVP+BDpT4fEqsQWYSp37GnyaVYK/zwS5H/AEzJ/pVtLKAwFI4SiHuy4P4UtTV8ltEWbDULa9z9nkDEdR3FS3RwtZkEaWcix26BFJ5I71bupflqbmdtdDHvm61Q8FRi48XOx52Jx+dTavOIYXYnHFN+GMTPrFzcv93AH60Reo6r92x6PqCBcY9KpeD5NusSRn/bH8jWjqGCARWPojeR4qjXs5z+akf0Fbx3OTeDO/ooorpOQKKKKACsfxXkaLJKv3onRx/30Af0JrYqtqdsLzTrm2P/AC1jZM+hIqZK6aHF2aZwepKr20hHQ/OKTw3L/wASZomP+rdl/DNVoJvP0lS3BVcGotGcrpt2R1DN/KvPh8R2xV9DX0Q/uZJB0d2YfnUuk/PfXUvYyYH4cUlgnkWMa/3V/pU+kgJbRnHLDcfqa2Q5Pcu6j80BHtXDaBiHUtQiOB+83j6Gu4u/mhP0rgfsjXPiOSJZWjjKAyFep5PFKW5VFe6zro9rDgg1JtrDvLKOyhEtmWVo+fc1p2N2LqzimHBYcj370JlONldFiQpGhdzgAZJrnr3xBeRhhb6TcDnAeQcY9cCtieU4wKigmkzg8ihiTS3Ry4/tfUHMjAc9Mnp+FWY9K1coQbhF9ODXVNEHjIBKE9161nXFnIAS9/Nj0AFJo1VS5zNpd6lZXRgmi81c4LA5H1zU+rXH+jlifelXKeaUzg9yck1jeIbgrboi9ZCFqBvVnSeAISLZpW6uS35100/y31m/pMh/8eFZnhdFt9LTdxxkk1DqOrs8oW0jB2nIdu+PatLpGShKctD02iuHsvF915q/aUgdD94JkH8Oa7WJ1ljR0OVYBh9DXXGalscNSlKn8Q+iiiqMgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIrv8A49Zv9w/yrgNHUSSvNjgAIPwFdzq8y2+l3cznASJj+lcT4cGbDB6qTmsahvS2ZneKLczSWjx/6wSFcj0I/wDrU+LT5BFmbduxxuOeK0bpQ81sp5Pmgj8jV+8Ax+FYnQpWscbYzpa64I9wAkHI9wa6sEHnNeZeLne21+NoWwwXd+v/ANat7QvEa3CCOYlZF9alOxrL3nc6mSIl9604eZUEV2rAEHIqZJ1JqiGmK3mkcCq7wuzfP0rRSVAtQTzKTxSaEmzNuoVQg46c1kXE/Lc8Vp39wApycCuH1vVf3n2e0+aV+OO1ZvVm0XZXYt4z6lerBFyoOPbNdzomgJpViZDctGzfMTuxzXOeD7ALcMHIZ1UFj7kmus1GGeZB5bKAAR8xpwSepEncm02/e8E8Tt5gixh8Y69qhYGLXdNmHTzlRvoSKl8PQeTpTseXeRiW9ccf0pt8QFD55jdZPyOf6VstDF2bdj0CigUV1HEFFFFABRRRQB5Vd/6DrGo2UhwvmsVz/dbkfzo0dS9mUx9+TDfTPP8AKp/inB9l1WzvVHyzJsb6qf8AA/pSeHxiFQfSuHltNo7oO6ubjA+SwUZO04FSWq7Y409ABSVLbjLirE9izKmYT9K4qG0c61dMuc8AEcV2t1II4CTxgVi6UhdJrlh/rWyv06Cky6MnFNleW0JgfzWYjB6sTVXRn2afGue7fzNS+KLtrXSZ3U4baQPrXFaRrUttGsdyCU7MO1S9DVPmVmd2x3VdtIgRk1z1nqcUygq2RW1bXakDDCmmiZRZqmNdtZWpRDYwB61cE+V+8KyNVv4ogdzjP1psmEXcw9RkEMbKMCuctUOp6kEP3FIVf97NWdYv/tEwht8mR+B7e9a/hHTQl6MjiEc/7x/z+tQkby0OgnhI8mzj4BG5selVdUhS1UNtDKOo9a1ogHupZx90DYD9P/11i69KDE+e1UkZ87VkbnhPSRqMQvLpCtsThEP8eP6V3CqFAAAAHAArJ8JSJJ4c08xggLEFIPYjg/rWvXVCKSOCrNykwoooqzIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDC8aPt0N48/62RE/XP9K5zQGwLiPsCD+dbPjOTe9hbermUj2Ax/7NWJZZS6nCA7SBz+dYVHqdNNe6St899EF6plj7Z4H9a0XhLpk9apwxhJHfqXOTV/z1EfJrM0d+h5z4wsANUgnPpsJ9P881i3NoIZVZCVPt2rpvFk3mXCY52sDj+lYd4wMIAOcEqD7YyP6Vzydpm21iaz1C4twFkyy+orUh1dCAS2PrxVewgElsC6g1sxaREy/dFaW7FOVtyqdXAHDZqpca6FP3hn61sHQ7bacxqT9Kz7zTLeFSQgH4UWYuZHNahqlzeEpCDg96j0PTNt28sx3OB+tX/lEwVVA5pqXP2eeVc4OcVnUbUdByOi8LRf8TG5f+6oUV1Eqjp2rnPBeXS4kPO6Tr+ArpJuSRWlNWijGW4lkoTTIgOhLEfixNZt9jzgp+66FTWhbyBrGJV/hG0/UcVl6ocSQ/U1oStz0Oyk860hkznegP6VNWT4Wl83Roec7SV/WtaupO6ucclZtBRRRTEFFFYGsa4+m6qkLRq0LRBueCTkg4P4CplJRV2OMXLRGZ8UbZZ9EtXP3o7pSPoQc1iaEpCirPi7XF1Vba1gidEV/Mct3OMAD8zS6TFtjFc8mpO6OynFxhqadWbcYGar96kD4SkD1INTzcMlup4c/N/ujrVhkWOIIgwoGBTIlAlaQ/eIxUzYI5pBtocb42bdYpH/AH5AKwoNOEsYBFdB4tZJLi1hXltxY/lS2EOFHFSzZbHOHR5oW3W7stOL6hCOma7FYs9qJbVShyoqeUpVDhLjWL+FTvzge9Yd9qV3O4LHGfxrqdetwzhVXknFYGqWnlqpC9MUR3KcuxqaFZp5yyNzsXcxPrXXaFBIbYFQQ87FmPoDWJokP/Evdj96XgfjxXe6TCqQoAOAKtamcp8qEeFYbcKowAK5TUk826jjPIZwD9K7TUMCI/SuTMfmXqN2Vs1WxlB31Oy8GtizuIeySZH0IH+BroK5vwbz9uPbco/Q10ldMPhOSp8TCiiiqICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorI8R3rWtl5cJxPNlVP90dzSbsrjSu7HN6xdrdatcXC8xxgQx4/iwTk/mTRawmKPL/fc7jUdlbqPmP+rj4X3PrU28yScfdFczd9TrWmiJKhnbahqUnAqvPgoxbhQKllxOL8QS7JFZjk7wf1zWVDmZo4xz0J/LFS68Td3flpkqDzWjomn7SpIrLlu7m0tzXs4NltjHOK3rYfIKqRw7VHFXYBha1SM2yRhkGsPWRhDW6axdYXIxihgtzlETM+fQ1V1WDcd6ttYcnjrW1DbHJJFUdUjOxuO1Q1fc0vc7HwPbFNGic/ef5j+Na8ykMc1W8IEf2Rbgf3RWleAda0OZv3jNiAUyADHzZrO1QZZD6ZrUxjPvWZqfQUFHT+Bn3aTIPSU/yFdFXM+Af+QXP/ANdj/IV01dMPhRyVPiYUUUVRBBezm2s5pwhkMaFtg74HSuZ1O/03WbJftNvOGAykke3KH2Of5iutIyMHpXBeJdDh09g9pcsgmbiArnHqQc8D8Kxrc1tNjWkk3bqc9ZwPJcksd2DgHHauotY9iCqdjbLGo4rRUYrFKysdkn0FqhYa1puoXt5Z2V/bT3dm+y4gSQF4j/tL1FX65vxN4J0XxFcx3l3BJb6pEMRajZyGC5j9MOvJ+hyPamjNnSg4qveTtHGSDXEmx8d+HlP2HUtP8SWa9ItRX7NcgeglQFWPuyj/ABzL74g3MOY9c8Ma5p0o4LRwi7i/B4iT+YFDXYqMl1OgET32pvKOQny5966S3syIxxXP+G/HPgBbeKBvE+nQXIGZFvHNswY8nIlCkfjXYWviDw1cpm18QaPMoAOY72NuvTo1UqTIlXTZClsR2pl1GRGQBWh/a+hf9BjTf/ApP8apXvifwnaki88S6HBtwD5t/EuM/VqfsyfaowV0p7iYyMOBwKz/ABDo7LYyyBfuru/KtST4oeAIHMUPiC3vJR/yzsYpLpj9BGrVV1Hxjc6zZXNt4d8D+KL15I2VZrq2WxhORjO6ZlOPopoVKwe31KlvcWemaTHc6ldW9paxhd01xII0XPTLHgc1pWnj/wAHIoB8V+Hx/wBxGH/4quQg0vx1r1m1tdyaLoNhMhR41iN/MVIwVO8LHyPY1xfwp+B0Nn4lvdZ8RwvJZW13IunWlwo3SqrkLLKoGMHAIX8emMpRSWpU5OT0R9CXNzHcWqywSJJFIoZHRgVYHkEHuKxI1+djWheMx+UVVKbIyagtKyN7wSc294f+mo/lXS1yvgRvkvl/2lP8/wDCuqrph8JyVfiYUUUVZmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAATgZrl9URpbppZOvQD0HpXTt0NZF/Dk1E1dF03ZmHIAVCgYFNACirMkRHaqV3IIkYntWD0OmOpDd3aQY3MM+lZcz3uryfZ7KNgD1bGAB61NYWc+p3myMfO/c9EX1NegaZpsGn2whiGT1Zj1Y+tKEHP0HOoqfqcPB4VESqCpZh1Yjqa0rfR/K/h/Sux8tfSkMKntW3skY+2Zyr2R7ChLVh2rpzbKe1J9mX0pezD2pzZt29Kp3Vg0jfdrr/ALKvpS/ZU9KPZj9scSdKIXhf0qhdaI0ikbf0r0b7MnpTGs4z2FHsg9ucN4a3QWQhPWJih/CteYlhUV9afYdWkAGI5x5i/XoR/L86nA3JWbVnYu99Sm1ZWonPFa0wxWXdoSxpFo6TwFj+yph3Ex/kK6WuT8DOUN1Ce+HH8j/Susroh8Jy1fiYUUUjsFUsxwByaszIL66is7ZppjhR0Hcn0FcPPNLf3j3M/wB48KOyjsBWxq7SX0wJyIk+6v8AWqSwba56kr6HXRioq/USIYFTCkC4FLUFth0qC6uVt4yzsBSXd0luhZzzioPD+my63di7uQVsY2+VT/y0I/pTSu7IltLViR2WsamqtbwCKFuRJK20EeuOtdBoPhuLT5BcXT/aLvsxHyp9B/WugAAHFFbxppanPKrJqxXvLK0vo9l7bQXCD+GWMOPyP0FYVz4C8H3LBrnwpoEzDvJp0LH9VrpaKszOV/4Vx4H/AOhN8N/+CuD/AOJq1aeCvCtnj7H4a0SDGceVYRLjP0WugooAjggit4xHbxJFGOiooUD8BUlFFAGZdWCDLRqAPQVnyQEdq6MjI5qCS3Vu1RKFzWNS25zMsOT0qpcRHYRiuoexBNRnTA3Wo5GX7VGV4PjMU9wCMBlH6H/69dTVWzs0tiSvUjFWq0irKxjN8zuFFFFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUE8QYVPQaARjXFvgHArFvLJpMjHHeuwaMN1FRi3TcCQKzcLmsaliloOmpYW24j99JgsfQdhWpRRVpWVkZttu7CiiimIK5P4pLv8GXEZLBZLq0jbaxUlWuYgwyOeQSPxrrK5f4lQzzeELgWtvPcyJcWsvlQRmR2VLiNmwo5OFUnj0oA8X+NWtaR4E8TaXp2keHbe9gjgF/rBklnZobUzJECm2QYYksOQRyvFep+HdM07SfiGY9FQx2dxo4n2rKzq587hhkntXn2ueDfDHiPxD4n1jxHp/iq/utXjSG3/4k11GLFVQqNu3hj90/NxlenJrrfhdZT2eq6fabNWmttM0RbAXl/p8lp5hWXKgBupCYHBPSgD1GiiigDP1mz+12mVH76I70Pv3H4isiJDtGR1rp6qNaL2HFRKF9TSM7KzOeniJ7VSe1Lt0rqXswe1KlioPIrP2Zp7RGXoVq1tcCQDgjafpXR1HHEqDgVJWsVZGMpczuFMmTehHan0VRJkzwAdqpSRYNb0se6qU0HtWcom0ZmQyVVuHEak1qSxEA8VmzWUt3MsUeRk8n0HrWTTNVIybLTpte1EoSUtIz+8cfyHvXodvDHbwJDCoSNBtUDsKh06zisbVYYVAUdT6n1NWq2hHlRzznzMKKKKsgK474mWsF/ZaFaXkSzW0+r26SROMq6/NwR3FdjXK/EJLj7FpFxa2dzefZNTguJIrZN77F3ZIHfrQB81+KvGVhpGueKraLQ/Aif2RqJs7bT7izmFzeJv25DiTaCB1JAHFfQHw/sLLTvFmvw6bYw2FvJY6fObeEgort5+cEcHoOR1xXmepeDr26uPFUVvd+K7XSfEl01zfWiaDG7EMeVWRnJHHGcV6Z8NrE2mqakLbTdSsdLg0+wsLX7fHskcQrKvrzgFefegDvqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApGUGlooAha3RutLDAkWSo5PepaKVh3CiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKbI6xozuwVVGSScACuT1DV7zUpGi01jbWYOGuTwz/wC76D3/AJVE5qG5UYuR1FzdQWq7rmeKFT3kcKP1rB1rxfpmm2pkSUXMp+6iH9SewrFFnbqxchriY9ZHOSfxPP61g+IrCOSMubcLgdQMVzTxLS0No0o31NL/AIS7Ur1SxlhtIz91Y03OR9TmmNcX1zyZ75h6mRh/IVy2nailvCq24BmPWQ8tnsF9K6WzIEQl1G9cMf8AlmjZx9aw55S3Zq4qOyJEXUkbcl5cx/WVqvwavrVsOJkuAO0ig/ywaitrqwZtkVxKG92qeZCPmBEi+o4IovJapidnui/ZeMYg4j1O2e3P99PmX8uo/WuntbmG7hEttKksZ6MpyK4GRUlXbIoYdiRVJXu9Jm8/TpWQ9Wj6q31HetYYlr4tTOVJPY9RorD8OeIbbWYtoxFdKPnhJ5+o9RW5XbGSkrowaadmFFFFMQUUUUAFFFFABRRWdqGppbExQgSz9No6L9aTaW40r7GjTZHWNGd2CooySTgAV5d4m1t5pjCJnumBw6K2Ix7Y/wAmsI6pJbQvuQwjglQ3yn681zyxKT0RsqLfU9Nl8T75CLOyeWPs7uEz7gHnFYesa/rhLeRHHbR542Dc2PcsP5Cuf0PUrSchZS7yH+M55+n+FdPGoIWORt8T/cb/AANY+1lPqXyKL2MGK+vZpM3GoXDP6CQgj8OK17a6volDw3cjqP8AaOR9QazdX0vzmdA5imXlXHQ+mR6VnaLqU0F2bS9+WZDjnj8/b3rLmknqy7JrQ7S38R3UbATxxyr/AN8t+fT9K2rLXLK6ZU8zyZTwEl+Un6HofwrlriAMFkQcHqKrTQKwKSKGU+orWNecd9TN04yPRqK87sdZvtHcKztc2nZJDkgegPauz0jWLTVEzbviQD5on4Yf4/UV1U60Z7GUqbiaNFFFamYUUUUAFFFFABRRRQAUUVFdXEdtEZJmCr+p9hQBLRXGeIdeeO3LNK1sjf6uND+8f8f8K4T7fKZDMbcjJ5cvlj9ea554hRdkaxpNnrGra5DYSiBY3nuMZKLwFHuegrHvvEWpNBm0soY27tJJvwPbAxn6mvP4dajkvMXLyOAeVyTz6nmutsXjkiEto3QZKZ6j/CsXXlLY09komXPq+sTyEXd9LEM/dBEY/SrllPckgpezbuwZ25+hBqzqNtFJAsoUGNuGH92uVuxcaJcrIHMlk56v/CfQmsZOSerNFZrQ7WHWtQtvldw+O0gz+owa1rTxLA4Au42hP95fmX/EVz1lIl9aAg5OOD3+lMMJVc4781oqs49SHCL6HfW88VzEJIJEkjPRkYEH8RUteaZubKX7Rp8rxSdWVTw/1HQ10ejeLIbgrDfqIJem/wDgJ/pXTTrxlo9DKVJrVHUUUgIIBByD3pa3MgooooAKKKKACiiigAooooAKKKKACiis3X7/AOwWDOhAmf5I8+p7/gMmk3ZXY0ruxj69ei9uWtVfFpCf3uP+Wjj+H6D+f0quiPOQPuxjoPaqenxb1XOdvbPU+5qxfXXlqsMWN7nAH9a4JS53zM6LW0Ql5qFtYrtQb5OwAzXO6nrtxOGiSNMEdG5P5Cm6m26dra35bPzv3NWtP0pEQEjmp1kbwpq12cjBpF0Z1ljwmG3Yx/KtCW1vJEHyqD6uxJ/OuxW0UDpTJLUY6UeyLujivsuoQHcjBgO28810Ohai0oEU+4OOPm6ipri2xnFZkkbRXEbqPmzily2CUU1dG7MroSUxu9D0NNytzBvTtwQeoNWJTmNGPUrk1RglEd6CnMc4P/fQ/wDrVDRijKmWayvI7u0YrLG24Yr1HQdTj1fTIrqLgnh1/usOorg76DO7H1q14Du/smsSWhbEdyMqPRxz+oz+Va4eo4y5X1Jqx5o3PQ6KKK9E5AooooAKKKq6nex6fZyXEx+VRwO7HsBSbtqwSuV9Yvvs0flxH98w6j+EZxn6noP/AK1cb4nuzpumFUP7+bgtnnHfH+e9akMst2Ybm5I8yU+YQOgAGAB7cmuP+JMxSGM9gM/mTXJUnzbHRCNnYxYJkhi3MfmPpVG8zqUbxQ78k9T0qhb+bqFwsMZIQfeI9P8A69d7oWjpFEuVx7VzpX0OuMVuzntP0maFVI4I7jiux0q4eSF4ZTiQDcPqO/4/zFXhaKBgCoLi38ho5k/hYZ+h4P8AOr5LEzs1oWNScGO3uAOvB/KuX8WW2Da3sWFkHyk+uP8A61dBqDhdHH+y5H6GsTxCTNo1tGeSTuP5VLV2ZQ6G9oF2L7TI5D97GGHuKnuFCsMjiub8DTlDLbuehyK6u6TdHkU7XQpLlZQlhV1KsMg1kpHLa3IMTlJVOY2HGfathGyxQ9QMj3qK5iEi8dRyDUFJnSeG9eXUF+z3PyXa/gH/APr/AOfp0FeYTxPtS4gJSdOeOORXceG9XXVbLL4FxHxIv9a7KFbm92W5hUp21Rr0UUV0mIUUUUAFFFFADJ5VhiaSQ4VRk1zN1ObqaS5uOI48hV9Mf559T9KdqOpfbtRktoTm3thuY/33HQfQfzFUNS/d6PKo6+WQfxrmqVL6I1jGxwV9fG+1KSaZjweB6DsKrXN8jFUUuewC1hT3jCadU5bcVAHeuk8NaKz4knyZG5J9PauM7Ywv6GdZaNM88kp5DnIFdRo/nWDqGyy5yB7/AP1+ldDb2CRxgYp8lkjKQR1rRQHLltYlg2yLPEOY2UOv0P8AkVkTQre2FxbSDOUI59R0/rV/SyY5Vjf7y7oz9M8fpis6ymP2y6A6KpH4nNJ9DnStcy/Bt20N21nI2QRlefTtXYToCpIrzezLW2rRTrwC4z9DXpcbCWEH1GaEug6is7mftDDI7Vm39qA3mqOD94VpzHyWJPTv9KHUEeoqWgTDw/rsumOkN0Wks2+6epT/AD6f5PdxSJLGskbBkYZBHQivOPs4y8TD5DyPatHwvqzafdjT7tv3Dt+7c/wk/wBP8+tb0a1nyyM6kL6o7miiiu05wooooAKKKKACiiigAooooAK4PxBff2jrbRK2ba2+Tjozfxfrx+BrrtbvPsGlXVzuAZEO3P8AePA/XFcLpFoy2/myggHnnqTXLiJbRRtSX2jTjcRQF2wOM/QVl2TNNLcXrjO0ERg/pU2qOWRbeP7z9fpVe/cQWK20Z5P3iPU9B/WuY2SuVNKj8yV5G5y3B9RW/GMCs7TYgigAdK0xWsVobSH0xqdmmmrIRBMoIPFZMsebyBQMkuP51suODVOBAdUtyemT+eKiSKvoxuvP5UUUK/efg/Sql2PKS1I/hf8ATAzUmvZfUUHZf8f/AK1RX7Bio7Dc36Y/oaxluZx2NCYYWNvwrFvS9jfRzwnaUYOh9K2C3maejeh/pVLU4/PtDj7yc/hUPRjR6XY3CXdnDcRnKSKGFT1yPw5vvP0qW1Zvnt3yB/st0/XNddXqU5c8VI45R5W0FFFFWSFcR4ru/tupJZxnMMRw2O7d/wAhx+ddjeTC2tZp2GViRnI+gzXnumhpZpJZPmfO0t6seSf1rmxErJR7m1Ja3NaaTylgxwMYrg/iNMZIIEXlnAAH4tXV6ldfvlSMZI4A9T/nNcv4ijFxdWq9SnH4j/8AXXM2b043aQzwlpgijUsuWPLH3rureMKgAFZGiweXEoxW8owoq4I2qPoNxUcyeZGy+oIqTNJVmZzt5KZdMkQ9VlBIqtKvnQxg8hUH8h/9erupw+VcSrj93OuR/vDn/P1qKxUNGy9flGPp/k1jazCK1MvTT9k1VD0D8V3GQyexGa4vUYygDjqh3V1OmTia0ibPUYp9RVVrcq3n7siQfwHP4d6lkIDD0PNR3GGRgegNQRsWsgM5aElD+HT9MVDJLRXr71Wsp30vVI7iPOzOHUfxL3FSwS7xj0psyCRKm7Tuh+TPRIpEljWSNgyMAykdCDTq5vwfel4Hs5PvR/Mn0J5H4H+ddJXpwnzxUkcko8rsFFFFWSFZXiS/+w6a5RiJpPkTBwQe5/AVq1xPi+Y3GsxWwJwiheOxPJP5AVlWlyxui6ceaRBosfl2crdC/P4dqi1K5J0+bP8Azzz+RFTyyrb2hxxu4A9hWLey7rGUk8MuF+g5J/SuLY6LXZwvh6xN3qLzuuV3naPU5616jpVssUQAFcv4as/LCnHArt7ZcIKcFfU6Ze6rD8YoNKaQ1qZGXdObfUoiPuv/AD6f4VhwkrNer0LH/E10GswNNa74/vxHcPp3rCBU3fmg/K2HP4//AF6xmrMVtShqNttBKDBHIrqdBuPOsEbPTFZ19ByaZ4Zl8uWe2bscgfrTvqXVV1c27xcmqds+6F1Jy0Rx+Hard03zIc9RWdEQl4FzxICh+vUf1qXuYrYtDDgEdqqX8HmJkDkU9JPLkKn1xUzYPHrUPUpaHUeFtSN9YhJWzcQ/K2epHY1tV59pVydO1OObOIycP/unr/Q/hXoI5GR0rvoVOeOu6OarHlegUUUVuZhRRRQAUUUUAFFFFAHL+KHN7ew2OcW8WJ5j6n+Ff6/lWZcXSKCeka9B61JqFxmS4kJ5lkJz/sjgfoBXNatfeWgWNWeRuQqjJxXn1J3kzqhHRIsz30cAe5mYBu2eg/xPtVPTnl1Gfz3UrECdinr9T71y0009xdAXIZSDwh4xXaaGryQjA2RjgY6mojqdMY8qua9sm0c1YyPWqM4it03ysqj1dq5+7u7IuSlym718zJ/Otr2Elc68LkUhFc7o+qsk6xSS+ZG3djkj0rp1ZWANNMlqxDsJqrcxMjB1xvU5GfWtGeaKGEu5CqoySa8/n1Frud5Z7grGpIBLYUD1pNjhqdNqm2TyruPJjcbX/wBk1l3DMJQzEGPbsLZ6def1qKy1KwjRliu4xuGGy2Q31zSz2IliaWCTPcbTkGsnG44xSdma9owfS3x/DtP6VHuA2Z+642ms/wAO3Q2yW8p6koc/pU07GNXjY4ZDmspmdrOxY8F3DWHinyWP7ucGI/zH6jH416hXj0s3k6lb3Uf3l2yDHqDXsCMGRWU5BGRXZhJXi49jCutUxaKKK6zAoa8caNef9ciK4OGf7NYptHzsWI/Emu814Z0a9x/zyY/pXntsBKiNIP3aAkj8a5MR8SN6XwiFjBGZ25kbIjB9+prPtY1nuRLIwCLwpJ6+/wCNZup6p9v1eGzifCMcEqe3f/Cuim062itgWjiVQOWbAx+NYpXOmnpqatkYQQokXd6ZrQx8uRzXn93YQD5rZ41bt5ZHat3wxquYVs7hy0qDALHlhWq0HKLep0IGTUF5dQ2ibp3Cj8/0q2cJGXPYZri9fuxd3KRgbiCcChkxXMzVuNSsb6Exh3/vBwh+U9jWdbTGKboMev8AnsajhZbYqsjO8p52RjOPr6VphkmRfOgmUDo4AOPyzUSVynHsQ3QjnVlBw+MlT1qPw9dGJJrWTrEcj6VpxxW7RK0YRwOjDtXPasHs7xbqIcDhx6rUtBJcyNiWZTI39xxn8f8A9VQ2EoS+khkPyzKOfcdDWfFdIy7GbKdVI9P/AK1Ub+6mWVEiRpXHKtGM5H9Kze5CVzowDDOVbjtUhYq5B+tVrG5/tO13EbbqIYdDwSPWrABmjwOJU7etJoPUsWVybHUIbhfug/MPVT1r0FSGAKnIPINeWvIdhz1XtXeeFbr7Vo8RJyYyY8/Tp+hFdOFnq4mNaOlzXooortOcK4DViP8AhJLt2/gz/JRXf1534g3L4gvVA+90/Ja58T8KNaO7KsjveS9dsajr6D1rOvpPtMvlR8LwgHoo/wAT/I0niDUE0qyESEeaRz9aXwzZpeaeLqdRI8vPzDPHpXMlc6aa1ua+mpBCi/vEGPetyLaygowII4wa4y9sLJ2YZtw464IyKg0m6bR77c8jNbvkYzkDJHNaJJGjTkd03WkchELMcAckmltpFuUV0IKmsvxFerBA8QPVSDg0yFvYWXWrKORo/MZnU4IVSf8A9dYt4YhP5lr9wnO1h90nt9KpafH8hlY+VFng9zWzaTb1KiCZ0PByBz+BNRKz0LcRI7mN4B5p2gcBj/I1nTP9g1KGcfcb5Sf5VuW0FtuICncR/q5Bg4+h7VV1q1SW2KBNoxxjt9KmwLVWZYupwy/Jyy4Ye/8An+tZt5LhVmjP3SG/Ks21vXChZj+8i+Rx6jsakvLkJE0kZBGPmT+orORml0Ny62yxx3Ef3XHPsaN5Mav6daw9B1FkY295HJHbycIzrgA1thTBKY5PuN3pA1bQVsPH7iuy8L3hutMVHOZIf3Z9x2P5fyriJd0L7W+6eh9RWr4PuxHqrwE8Srj8RyP61pQnyzt3IqRvE7miiivSOQKKKKACiiigAqG8m+z2k83/ADzRn/IZqas7xE5TRL0jvGV/Pj+tJuyuNas4LUpCkUSscjgH3qjpmZJLi5KZ3MI1J6cAn+tO1+QrZB+hADCr1lat9jsIXBB8vzCOnP8Ak15sFeR3x01OV1y1ddVjlZAoZduQeCf85rqrImHTcxAbwvGegqh4hjD3dpH38zcfoAa0fsnn2bw7mUMuPlODWiWptN3SOW1DU7RHeSWC41KdGCnaMqrHoAOmfasXTfFVjqt49nHp7LIGMZXYMgjPH14Nb+qadKdJl0yKJUty+9SM5De57isTwt4M/si+W5SRBhxJ0ZiWHTOccDNbJU+XXc5pSqKSstBzZtJBJBITCTkeqH0Nd74c1AX9kGB+ZeGFcfq0cUU7MQXnYnPGM/hW14FiMXnqehwaxTuzeS0uU/HWqy+elhFkDG58dSPSuOjEksjPchzFGCwjUZOB1OK6rxpEYPEMM+Mo6Yb2/wA5qxpOnI1rdLbuB9pjMbl1zwfQ1el9Qs+W6OZtvF+m29wLGazuUlKK+10A+UgEH6YINa8F+lvcObRmRM/PCwxt98VhD4eSW2rNcySxsH4ZxJnAPXAOOa6jUrO3u7lJPLKugCKEPOB6mrqci+FmFJ1JP3kUmuDDdmdQdjfeHtXa6RZw3mki+uwJnkB2Z7L2rk7y322zYHQV0Xg97ufQo1OEhjG1eMk1kop6m1RW1Mi9XydQWLPyKOPp1/rXr2ltu0y0brmJP5CvJfEqhJ7eZVC5RlbHTIIr1XQDu0PT29YEP/jop4ZWnJHNiNkX6KKK7TlIb2H7RZzwZx5sbJn6jFeTaneG306eEjZKW2sPQ55/XNev15p8T9GeH/iY2ykxSN+9AHCt2P0P8/rXPXhdcy6GtJ62PMbGVodVjum6B+Pp0FbHifxhDZzeYYzOkAG1M4XPck/pU2u6fDawWYAw/wAoI9e9Zd9pUd5G8BgHlSEM21ckn3/P2rGCV/e2O2SlGPubm7oPiOXxJbNFPo/ljyROgEnLpkjcuQO4x1qHTIpP7ZhWFnPz/dkGHT1z6j3p3hPSBovmzh3DPH5SRiPbsXOeOTXQ6DZBbma6fezD5QXIJ9T2+lXPlb93Ymm5qPv7ljV76W3QoG4IrnrQs0003G/GFz2FaGrOLi7KKc4ODVG4tpYMNFn6VD1ZolZHIeN7rVYLKGXTmdFmZsqn3zjbyfru/StD4ewXV41zFdX175iwJOJdxBjc9UIOQf8A61dFtj1C1EVzGku05G4YKn2PUU+x0cRRSRwqsaSHLYY/N9a2TioWtqYOM3U5r6Euk3U41GWC4nilKLnzEG0t7MPX3q5qG2dGAHNR2ulGHiFfl9hgVaWxZCS7fhWMjeJx06y2rNgZQcjPar/h6ZraJ57mB8TOPmP90dv8+tWtUjVru2t8ZEkgBHt1NbF2sdraTpJGwdyFVtuRjj8qhIbSRSeVZb57i2YwTIAFUr1HuB2rUhYXSCaIBJB154z/AIVVkRY9cO6IujIG2jv1/wARTdNmxJOyLtUSN8vtmlJW1M5rqia9TehkC7ZF4dfX3rZ+HFwSt9bMfuMCP1/+tVWRRJGGXrj8x6U74fKY9b1JD0CA/qKKOlVGM9YM72iiivSOQK4fxen2XW452HySoCD7jg/0ruKyfE2lDVdLkiXAnT54j0+b0+h6VnVhzxsXCXKzwjxRM99fMRkqWJx7dB+tathry2XhtYg5WUt5YI6gZ5I96l0/Td6aibyMq8Z8sgjBU8kisq3tleINEiPLHJvjZhnBByD+grjiu56EI2VzodV1ubwxpkUs+mGYPG0pjib5lRerHj0rAi8Qad4hRZ7BJrV2G4pKuFbnHBHvWtrcM/ia3hhv4PK2KVMgXcCp6gjP9ah0nwzBaTRw27SupHl9AqBep4/+vW3ucum5mnVU9djqdFea30ONySDgkA+nasW+uWvLgCQ8Z5roNYkS3s1iBC8YArAFmzxlxkN61m9rGq7izrLcXENpbusbN/y1b7sY9R6nisr4lWUukaREumz3AuSjSCVWJZ3GPl6jHUnitC3u3tZljndVLnaobGGPoPX6Uurw2jWTy6nLDFZRfO7SSFI09yc4A96uFou7VzOonJWTscn4O8Q660AXUpo5lVN+yQYcHOAAexPUV6fPcRvEozuJHJ61zOh22jX8bzaFc6fdAYDPZyLLj0yQTit5dOkCAM20D3pVGm9FYdOPKtXc57V7VhN5kXDD9RWdamabUYFMTOkZ3uAeMD1rrb6FY4SWOcDrUPh62UWMVy8ZZXffJgZOO39KxtqaNL4mNubyC5sxE8bKzSYd8dBnI5+mKtWUvAtZm8wf8s3IwQPQ5qO92T2V3NGvC3APTB4C9vwounRXsFWEoxDZfjLHjn3pyXUmaVi+8fyeTMMoeFb0NZttM1jrdm7cFZACfxzWxC4lUq/XHI9RWNrsRSe1cc4kAzWT6NGS10PWaKF6CivWOEKKKKACiiigArI8Wkjw7fFeojz+RFa9UtbhNxpF7CBlnhcAe+DipkrxaHHdHmbxjUzaWw53OAwH93qT+VdFIwOqFVxiKLHHuf8A61ZXhVY0+03DYLqoVfYdavac3mSXcx7ttH4f/XzXFTVlc7GYOqMX15R2SP8Amf8A61bVtyowawNTfZrzE90GPwJ/xrVtJ+BTR0uPuovuOclQaikjZlwg2571MkgbrUnUcU2jLY5i+soY2Z2ALdSTU3hKTzXnZB+7BwDVTxO0rzxWcHDzHr6CtvwjZra2Yhk4YdaiO5rJpQMrxxHhrabblVbB+hp+iQmMAwt8p52mrvjNoViWIMuXIHJqhpDskzQN99MEe4NVfUUdYG4y7h86g1VmiXHyqB+FXSxC1QvJtoOaTJirsyNWZY7SbHZTXVaPGsHhy3WPj5BXCazcZgkHsa7LwvJJN4ctzIP4Bg568U4sdeNkjn/FakacWxykjL+fNer6Knl6PYp/dgQf+OivO9ZtTeWN7Cgyw2sv1/8A1V6bAnlwRx/3VC/kK1oxtJs5K70Q+iiiuk5grI8VvjRJ04zKVj/MjP6ZrXrnvFUgZrSDuGMp/AYH8/0qZu0WXSV5o8v8TK1zrsMCfdjTP4n/APVW/pul7EUnrWPcc+J5c+grsbZgI1rj3Z6TbSK1zClvbtJsDMOFB9TwKvW9t5Vvg+mST61R1kmS0ESNteRgA3oRz/SoE1+K7syGVopgMOjDH4j2p3SIs3sYusW/2e9W7gyQG+YDuK141jngDoQyHuKqafqdvcXJt54DGGztYnIOPX0qrZ3KQandwQt+5OGA7A1N+pq03oacVlHuyqjJrVtbLaM1DpibwCa2ThFq1qc83bQqSIFXisy6faDV66m61galchQeaUjSmjOR1l8R2eTnBNdhr0Ik0uTA5xXAaU5n8Qwbf4ST/n869FvATZMG7rSjsFXSSMfVF2w2d8g5VQW+h61zvh+73Xt5ETnMrFefc12NnCLnQI1POEx+VeaqW0nVZg5+6xYfTqKipsTurdju4rhItys4x1Ga0/AhSXVtVkQg7Qi5H41xS6bd36pczO0UcnCLnHHvXa/DayW0XUirl9zoCT6gE/1ooJ86uRVhywbudrRRRXonCFFFQ3k4trSacjIjQtj1wOlAHmvjG4222qXC/flmKKR3x8g/lXLWXhu51CC3e21O809488wCNg+ccMrqwPTtg89a3vFqGPSIFY5Iddx9TmtHw7gWi4rhb1PUStE5XX/Auvatoslmvi26gl+UxywwJCysD94snPTPAxn2rp/BuiDSdPWy+2Xl99m/dm5vJTLLK3VmLH34A7YrdEgxWJaasthdSpcbjDcsZUcDIQk4wfyFO+liOV6tE3iO0juIihI3gcVl6HJ5kZgmI82M4wepFSajrCR3IYQtMDySDjA9qi1ya2WO0urY7ZNysOxwexqW09UbKLskyXVdE0/VYTbalZW93ATny54w659cEdeaoD4c+Hbm3kibTY1jdSu1Sdoz6KTt9+lblnL9okB9s10NsgVBVpvoYTSW5i+GfDWmeGNHh03RrVLa1iHCr1Y92Y9ST6mrN0cVeuJQM1jX04APNDHTRka3OBbuueoroPCqKdEtwAPuD+VcPrt0Cp54rt/DCumkwA9kH8qiO5pWXukNrbh5tTtyOCQ+Prkf0rlNaunt7nTUYkGFpEP0+XBrtbUY1yYf34ufwP8A9euR+IFg0d3Dcr9wZDfjRJaGd73RsxzKFSUHA4P4VFqUsU89nGGBLToB+dc/p73WrRi1tchVGXf06f8A160tL0cR6rprPMxY3CFVJJyMg/yFYpNsFDS9z1+iiivVPOCiiigAooooAKKKKAPP0sW0++1W3A+QNuT/AHSMj/Ck0kFdOTj7wyT6mr2pXizavq8ZTY1sqITn72V3A/8Aj1RaSM6PCT121yuNtEdaldJnEeJJzBq1u56MSh/H/wCvWrZE4FZXjNMSRt6SL/Ot3TIt0SH1FZLc7b+6XYiQKvQDIyarrFipJX2x7R1qzB6nM61Kya9DdRxmSKIFGwOee9RRp/xM5LuzluGkkbcytkAD0+n4V0UUCnsKlnhUwMi4DGoSZfMkcbrdstzdxzakXEajKAcjOev1rR0iR7jVzdGNo7Zk8tNwwWPXNb8carCqNtJA6GmMisNpAxTtYblfQsSD5eKw9TJGa19xWPBOcd6x9QIJNDHTWpyetE/Z39+K9Q0eIQ6HboOgQD9K8u108xoOrOBj8a9Us2YadGjRso2jk4ogicQ7tFCP/j7uF9VU/wA69BFee526oMnqoz/31XoVdNLqcVfoFFFFamAVy3iDJ1ojsLdcf99NXU1y+v5/ttfQ26/+hNWdX4TWj8R51rwa11+KUdJBj8j/APXrpbafdEuD2rP8ZWnmWYnUfNEwbPt3pdFbzLZGPTHNcnU9LeJd1KRfsTBgST0xwQfWs3SI2miuZrkNKEwFyAPr0rQkQzZ9BTrWa3tLR4pW2lySadiNdkUr/SY5M4yp9VODVCDThbMSucnqSck10P222nHysBUTIH+ZCGHqOalxLUnsy1pTFYh61dnmOKp2fyjFSTnINWnoZNXZSu5jziuc1SQ7Sc1t3QrndTPUVL1N4ITwcvma/k9l/rXoup5NqwU7eOTjNcJ4GhJ1GaTHQgV3WqKTauOhx64qo6Iwqu80N8OrnSQuc4LDJ+tcVrekCfxXp8KgFZHy47lRgnNdt4YB/sobjk7mz+dZsdvH/wAJb5qjDLGT+ZoaujNO0pE3i1orTSWAGAi8AcVY+F0gOjXCNnzTL5jE9wRj/wBlNc/49uDII7YE5dgMe1dD8PIjHFKAMDy1z/301EH+9SJqK1OzOzooortOMKzvEJI0mYj1UH6bhWjWf4g50i4x6A/+PClLZlQ+JHA+LrczaXJtHzKNwqj4Yut9mvNdLdxCW3KsM5FcZoyG2v57U8BXOPpXC9z1Iaqx1qSdyeK5253y6msUJZIpH+ZRjHJ5I9M1tOflCDqetRQxJb3SyzcBRn6UE7bBcWEUquoj27Tj/wCvWNLoyLJuy5xyAWyBXRHUrQuyq2dx59qY5ilOI3Un0zzQ4oqMpLcqaSpjlwa6ISkJWPAmxxWkT8lESJ6sr3M3B5rDv5SQa1LnvWHqHCmhs0gjmdUYu5HqcV6ro6hNNjAH8Iry14zLewLjO6Rf516vp6FbJBjHFOCIrvRFG0BGvksxJaMjGMDtVfxvZpNp0rsQCqHk9vp71Ys0I8QkknaUJAyfan+MYkl0uQOM8cGn0Mr2min4H05bDw1HJIuJpV3sfr0/SsjSLlD44iJz5UT4xngMeM/qK6e6kFpoigHCrHj9K4vwvG01/LOclpHyP++hiok+W1gXwt9z2aiiivQOAKKKKACiiigArlvGF+Y5Et7bxCdJuFj8xx9lEylCcBmyDtGQec+tdDqE6W1jcTSSiFI42YyMMhAB1x3xXmuoX0kwil1O5092AxHcanAyxMOvANuvX0D/AJ0AWFkgbTJ7iEu808ReaV33+a4LLuDcZBCjGABjHFW7e6S10qPzM9AAAOSfSs7y3isUhZWWRxGCjDG0soYrjsBkgDsKn8QBrXT4Z4QCYHDkEcY6f1rmluzsgtEjC8UwT3NrvjtpgFYNyB0z9a2NBkWSziIOeKePEBubLmKPLDGN3X6VlWMpstRA6RStjHoayejOlXlE6rFQXckdvE0sudo9Bk1ODkAiorh9gHGQaoyOWvPEjs2yztpgP7zLg/lWdNql8zbjbyN+PNdw0EEwBZF3euKrT2cmf3IhK/7YqbM3jOK6HJW0+oXLZFsynrndzWnp2qXhuBb3FuWA4MoI4+taywzJnzDEg9E5JqtcRkIRGuBSegOSl0L8jBo8g1i3x5NXBJshVT6Vl6hMEjZmPSk2ENDnb5xJrFjH/wBNk/mK9iKgWK4HavGNIT7X4jtZJWCosm7k44HNezxzJNaDy3VgB1U5qoO6Oes7tM5rUmMd9Gw7oR+Iwa9KRgyKw6EZrzjXUwkco6o4P4Hg/wA69A05t+n2zesSn9K6KRhW2RYpkzFInZV3MASF9T6U+itjnPLne/1AtPNcTbyc7Q2NvsBnii3nvYZleaaS5iA2/OxZgPYnn8K6bxVpHlhr+zZosHM6LjBH94eh9azbWJGRSvIrjlBxe56cKqlG9iHUVS6sHCkFXWub8OXBWBoWPIOK6l4fIlMf/LOQFl9j3H+feuJtwbXX5oP4S+4fQ1DLi01Y6O+mktrUGOJpNx5C1hXFgb8+dqF20TnpHGcAD6107MCI/SpPLtphiSBGx6inYIT5TmLLTLWNgIp7gue+/P6dKvjTL+N/Mguiidy6g5/AVv29vBGcxwIh9lp90C8ZUUco5VWyraMcc8mpZDUEKmPg1I/tSRHUqXK5U4rA1KPrV/VL+QTC3tRls4Z+wPp9azr+znWBpHkkDY43A4J/Kg1SdjW8AJl52x/y0/oK6zUYXdW+fAx0rF8CW5TTYpWGGl+c/j/9aukvB8hq1scc375Q8NrssHXcTh2/nWcrFfErkf8APP8ArVjQZ9k13A3Zt35//qqOJQdcuHP/ADzH86OhVrSlc5fW5DdeIQgOVQZx6V33ggIIrtVI3RlI2Hpxn/2auG0+NZdYvrmT7iMR+A/+ua2Ph/qBh1OUTH5L9uD2DjJA/EZqKbSqXZNbVOx6RRRRXecRxvjG6vG1OOzhkkig8sP8pxvOT3/DpXPul/CWWO7mXI5QsSrD6dDXouq6dDqVsYpcqw5SReqH1FcVbQutxJBdOzTxsVOe30rlqwd73PQw9VcvLbYlsrozxlJl2TKOR2PuK5fVCbTxEr9FkUH9f/1V1s9sQgliHzx849R6Vy3jRAEtruM/dOCfY/5FZM1g1fQ2YG3/ADjnvWLdvc6ixikJtYc5dj94n29q0tHk3WQPcir0JiK4kRWz6imtUClys5JNGsUfJu7iT28zH8q1F0uWWIfZJ5s9t+MD8etbqWlpuytrED/uiroAVMKoH0oSLlWZiWEdzB+7vJ1mfPBC4x/jWpu+WqssTCYtUynKUiHrqQzc1kX8eRWhqFytpAXI3MeFUdWNYiJd6ghkkZlX0QcCky4oz7VM6zaLj/lpn9DXqcK4tVHtXnPh61aTxCUdiywrvyRzk8c/rXpajEIHtVxOevo0jIjAj1qMn+JSKb4tP/Etk+lRarIYNQtZewfB/Hj+tSeIyJbHHYkfzpit70WZniu6MWhAKcMVwKp+FY1gnsVkwPMlRB+ef6frUnjABzYwDozDI9hzVO+LRX1lDAf3luBP9Wzx/Kspu0k2Dd1ZHrtFVtNvI7+xhuYT8kihseh7irNejucAUUUUAFFFFAEV2/l20jlQ2FPynofboa8/8SLb2UlzBp1toKTT/uVt1sj9pbIw4XHDHGSDjHrXSeObqay0F7i3nnhaN1J8lVLOP7vJGPqDn61yegarbeIJ4Le9KspkVvLfVnckg5BCbRzkA4zQBcuYVTX2tQ7OtuF5c5JwigE+9T6onm2k0ZGcoRj8KqQTG48S3c2MCSRgPoMAfyq/qL+Wkrf3VJ/SuWW52R6IydH0oJZRTEn5gD+lZPiiRbKNZCMAMDn8RXYWo2afDGeoUVx3xAH/ABKSQOd6j9aiRrCTN7Sr+K7tEdGBOOauELIMGvKtKvrjTGUrkxHt/hXbadrUVxGCG5pKRXLfY3hEB0NPEBboTVGO8HrVqG9UDrVXJcWge0xySahmRRGRxU016pHWs29vEWMksKl2HFPqZ1/JtfA6VzOp3LXVyLeI5A+9j9BSeINa58q25kPGadolp9me3a4yZJJAWPpmsnoaN9DtvDWl2VjZCaZAZMc5HJqSCfz9cjS0QRqMlsf3R61ea3V4AjZC4xxUWi2sdvqc5jB/1XJJyeT/APWrdKxlKS1ZJqcXnQyx/wB4EV1XhxzJoViT18oA/hxXNXbhDk9CcV0HhVs6NGv9x3X/AMeNbU9zmq/Ca9FFFbHOMniSaGSKRdyOpVge4IribWF7aee2dtzQuUz6jsfyxXc1xrP5muak3bzdv5KB/Ssqq0N6DeqI9XB+w+ao+eIh+PTv+ma4TxEhttSgvFHyZAJHoa9Ikj3RkYyCK4nV7crHJZz8rgiMnuPT61ztHXSfQv2Mqzxrmtm1hTHSvPtA1T7PObO7O10barHo3/167aC8UKPmFG25c12NYKgHao5NtUHv0A5cfnVSfVIk6yAfjRzIzUGaFxtPSqc8nlwSOf4VJrJudft4/wDloDWTd63LdRPHBG2GBGTxUmii0bDWz29payoyiVlLMWHUnvWPqs91JEyySFgeAqjr+Ndppapd6VZyMAT5YBHpxWdrdkqyQbV4MqfzqntoRB66m/oEPk2EKYxtUD9KuXjYQ0lmQsKj0FQ3slV0MN5XMizTZqM0g43KAar3d19jvZZME7kIrSgCksR1rB1hw+9hyBkVNjdPmepR0gmTR7+Ufefef/HmqXTIy+iqYiVmjbKkdQw5B/QUeEAJtLeNujbgfxNOjH9nTSQOcKxDIfWuZvW5G90en6JfDUdLt7odXX5h6N3/AFq9XH/D263RXdsT9xw6j2PB/pXYV6dOXNFM4px5ZWCuY8S2oh1C3u04Ex8t/cgZB/LP5V09YHi58RWKDq1wD+SmiavEqk2pFWLpg9DXKa5atNZ3NsRny2IA/wBk8j/PtXXRrkCsPXoHjkFzGCRt2yKO47H8K5mjsg/eOa8M3ha3ETn50O1hXVWkaNg4rgb2Y6bqKXUY3QSnD7f5112kajFNAskbhlI61OxtLVHRpGoA6UrhcVnfbkx94VBLqUYB+cfnT5kZcrNCTbjFUnOG4rMuNbgQcyD86yrjxGhOIQzt7VLdzRRaNWeH7VfT5PywxYHsT3rPuJ7uNNiSIqgY+VTVnwjcvdXt4twoUyKCB1rfvLKMwEqoyBVdNCL2lZmH4IjZ7i6mfJZnClj3wP8A69dyxwlc54UiEVq5PUyN/Ot6dwEpx2M6usjD1pPNCj0IIo1bLWWPQVYlKvIN2OtVtVcCMIOpFFi1LZHPX959u16yBHCITj34FPYD/hKJd5+8oA/z+dZytjxHAB2Qj/P5Vs6xblJo72MH5eWx2HrXPUFKylY6PwTeeTd3WmuflP7+L8eGH9fzrsa8r0+/WDWbK5U4UPhj7Hr+hNeqV24efNG3Y5KsbO4UUUVuZBRRRQBka5bXsxjeykIHR1M4jHseY3yfyrC0IatFqN9JdSf6PbTHcpugfk8oHhfJGRnPOR0Ppzfu4LGHWbp9dt7aSG4ZGtri5RWVPlCmLLcLyNw9dx7isXxbpujW94oh0/Ty1xaSIUWFODvQKw444Z+e/wCFJuyGld2M/TwyXNo7ZyTz+IrU1I+YwiX/AJaHB9h3qmIwrWsMQC7McAdAK0dvzBiOa5mdnmW7WMGMD04rB8X2qPp0oxztyPqOlbUc/lriuf8AE1yXiKg1MtioJ8xx3kxvZ8AAjB/Pofp/9eo7SBj88JKuOCKljcfZwvby8fhgH+eat6HGXLMehOa56fVGiFgnu04Zd304qz9tuenkv+lbljbq6fMoPJ/nV9bSIfwCteW4+c4ye9u+gifP4VmXT3txlW+RTXd3kEaqTtFcnqLYdsUWsNO5mWumRx3EbSEsc5NdBAitqtpGMfeyQPbmsq8YxiFx0HX9P8KveFibvVo3HOxSTWTTc0Sz0DGIxTLP/j5uG9EUfnmnyjCgVXidkupBj5XQc+4z/jXSYPVEOpH/AEeQ9wM/lW54On3wTxf3WD/mP/rVhakf9Fl/3TVrwVLjUpI/70WfyIq4O0hTV4M7Wiiiug5ANcHpTGS6upG6yTO/5sa7w155YTKl/exKfljuJEH0DHH6VlVN6PU6VI8pXP8AiOyD27kjpzn0roLaZWTrUOpRiWBxjqKxKi2meKeILbzTIyEiRXDZH0xSW9/qKWzr5vmbBkbhk4ra161EVzhh8rZU/Q1l2YAjJPJRirfSsql00zpb6jIbi9ul3HIX/ZNasehTzRK7yllIzgU7R1T7E4IGQTiuw05AbRB6Ci9zS9jkk0QRclc0826xqcDFdZcRqEPFc/fYXdUMpO5u+EGLaWgPbOPzrQ1W2M8I2nDKQwPoR0qj4KAbSYz7V0Eygqa2WxzTdpFC0ufMt0YcHGCPQ96gupSTTYV8q6nj/hOHH49f5VFdGqQMXT3LGbJzhv6CsPU2/c3AHZjWzpykecT3Of0rG1Af6PcH/aNJjh8RU8Fy7YTGTjn9a19dtDd6ezRf6+H51x3x1FYHh4bSuO/H9a6+2bnLdc4P5Cubcl6O5V+GFz5+qTkdDDz+Yr0uuA+G2mNZ6rrchGI1kEafj8x/pXf134dWgrnNWd5aBXLeLmJ1LTk7KHf9QK6muT8ausV/prE/M29f5Grn8IqPxlq2XKim3tuHiYe1MsbgEAE1eYhkrnNW2meV+ILZIpGQjC7847DPFclp7XmmzyJbzMIw5BU8jFek+LrLcHbHBFcKyD7RGzdXBVvqOP5fyrOotLo6b3jcRtQv3uGiYAt2IyKv2On3d6WBkZSOoP8A+uo7ID+0Yt4GQNp/A11mjKgupNoGDSTui1tcwh4eKnL5Y+9SrYLDxtrsniXHSsfUFA6CpkmVF3KOgsY9bQDoUI/UV3DJujI9a4jQiG8QIuf4P6134A21pDYxquzMWxzaXMkB6NmRP6j/AD61cuJTtqDVU2NHMv3kcH8Dwf0NE5+U1RL11KUkh+0RDPU8/lTdWbDwnvyP0qMgtcRkdA2f0p2qDM0A+p/SmHVHHyuU8Qxt6f412sbLLGM8oy9D+ori7tM6sfWuosGJjjJ6Ng/p/n8q5pbjnuc1do2n6nJZscqGDxn/AGSa9whJMSE9SozXlevaY1/qWjPH983AgY/7JP8AhmvVxXVhVa5z13dIKKKK6jnCiiigBsiLIjJIqsrDBVhkGuH12Kyh1AW9ha29vBB88vkxhN8nbOBzgfzNdbq94bKzZ0AMp+VAfWuPgti0m6UkjO9mPVmrKpLobUo/aYtrDsDTS/ffoPQelT1E5aV8DhRUnQVkzdDZDgVy/iGQJFI57CulkHG5jha4vxFKb6dobcZA4OOwrN9janoc/bSGdQiZ6AHiuv0a28uAcc1naRpDJglTXV29r5cQGKUYpbCbSJLJdox7mrtV4UIPSrOKsm5Q1AfuzXHXaFp/xrtNQUmMgVzxsy0u7FJlxdjKuox5WGGR6Gtb4eWyCe6ZVxhgP0qC9tjtxir/AIG/czXSsMHeD+lCWopv3TsLmLAzVBhiRfbNaszgx1mv1NUYRKt9zEw9qb4PbHiBF9Y2H6Ut4f3ZpnhAZ8Rp7I38qqO6HL4WehUUUV0nGU9YvBYaZcXJwSiEqD3bsPzxXnEMb28UcuS2T85PcnvXReNLtp7mDT4z8iESSfXsP6/lVZYFNvsYZBGK56krux10o2jfuT6fJuAwetaxXdGc1zlk32aQxuTg9Dmvnb40eH/HfhXUv7R8P+LfEc/h25kC5bVJybNmOAr/ADZKZPDfgecEqKuTUdj2rxrEEbI65rlLQbr64j7OB+f+cVz1vrt5oGl29h4l0vxEHT5ptQmuG1JXPdi65Kj22gCtbw34h8Papeq1prFi0rMf3TTBH/75bB7elZ1Iu2hupLk13NzTEYWx69a7DSXBgANZ+k6fusi2M55rTsrZo1xUJNGraaJrkfJXN6upEMpHXaa6aZDisbULcsjcdRRJDgy/4MjaHTV5BjbkD0Nb80wUVzvhKX/RPIb70Z20/wAR+JNB0SNjrGs6fZED7s1wqsfopOT9AK1RzTfvXZfeVWJI61SuGya47/hPH1M7PB+gaprWfu3Lx/ZLX/v5Jgn/AICpotvDPiDVr2C98W615ccMiyx6bpJaKEMDkeZIfnk7cfKOOlVbuLmvsdpDII0OaydRwbWYgdcmtV1G2sq8cCJ0I61LNIbmZ4dZMIzHlfmwOp4xXQhmjVC4xLK+4J6Dp/n6VyOmapJpjvCDDgHgyHBx2+talrfS3EwMIa4unOFCjv2x6CuVCadzvvBnzXGryL90zqPxC8109ZfhvTTpmlRwyHM7EySn1c9f8K1K9KmrRSZxTd5aBXA+IZ/7T12URnMdsPKX/e6sfz4/Cux1m9Gn6dNcAAuBhAe7HpXFaTAQpd8lmOST3NRVl0NqEd5C6ZMfuPw6nBrorb5lrn7qLypxMnGeta9leIYxyKyNKhS8SxBrRyfSvKNR+XkdVlyPyr07xJfobd41OWx2rz17UzsEP3uXP8v61MtjSl8DuLChN9E6/wAS5rpdGYpOc+tVtO04m5gyOAn9a2lsTHcZUVnFNGkZLlNE4K5rI1AZBrWCMExVG8iLA8U5IIuzMLQoWbxAWQ4ZMHnuPSvQBJhea4Wyzaa0jkYWQbfxrtAN6CrhsZ1ndkM8yk4qnO/FSywkPmonTIqiFsVoj8+aS7cPKnqKmEYUVUuSEYGhjS1OXuSF1lgxA47/AI10tmAVjH/LGFcs56HjoK5nV5TBfx3Ue3jhg3SrQ1prwKJXjCLzsiPf3Ncz3Lmnc6W1fzbnSV/iN6rD6Dk16LXC+CdPmu7tdSuEKW8ClLdSMbierfTHFd1XbQTUbs46r1sFFFFbmQUUUUAZGsRmRgTyB0FYrqVBHaunu49y1jTwHJ4rGaNoPQzcYqne3QhX1Y8ADvV65BRTWNDaz39+EjXLE7Vz0HqTWLvsjpjbdkMNvqGrT+RBlV/ix0Ue5rpbPwvBawBFXc38TEcsa6DStPi060WGLk9Wbux9au4reFJLc55123ZbHOroyx9EFObTyBgLXQYFJtFVyIj2rOcFgQelO+xn0roPLX0pPLHpS9mh+1Zzkunlx92ohpH+zXU+WvpS7B6UezQe1Zx8ui7uq1liyOnawo27Umj4+oPP8xXoZRT2rJ8Q6f8AaLQSxLmaA+YoHUjuPy/kKUqemhUautmZYyyVA4waltmDICDkEZonTvWJr1Mu9Py0eEmCeIYs/wASsv6f/Wp10mRUekqYtVtpegVxk+3enHdDlrFo9EooFFdRxHI6ja/6fJIRksc5puK3dStt2WFYjqVODXNNWZ1wldFeaBJByOaydRsopbaWG5/fQSKVeOTlWUjkEdxWzK4VSaxblpLy5S1thulkbaB/j7VDZpFXMyLTbjWb37Nag4HMj9kX/Gte/wDh/pF+Amo6RY3ihQo+0QK5/Miu40LS4tJsVgj+Zz80j/3m9a0cD0reNOy13OepW5nZbHkifBzwvChNlZ3mnSn+Kwvp4P0V9v6Uq/DFo/8Aj28X+MIB6f2iJf8A0YjV6yUB7U3y1quQjnPKD8PNXT5YfHfiQRjoJFtnb8WMXNVp/hndyLm48Z+K5WPLBbiGMH6bYgR+Br18xL6UhhU9qTgNVDwy4+FulwSrNqVzrepwZ/eLdalMR9SFYDHt0rrPDvgrwrpAWTSNB023lHSVYFMn/fZy3616G9pG6lWUEHggjrXNTWjaVd+XybdzmNvT/Z+oqJRcS4yUvUSaLnOKqSJWtgOuaqTR4rM0izNkHFZN5FuzW5KnBrOnTBNTJm0TO8O2emTa0sWrW6yJKNqMSRtbt+fSvT9P0mx04f6HaxRH1A5/OvLLyHnI616F4R1j+0rARzN/pUIw/wDtDs1aUWr2e5liYtrmRv0UUV0nEZHiKDz4YweQpziseNBGuBXVXMYkjIrn7mEo54rCotbnRSlpYquocYIzVGe0CklXZR6A1oVnajciNTzzWT0N0rsxNRAXKKCzE4AHJJ/xrT0nwpcRWxmulxcS8lf7g9PrWr4S0UySrqV4vvAh/wDQj/SuxwMVrCndXZlWq29yJylppBjcMy9BgVb+xfP92t/aPSkKL6Vfs0ZKq0YbWef4ahlsAQflroTGtIYl9KXsxqqzhr/RmlU7Bhxyp9D2qxpdwWj8qYbZk+VlPY115t1PasfW9LPy3dqv71Bh1HVl/wARUOnbVFqqpaMrSx7hVORMVctZRLGDmiWPPNQWnbRmWykVQvFzWxIlULqPmpZrE5m/gUn50DrnJU9DXoPh3RdBms4byysIvmHIYltp7jmuRuotynir3g/VRpd61vcMRbTkfRW9adNpS1CtFyhpuj0VVCqFUAAcADtS0DkUV2HnBRRRQAUUUUAIy7hVOa3znirtBANJq407HP3NiZMirei6clqGlI+duB7CtMovpTgMDipUEncpzbVgoooqyAooooAKKK8/t/iHdTeH7LW28MXdvpd5DHcQz3N/ZxKUdQy53SjBIPQ0AegUVxVn45nmfTXm0C6jsb+4S2jvEvLaePc2cf6uQkjjtXa0AFFFFAHPyWPkXEipnZnK+wNMlgJHSuhdA3UVG0CntWbpmqqdzl3sy3arNnpvzAkVvC2XPSpVjVegoVOwOoEedig9QKdRRWhkIyhhg1m3dgGyVrTopNJjUmtjj9TspgpEYJJrR8M6KLBTc3AzdOMf7g9PrW9sXOcClqFTSdzSVVuPKFFFFaGQUUUUAFFcx4i8VSaTq66fbaRc38gtTdyOk8MKRRhtuSZHXvVGx8Z6jf7vsPhe5udv3vJ1KzfH1xLQB2tQ3dtHdQmKZcqfzB9RVDwvrK6/okOopby2vmPJG0MpUsjJIyMCVJB5U9DWrQGxjrpjxZCtuXse9RzWT46VuUYqPZov2jOXksXz0qlPprt0BrsyinqBSGJD/CKl0kzRVmjgJNJkbjaafpmm3VhepcQZDr27Eehru/Ij/uilESDoopKik7jeIbVghfzI1fGMjp6U+gADoMUVsc4VWubVZQeOas0UmrjTsc/d2LKpKisqy0KS+vg1yCLZDlv9r2rtCoPUA0oAAwBgVHsk2aqtJKyERQihVACgYAHaloorQxCiiigAorL8T6wmgaFd6nLBLcLbqD5URAZyWCgDJA6kdTXNXfju7s5zDd+HJYJl5McuqWSsM+xmoA7miuY0LxTPqOtppl7ot1p0sto15DJJPDKkiKyKcGN2/vrXT0AZc+lL5xktzt3HLL2z6imtZOByK1qKhwRfOznZrJ89Kqy2DsOldWVB6gUnlr6CpdJFqs0cNLpkhJ4NVZNDkc/dNegmFD/CKUQoP4RU+xRf1hozPD7zLaLb3OS0YwrHuK1qQIo6AClrZKysc8nd3CiiimIKKKKACiiigAooooAKKKKACiiigAr5embSYdZ+EU3j9I28G/8ACK2625u13WovvLXPmA/L9zb14/I19Q1wln8PZrTRLTR4vGHiA6Zawx28NvLb6fIqxooVR81qScADk5NAGHayeEpdG0d/AK2i6UfEsPmfY1Kwmbb82wdMY2/d46+9er1x0HgiRZtON34n1q8tbCdLiK0khso4ty5258q3Rsc9ARXY0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5B8a/8Aj28X/wDYpT/+jDXlXh4+GbmT4Ur8NI0/4TWJrM6u9hGyqtv5QFz9oIG05br36+or6Q1/wqdV1dNStta1PS7gWxtXFolu6yR7t2GE0Unf0xVSDwfqNuCIPGviCIHkhLbTlz+VpQBL8Mf+RQj/AOv29/8ASuauqrL8M6NFoGjQ6dBcXFysbSOZrjb5js7s7E7VVerHoAK1KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4pf8AIian/wBsv/RqV87fE8acfj/4o/tW88L2ifY7XY2v2jXCMfLXhApGD7+lfUPiTR4df0S60y4mngjuFAMsBUOhBBBXcCM5A6g1z8vgq9mkLzeMtekc9Wa000n/ANJKAK+j+SfGvhz7I0DW/wDwjkvlNbrtjK+Zb42DsuOg9K7qua0Twq2na2uqXeu6rqtwls1pGt2lsiRozKxwIYY+covXNdLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    At rest the patient is asked to fixate on a distant target. The patient's head is rotated rapidly&nbsp;by the examiner, first to the left (A to B), then to the right (C to D). In a normal response, the eyes remain on target (B). In an abnormal response, the eyes are dragged off target (D), followed by a saccade back to the&nbsp;target (E). This response implies a peripheral vestibular lesion on the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17715=[""].join("\n");
var outline_f17_19_17715=null;
var title_f17_19_17716="Global costs of fires and burns";
var content_f17_19_17716=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Global costs of fires and burns",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17716/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17716/contributors\">",
"     Michael D Peck, MD, ScD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17716/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17716/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17716/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17716/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/19/17716/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn injuries are one of the most devastating of all injuries and a major global public health concern [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This topic reviews the economic burden of burn injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COSTS OF FIRES AND BURNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The global costs of fires are an estimate of the cost of anticipation, cost of response, and cost as a consequence of fires [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The global costs associated with loss of human life and property from burns are estimates at best, based on hospital care charges, destruction of property, loss of human life, disabilities and loss of potential income, and costs to the criminal justice system in cases of arson, neglect and assault [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is estimated that the United States, United Kingdom, Australia, and Denmark spend 0.9 to 2 percent of the Gross Domestic Product (GDP) on costs related to fires (",
"    <a class=\"graphic graphic_table graphicRef82340 \" href=\"UTD.htm?1/48/1806\">",
"     table 1",
"    </a>",
"    ). The US and Australia allocate the greatest resources to cost of anticipation, cost of response and cost as a consequence, in that order. The UK, Canada and Denmark allocate resources to cost in anticipation, cost as a consequence and cost of response, in that order [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/5\">",
"     5",
"    </a>",
"    ]. Ninety-three percent of the cost of a fire is not associated with direct costs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cost of anticipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Costs in anticipation refer to the costs of protection from fire and prevention measures taken to prevent or mitigate the damage caused by fires. Approximately 48 to 55 percent of the total fire expenditures are associated with cost in anticipation for high-income countries such as US, Canada, UK, Australia and Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/5\">",
"     5",
"    </a>",
"    ]. These estimated costs include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Capital costs for fire protection of public buildings",
"     </li>",
"     <li>",
"      Capital costs for fire protection of homes",
"     </li>",
"     <li>",
"      Capital costs for fire protection of infrastructure (eg, tunnels, bridges, power stations, roads, rail, waterworks, oil and gas facilities)",
"     </li>",
"     <li>",
"      Capital costs for fire protection of consumer items (eg, airplanes, trains, buses)",
"     </li>",
"     <li>",
"      Fire safety equipment",
"     </li>",
"     <li>",
"      Firefighting equipment",
"     </li>",
"     <li>",
"      Fire safety education",
"     </li>",
"     <li>",
"      Fire safety research",
"     </li>",
"     <li>",
"      Insurance",
"     </li>",
"     <li>",
"      Maintenance of fire equipment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cost of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Costs of response are the costs incurred in extinguishing the fire and cleaning up. Approximately 15 to 34 percent of the total fire expenditures are associated with costs: 10 to 30 percent for high-income countries such as US, Canada, UK, Australia and Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/5\">",
"     5",
"    </a>",
"    ]. These estimated costs include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fire",
"      <span class=\"nowrap\">",
"       department/service",
"      </span>",
"      response (eg, emergency call responses, false alarms)",
"     </li>",
"     <li>",
"      Regulatory inspections",
"     </li>",
"     <li>",
"      Community fire safety advice and education",
"     </li>",
"     <li>",
"      Volunteer fire service",
"     </li>",
"     <li>",
"      Private fire brigade responses (eg, private or remote companies with own fire services)",
"     </li>",
"     <li>",
"      Criminal justice costs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cost as a consequence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Costs as a consequence are those costs that are incurred as a result of the fire exposure to property, individuals",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    environment. Approximately 15 to 34 percent of the total fire expenditures are associated with cost as a consequence for high-income countries such as US, Canada, UK, Australia and Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/5\">",
"     5",
"    </a>",
"    ]. These estimated costs include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Property loss",
"     </li>",
"     <li>",
"      Fatalities and injuries",
"     </li>",
"     <li>",
"      Healthcare costs",
"     </li>",
"     <li>",
"      Loss of business (eg, production, market share, public goodwill)",
"     </li>",
"     <li>",
"      Loss of",
"      <span class=\"nowrap\">",
"       wages/employment",
"      </span>",
"     </li>",
"     <li>",
"      Environmental costs",
"     </li>",
"     <li>",
"      Heritage and cultural costs",
"     </li>",
"     <li>",
"      Removal of debris",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the US, a country with a relatively low incidence of burns, there was $8.5 billion in property damage, and 3320 deaths and 13,560 injuries from residential fires in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23865?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology of burn injuries globally\", section on 'Incidence'",
"    </a>",
"    .) In England and Wales, the economic burden of fires in 2004 was estimated at &pound;2.5 billion and includes property damage, casualties (395 deaths and 12,300 injuries) and business disruptions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/6\">",
"     6",
"    </a>",
"    ]. In Australia, the estimated cost of fires in 2005 was AUD$12.5 million, with an estimate of 100 deaths and 3000 injuries annually [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survivors of moderate to severe burn injuries may suffer a disability that will prevent or diminish employment and income. In 2006, there were nearly 70,000 total years of potential life lost in the US alone because of burn fatalities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23865?source=see_link&amp;anchor=H20#H20\">",
"     \"Epidemiology of burn injuries globally\", section on 'Morbidity and mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COSTS BY CLINICAL AND PHYSICAL VARIABLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cost by age",
"    </span>",
"    &nbsp;&mdash;&nbsp;When medical treatment charges are viewed as a surrogate for intensity of care, certain trends are apparent. The presence of comorbid medical conditions typical in the elderly increases the need for more complex services and longer hospitalizations.",
"   </p>",
"   <p>",
"    The American Burn Association National Burn Repository analyzed cost data on 67,242 survivors and 2887 nonsurvivors of burns incurred between 2002 and 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/9\">",
"     9",
"    </a>",
"    ]. The mean US hospital charge per hospital day for survivors was $6478 for children from birth to 10 years, and $7165 for elderly adults 60 years to 70 years of age, compared with $6223 overall. The mean hospital charges for survivors was $35,627 for children from birth to 10 years, and $950,802 for elderly adults 60 years of age or older, and $77,287 overall. The hospital charges for nonsurvivors were comparable between the youngest and the oldest age groups.",
"   </p>",
"   <p>",
"    The mean length of hospital stay per total body surface area (TBSA) burned for survivors also varied by age. The mean hospital admission was 1.3 days for children from birth to five years, and 3.5 days for elderly adults 60 years of age or older, and overall 2.2 days.",
"   </p>",
"   <p>",
"    Elderly patients admitted to a New York City burn center from 2000 to 2004 for treatment of a scald burn had mean hospital charges of $113,000 per patient, even though the burns were relatively small, mean 7 percent total body surface area TBSA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cost by burn size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The length of stay for survivors is approximately one day per each percent of total body surface area (TBSA) burned, up to 70 percent TBSA burns. After that percent of burn injury, hospital stay is a function of age and injury severities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/11\">",
"     11",
"    </a>",
"    ]. The US hospital charges for survivors increased from a mean of $47,875 for those with burns less than 20 percent to $432,746 for survivors with burns greater than 90 percent TBSA. For those who did not survive the burn injury, the cost was $185,737 for burns less than 20 percent and $114,519 for those with burns greater than 90 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cost by mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are cost differences between burns caused by fire, with or without smoke inhalation, and those caused by scald. Fire and flames are responsible for the bulk of the cost of burns (",
"    <a class=\"graphic graphic_figure graphicRef73977 \" href=\"UTD.htm?31/16/32014\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73840 \" href=\"UTD.htm?37/51/38718\">",
"     figure 2",
"    </a>",
"    ). The majority of the lost years of life are due to fire and flames (68,272 years), with only 1218 years of life lost due to scalds or contact burns [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/8\">",
"     8",
"    </a>",
"    ]. The global costs of fires related to cigarette smoking alone are estimated at US$27 billion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fire/flames alone and fire with smoke inhalation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Costs for treating burns resulting from",
"    <span class=\"nowrap\">",
"     fire/flames",
"    </span>",
"    are greater than burns from scalds or contact with a hot object [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/11\">",
"     11",
"    </a>",
"    ]. The cost, in terms of life lost and hospital length of stay, is greater when a burn is complicated by smoke inhalation (",
"    <a class=\"graphic graphic_table graphicRef81666 \" href=\"UTD.htm?39/54/40811\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Length of hospital stay &ndash; The average length of stay for all US patients sustaining fire burns in the US between 1998 and 2008 was 13 days (13 days for survivors and 17 days for nonsurvivors) (",
"      <a class=\"graphic graphic_table graphicRef81666 \" href=\"UTD.htm?39/54/40811\">",
"       table 2",
"      </a>",
"      ). The average length of hospital stay for survivors with burns and smoke inhalation was 28 days compared to 11 days for patients without associated inhalation injuries.",
"     </li>",
"     <li>",
"      Mortality &ndash; US patients with an inhalation injury have a higher proportion of deaths for a given sum of age and total body surface area burned, which is called the BAUX score (to illustrate, the same BAUX score describes a 20-year-old patient with a 60 percent TBSA burn as well as a 60-year-old patient with a 20 percent TBSA burn). For example, the mortality rate is less than 5 percent for patients with a BAUX score between 70 and 80. However, the mortality rate increases to 20 percent if a smoke inhalation injury is present.",
"     </li>",
"     <li>",
"      Global estimates &ndash; Data from lower middle income countries (LMIC) and low income countries (LIC) regarding cost of burn treatment are scarce. In 2003 in Cape Town, South Africa, the mean total cost per patient burned by kerosene stoves was US$6410. Extrapolating these costs to South Africa nationwide gives an estimated annual expense of US$26,250,000, which is more than 50 times the amount expended annually for kerosene in South Africa [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Scald",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean hospital length of stay is shorter for scald burns in comparison to",
"    <span class=\"nowrap\">",
"     fire/flame",
"    </span>",
"    burns. Children are more likely to sustain scald burns, contributing to the lower costs of medical care for their burns. Because of the frequency with which scald burns occur, the medical costs are substantial.",
"   </p>",
"   <p>",
"    Annual charges for treatment of scald burns in US children under 14 years of age are approximately $44 million, and total charges for pediatric admissions to burn centers average $22,700 per case [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/14\">",
"     14",
"    </a>",
"    ]. Indirect costs, (eg, parental income lost, cost of travel to hospital) are difficult to quantify. The cost of burn wound dressings is frequently not covered by most insurance policies, leaving the parents responsible for purchasing supplies out-of-pocket.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Contact with hot object",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact with a hot object is the third most frequently reported burn. The costs of treating a contact injury are greatest for the age group 16 to 19.9 years. The mean hospital stay is longer for burns resulting from contact with a hot object than fire or scald burns in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17716/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The costs of fire related burns are estimated as: costs of anticipation, costs of response and costs as a consequence of the fire. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Costs of fires and burns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mean length of hospital stay and the costs of medical care are the highest in the age group 60 years and older. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Costs by clinical and physical variables'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The length of stay for survivors is approximately one day per each percent of total body surface area (TBSA) burned, up to 70 percent burns. After that percent of burn injury, hospital stay is a function of age and injury severities. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Costs by clinical and physical variables'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cost of burn injuries, in terms of life lost and hospitalization, is greater when a burn is complicated by smoke inhalation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Costs by clinical and physical variables'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17716/abstract/1\">",
"      Forjuoh SN. Burns in low- and middle-income countries: a review of available literature on descriptive epidemiology, risk factors, treatment, and prevention. Burns 2006; 32:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17716/abstract/2\">",
"      Peck MD, Kruger GE, van der Merwe AE, et al. Burns and fires from non-electric domestic appliances in low and middle income countries Part I. The scope of the problem. Burns 2008; 34:303.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. The Global Burden of Disease: 2004 Update. World Health Organization, Geneva 2008 www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf (Accessed on April 02, 2010).",
"    </li>",
"    <li>",
"     Murray CJL, Lopez, AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020, World Health Organization, Swizerland 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17716/abstract/5\">",
"      Ashe, BSW, McAneney, J, Pitman, AJ. Total cost of fire in Australia. Journal of Risk Research 2009; 12:121.",
"     </a>",
"    </li>",
"    <li>",
"     Office of the Deputy Prime Minister. The Economic costs of fire: Estimates for 2004. www.communities.gov.uk/documents/fire/pdf/144524.pdf.",
"    </li>",
"    <li>",
"     Karter, MJ Jr. Fire loss in the United States 2008. Revised January 2010. FPA Fire Analysis and Research Division, Quincy, Massachusetts. www.nfpa.org/assets/files/pdf/os.fireloss.pdf.",
"    </li>",
"    <li>",
"     Centers for Disease Control. Web-based injury and statistics query and reporting system (WISQARS&trade;) 2009. webappa.cdc.gov/sasweb/ncipc/mortrate9.html (Accessed on April 02, 2010).",
"    </li>",
"    <li>",
"     American Burn Association. National Burn Repository, verion 8.0, 2012. ameriburn.org/2012NBRAAnnualReport.pdf (Accessed on April 01, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17716/abstract/10\">",
"      Alden NE, Bessey PQ, Rabbitts A, et al. Tap water scalds among seniors and the elderly: socio-economics and implications for prevention. Burns 2007; 33:666.",
"     </a>",
"    </li>",
"    <li>",
"     American Burn Association. National Burn Repository, Version 5.0 2009. www.ameriburn.org/2009NBRAnnualReport.pdf (Accessed on May 02, 2010).",
"    </li>",
"    <li>",
"     Shafey, O, Eriksen, M, Ross, H, Mackay, J. Costs to the economy. In: The tobacco atlas, 3rd ed, American Cancer Society, Atlanta, Georgia 2009. p. 42. Available online at: www.cancer.org/downloads/AA/TobaccoAtlas3Revised/TA3_Chapter_11.pdf (Accessed on June 10, 2010).",
"    </li>",
"    <li>",
"     Thorpe, T. Critical cost based analysis of inclusive expense to the South African Government of patients with burn injuries sustained from non-pressurised paraffin stoves. Fincore Financial, South Africa 2004.",
"    </li>",
"    <li>",
"     www.safekids.org/our-work/research/fact-sheets/burn-and-scald-prevention-fact-sheet.html (Accessed on April 01, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 823 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17716=[""].join("\n");
var outline_f17_19_17716=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COSTS OF FIRES AND BURNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cost of anticipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cost of response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cost as a consequence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COSTS BY CLINICAL AND PHYSICAL VARIABLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cost by age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cost by burn size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cost by mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fire/flames alone and fire with smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Scald",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Contact with hot object",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/823\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/823|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/16/32014\" title=\"figure 1\">",
"      Number of burns US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/51/38718\" title=\"figure 2\">",
"      Burn costs cost US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/823|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/48/1806\" title=\"table 1\">",
"      Direct global costs burns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/54/40811\" title=\"table 2\">",
"      LOS and inhalation injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23865?source=related_link\">",
"      Epidemiology of burn injuries globally",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_19_17717="Oral and enteral iron supplements: Pediatric drug information";
var content_f17_19_17717=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oral and enteral iron supplements: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Iron Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineral, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:  Multiple salt forms of iron exist; close attention must be paid to the salt form when ordering and administering iron; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or underdosing.",
"     </b>",
"     Dose expressed in terms of",
"     <b>",
"      elemental",
"     </b>",
"     iron.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Recommended daily allowance of iron: 5 mg elemental iron",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature neonates: Treatment and prevention of iron deficiency: 2-4 mg elemental iron/kg/day divided every 12-24 hours (maximum dose: 15 mg/day) (Baker, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Term neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment, severe iron deficiency anemia: 4-6 mg elemental iron/kg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment, mild to moderate iron deficiency anemia: 3 mg elemental iron/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis, iron deficiency anemia: 1-2 mg elemental iron/kg/day (maximum dose: 15 mg elemental iron/day);",
"     <b>",
"      Note:",
"     </b>",
"     In healthy, term infants, AAP does",
"     <b>",
"      not",
"     </b>",
"     recommend routine additional supplementation of iron be considered until at least 4-6 months of age if breast-fed (full or partial) (Baker, 2010; Schanler, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note: Multiple salt forms of iron exist; close attention must be paid to the salt form when ordering and administering iron; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or underdosing.",
"     </b>",
"     Dose expressed in terms of",
"     <b>",
"      elemental",
"     </b>",
"     iron.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recommended Daily Allowance: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Recommended Daily Allowance of Iron:",
"      <b>",
"       (Dosage expressed as elemental iron)",
"      </b>",
"     </caption>",
"     <col align=\"left\" width=\"175\">",
"     </col>",
"     <col align=\"center\" width=\"175\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         RDA",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;5 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         5 mo to 10 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Male",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         11-18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         &gt;18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Female",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         11-50 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         &gt;50 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Treatment and prevention of iron deficiency:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Treatment, severe iron deficiency anemia: 4-6 mg elemental iron/kg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Treatment, mild to moderate iron deficiency anemia: 3 mg elemental iron/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Prophylaxis, iron deficiency anemia: 1-2 mg elemental iron/kg/day (maximum dose: 15 mg elemental iron/day);",
"     <b>",
"      Note:",
"     </b>",
"     In healthy, term infants, AAP does",
"     <b>",
"      not",
"     </b>",
"     recommend routine additional supplementation of iron be considered until at least 4-6 months of age if breast-fed (full or partial) (Baker, 2010; Schanler, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Iron deficiency: 2-3 mg/kg/day or 60-100 mg elemental iron twice daily up to 60 mg elemental iron 4 times/day, or 50 mg elemental iron (extended release) 1-2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Prophylaxis: 60-100 mg elemental iron/day",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Iron Content of Iron Salts",
"     </caption>",
"     <col align=\"left\" width=\"220\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Iron Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Iron Content",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (% of salt form)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Equivalent Doses",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg of iron salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous fumarate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         33",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         197",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         560",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous sulfate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         324",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous sulfate, exsiccated",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         217",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F243714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amount of",
"     <b>",
"      elemental",
"     </b>",
"     iron is listed in brackets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ferrous fumarate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule, controlled release (Span-FF&reg;): 325 mg [106 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Drops (Feostat&reg;): 45 mg/0.6 mL [15 mg/0.6 mL] (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension, oral (Feostat&reg;): 100 mg/5 mL [33 mg/5 mL] (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: 325 mg [106 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Femiron&reg;: 63 mg [20 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fumerin&reg;: 195 mg [64 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fumasorb&reg;, Ircon&reg;: 200 mg [66 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemocyte&reg;: 324 mg [106 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nephro-Fer&trade;: 350 mg [115 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet, chewable (chocolate flavor): Feostat&reg;: 100 mg [33 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet, timed release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ferro-Sequels&reg;: 150 mg [50 mg] with docusate sodium 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ferrous gluconate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule, soft gelatin (Simron&reg;): 86 mg [10 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elixir (Fergon&reg;): 300 mg/5 mL [34 mg/5 mL] with alcohol 7% (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: 300 mg [34 mg]; 325 mg [38 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fergon&reg;, Ferralet&reg;: 320 mg [37 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustained release (Ferralet&reg; Slow Release): 320 mg [37 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ferrous sulfate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Exsiccated (Fer-In-Sol&reg;): 190 mg [60 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Exsiccated, timed release (Feosol&reg;): 159 mg [50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Exsiccated, timed release (Ferralyn&reg; Lanacaps&reg;, Ferra-TD&reg;): 250 mg [50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ferospace&reg;: 250 mg [50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Drops, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fer-In-Sol&reg;: 75 mg/0.6 mL [15 mg/0.6 mL] (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fer-Iron&reg;: 125 mg/mL [25 mg/mL] (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elixir (Feosol&reg;): 220 mg/5 mL [44 mg/5 mL] with alcohol 5% (473 mL, 4000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Syrup (Fer-In-Sol&reg;): 90 mg/5 mL [18 mg/5 mL] with alcohol 5% (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     324 mg [65 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Exsiccated (Feosol&reg;) 200 mg [65 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Exsiccated, timed release (Slow FE&reg;): 160 mg [50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Feratab&reg;: 300 mg [60 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mol-Iron&reg;: 195 mg [39 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Timed release (Fero-Gradumet&reg;): 525 mg [105 mg]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Do not chew or crush sustained release preparations; administer with water or juice between meals for maximum absorption; may administer with food if GI upset occurs; do not administer with milk or milk products",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of iron deficiency anemias; supplemental therapy for patients receiving epoetin alfa",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F14198755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: GI irritation, epigastric pain, nausea, diarrhea, dark stools, constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine (black or dark)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Liquid preparations may temporarily stain the teeth",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iron salts or any component; hemochromatosis, hemolytic anemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using for longer than 6 months, except in patients with conditions that require prolonged therapy; avoid in patients with peptic ulcer, enteritis, or ulcerative colitis; avoid in patients receiving frequent blood transfusions",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in premature infants until the vitamin E stores, deficient at birth, are replenished; some products contain sulfites and/or tartrazine which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F243708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption of oral preparation of iron and tetracyclines are decreased when both of these drugs are given together; concurrent administration of antacids and cimetidine may decrease iron absorption; iron may decrease absorption of penicillamine and levodopa when given at the same time; response to iron therapy may be delayed in patients receiving chloramphenicol; concurrent administration &ge;200 mg vitamin C per 30 mg elemental iron increases absorption of oral iron; absorption of quinolones may be decreased due to formation of a ferric ion-quinolone complex",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1059490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Milk, cereals, dietary fiber, tea, coffee, or eggs decrease absorption of iron.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F243710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum iron, total iron binding capacity, reticulocyte count, hemoglobin, ferritin",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1059482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum iron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 110-270 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 30-70 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 55-120 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Male: 75-175 mcg/dL; Female: 65-165 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Total iron binding capacity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 59-175 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 100-400 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adults: 230-430 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transferrin: 204-360 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Percent transferrin saturation: 20% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Iron levels &gt;300 mcg/dL may be considered toxic; should be treated as an overdosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ferritin: 13-300 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron is released from the plasma and eventually replenishes the depleted iron stores in the bone marrow where it is incorporated into hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Peak reticulocytosis occurs in 5-10 days, and hemoglobin values increase within 2-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Iron is absorbed in the duodenum and upper jejunum; in persons with normal iron stores 10% of an oral dose is absorbed, this is increased to 20% to 30% in persons with inadequate iron stores; food and achlorhydria will decrease absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Iron is largely bound to serum transferrin and excreted in the urine, sweat, sloughing of intestinal mucosa, and by menses",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May color the stools and urine black; do not take within 2 hours of tetracyclines or fluoroquinolones, do not take with milk or antacids; keep out of reach of children",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1059489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When treating iron deficiency anemias, treat for 3-4 months after hemoglobin/hematocrit return to normal in order to replenish total body stores; elemental iron dosages as high as 15 mg/kg/day have been used to supplement neonates receiving concomitant epoetin alpha in the treatment of anemia of prematurity",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baker RD, Greer FR, and Committee on Nutrition American Academy of Pediatrics, \"Diagnosis and Prevention of Iron Deficiency and Iron-Deficiency Anemia in Infants and Young Children (0-3 Years of Age),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(5):1040-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/19/17717/abstract-text/20923825/pubmed\" id=\"20923825\" target=\"_blank\">",
"        20923825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schanler RJ, Feldman-Winter L, Landers S, et al, \"Concerns With Early Universal Iron Supplementation of Breastfeeding Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2011, 127(4):e1097.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13390 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17717=[""].join("\n");
var outline_f17_19_17717=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059479\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443753\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059472\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F243714\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059484\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059483\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14198755\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059488\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059471\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059470\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F243708\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059490\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F243710\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059478\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059482\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059469\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059486\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059487\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059477\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059489\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13390\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13390|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_19_17718="Pathogenesis of vegetation formation in infective endocarditis";
var content_f17_19_17718=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of vegetation formation in infective endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17718/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17718/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17718/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17718/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17718/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17718/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/19/17718/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1168016430\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis arises when an adherent platelet-fibrin nidus becomes secondarily infected and produces vegetations, which in turn may directly damage the endocardial tissue",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    valves. The pathogenesis of infective endocarditis will be reviewed here.",
"   </p>",
"   <p>",
"    Other aspects of infective endocarditis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=see_link\">",
"     \"Epidemiology, risk factors and microbiology of infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40215?source=see_link\">",
"     \"Infective endocarditis in injection drug users\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=see_link\">",
"     \"Infective endocarditis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"     \"Complications and outcome of infective endocarditis\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endothelial lining of the heart and its valves is normally resistant to infection with bacteria and fungi. Experiments in animal models have demonstrated that a sequence of interrelated events must occur before microbes can establish an infective nidus or vegetation on the endocardium:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although a few highly virulent organisms such as Staphylococcus aureus are capable of infecting normal human heart valves, the initial step in the establishment of a vegetation is injury to the endocardium, followed by focal adherence of platelets and fibrin.",
"     </li>",
"     <li>",
"      The initially sterile platelet-fibrin nidus then becomes infected by microorganisms circulating in the bloodstream, either from a distant source of focal infection, or as a result of transient bacteremia from a mucosal or skin source [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Following colonization of the platelet-fibrin aggregate, microbial growth results in the secondary accumulation of more platelets and fibrin and the further activation of the coagulation system via the extrinsic clotting pathway, until a macroscopic excrescence or vegetation is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Endocardial injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is virtually impossible to induce endocarditis in experimental animals unless the valvular endocardium is first traumatized with a polyethylene catheter inserted into the right or left side of the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/1\">",
"     1",
"    </a>",
"    ]. The corollary to this observation is that animals with prior catheter-induced valvular lesions that are injected with bacteria such as viridans streptococci (that have the inherent ability to adhere to fibrin-platelet matrices on damaged endocardium) predictably develop a vegetation at the site of valve injury within a few days. Similar lesions probably occur naturally in bacteremic humans with congenital or acquired cardiac lesions that induce continuous endocardial trauma via regurgitant flow or high pressure jets of blood through stenotic lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Microbial adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microbial adherence is a crucial early event in the pathogenesis of endocarditis. As an example, bacteria that are typically found in patients with endocarditis, such as Staphylococcus aureus, viridans streptococci, enterococci and P. aeruginosa, adhere more avidly to excised canine heart valves in vitro than species that rarely cause endocarditis (such as Escherichia coli) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacterial adherence to a platelet-fibrin nidus involves a complex interaction of components of the microbial cell wall. The mechanism of this adherence is poorly understood, however, and may vary among different organisms. Animal models have provided some useful data regarding the pathogenesis of adherence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The relative frequency with which different species of bacteria cause endocarditis in humans is correlated with the ability of these same organisms to cause endocarditis in an experimental rabbit model [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/4\">",
"       4",
"      </a>",
"      ]. In rabbits, the amount of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"       dextran",
"      </a>",
"      produced by streptococci grown in broth is proportional to the intrinsic ability of various species of streptococci to cause endocarditis, suggesting that an interaction between dextran in the cell wall of gram-positive organisms and the valvular endothelium is important [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intrinsic binding affinity to fibronectin also appears to be a contributing pathogenic factor, since mutants of Staphylococcus aureus with decreased ability to bind fibronectin have less ability to cause endocarditis in a rat endocarditis model than parent strains with higher binding affinity to fibronectin [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glucosyltransferases (GTFs), which are proteins made by various members of the viridans group of streptococci, have the ability to convert sucrose into polysaccharides which in turn may act as \"modulins\" to express various cytokines (such as interleukin-6) or adhesions that in turn further recruit leukocytes into the vegetations [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors may be important in bacterial adherence. As an example, components found in damaged endothelium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    platelet-fibrin aggregates that may mediate adherence include fibrinogen, laminin, and type 4 collagen. Furthermore, bacterial-platelet interactions appear to be important in both the induction of a vegetation, and in its enlargement after colonization of a fibrin-platelet nidus has occurred.",
"   </p>",
"   <p>",
"    Acetylsalicylic acid was shown to have an effect on both platelets and organisms in a rabbit model of S. aureus endocarditis; animals treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    had reduction in the weight of valvular vegetations, vegetation growth, density of bacteria in the kidneys and in vegetations, and a decrease in embolic events compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Source of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bacterial source in some patients with endocarditis is obvious (eg, an infected vascular catheter, a dental abscess, or an infected skin lesion), but in many patients there is no history of an antecedent localized infection. In most of these instances, the source is presumed to be from minor trauma to the oropharyngeal, gastrointestinal, or genitourinary mucosa.",
"   </p>",
"   <p>",
"    Endocarditis in injection drug users can occur in patients without known preexisting cardiac disease. In such cases, infection is presumed to be a consequence of the trauma to heart valves from contaminating inorganic debris and bacteria injected along with the illicit drugs, from the paraphernalia used for drug injection, or from bacteria on the skin surface at the site of injection. These patients often develop infection on their tricuspid valves, although some patients only have vegetations on the left side of the heart, and others have simultaneous involvement of left and right-sided heart valves.",
"   </p>",
"   <p>",
"    Preexisting antibodies against certain bacteria may increase the predisposition to infective endocarditis in some instances. For example, horses that are given repetitive injections of live pneumococci often spontaneously develop pneumococcal endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/9\">",
"     9",
"    </a>",
"    ]. In some animal models of endocarditis, however, preexisting high antibody levels increase the median infective dose required to induce endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Location of vegetations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vegetations tend to occur when blood travels from an area of high pressure through a narrow orifice into an area of lower pressure. The explanation for this phenomenon can be deduced from in vitro experiments that demonstrate the physics of turbulent flow. If nebulized Serratia marcescens, for example, are injected into an air stream passing through an agar-coated Venturi tube, the highest concentration of bacteria is found in the low pressure area immediately distal to the narrowing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar phenomenon is presumed to occur when bacteria circulate in the blood:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vegetations in patients with preexisting valvular lesions are usually located on the atrial surface of incompetent atrioventricular valves or the ventricular surface of incompetent semilunar valves.",
"     </li>",
"     <li>",
"      Patients with ventricular septal defects tend to develop vegetations on the orifice of the defect, on the right ventricular side of the opening, and secondarily on the tricuspid and pulmonic valves [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vegetations may occasionally localize on the chordae tendineae of the anterior leaflet of the mitral valve in patients with aortic insufficiency.",
"     </li>",
"     <li>",
"      Patients with mitral regurgitation may develop vegetations (MacCallum's patch) on the wall of the left atrium where the regurgitant jet strikes the atrial wall and results in endocardial thickening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The propensity for vegetations to form at specific sites may also relate to a decrease in lateral pressure downstream from the regurgitant flow (which causes a decrease in the perfusion of the intimal lining at these sites) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY OF VEGETATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The culmination of this pathogenic process is a mature vegetation consisting of an amorphous collection of fibrin, platelets, leukocytes, red blood cell debris, and dense clusters of bacteria. The surface of most vegetations consists of fibrin and varying numbers of leukocytes. Clumps of bacteria, histiocytes, and monocytes are usually found deep within the vegetation. Giant cells containing phagocytic bacteria may also be seen in some vegetations.",
"   </p>",
"   <p>",
"    Vegetations are avascular structures. Following therapy and during the process of healing, however, capillaries and fibroblasts appear.",
"   </p>",
"   <p>",
"    Extremely high concentrations of bacteria (eg, 10",
"    <sup>",
"     9",
"    </sup>",
"    to 10",
"    <sup>",
"     11",
"    </sup>",
"    <span class=\"nowrap\">",
"     CFU/gram",
"    </span>",
"    of tissue) may accumulate deep within vegetations. Some of these bacteria exist in a state of reduced metabolic activity.",
"   </p>",
"   <p>",
"    A study compared the histologic features of vegetations surgically removed from 21 patients with proven prosthetic valve endocarditis with the histological features of noninfected but dysfunctional valves removed from 67 patients without endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/13\">",
"     13",
"    </a>",
"    ]. Infected valves showed microorganisms and inflammatory infiltrates containing neutrophils. In contrast, the inflammatory adherent thrombi from noninfected valves contained mostly lymphocytes and macrophages and microorganisms were not present.",
"   </p>",
"   <p>",
"    Polymerase chain reaction-based testing of vegetations may reveal the presence of bacterial DNA months and even years after completion of seemingly successful therapy of IE. It is unknown if such results are due to persistence of viable organisms deep within vegetations or persistence of nonviable bacterial debris within the vegetations, although the latter seems most likely [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL CONSEQUENCES OF VALVULAR INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vegetations often prevent proper valvular leaflet or cusp coaptation, thereby causing valvular incompetence. A number of other complications may result from valvular infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congestive heart failure may result from worsening valvular incompetence [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/15\">",
"       15",
"      </a>",
"      ] or leaflet perforation secondary to vegetation growth [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/16\">",
"       16",
"      </a>",
"      ]. In one study of 58 patients, leaflet perforation was documented in 34 percent and was associated with an increase in mortality (25 versus 5 percent for those without perforation) and in congestive heart failure resulting in early valve surgery (70 versus 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with mitral or tricuspid valve vegetations may develop chordal rupture when infection progresses beyond the valve orifice.",
"     </li>",
"     <li>",
"      Infection may also extend into surrounding structures such as the valve ring, the adjacent myocardium, the cardiac conduction system, or the mitral-aortic intravalvular fibrosa [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rarely, cavitation of periaortic abscesses occurs into the adjacent aortic wall, resulting in the formation of a diverticulum or aneurysm. Even more rarely, such aneurysms perforate into surrounding structures, resulting in aortic-atrial or aortic-pericardial fistulae [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2926042\">",
"    <span class=\"h1\">",
"     SIGNIFICANCE OF VEGETATION SIZE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with large vegetations (&gt;10 mm) have been considered by some experts to be at higher risk of complications such as embolism, and some consider this as an indication for surgery in patients with left-side endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"     \"Complications and outcome of infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link&amp;anchor=H10#H10\">",
"     \"Surgery for native valve endocarditis\", section on 'Relative indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multicenter prospective study involving 330 episodes of definite endocarditis concluded the following [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean vegetation size at admission was 14.45",
"      <span class=\"nowrap\">",
"       +/-7.66",
"      </span>",
"      mm",
"     </li>",
"     <li>",
"      Larger vegetations were observed in patients with native mitral valve endocarditis and pacemaker endocarditis and in patients in whom an embolism had occurred before admission",
"     </li>",
"     <li>",
"      Smaller vegetations were observed in patients with metallic valve prostheses and aortic valve infection",
"     </li>",
"     <li>",
"      No differences in vegetation size was observed by the type of causative microorganism",
"     </li>",
"     <li>",
"      Vegetation size at admission was associated with a higher rate of persistent infection and septic shock &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IMPACT OF ANTIMICROBIAL THERAPY ON VEGETATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac vegetations may disappear or persist following therapy for infective endocarditis. Echocardiography may reveal persistent vegetations for months or years after successful treatment of endocarditis. A retrospective study of the histopathologic findings in 480 patients with infective endocarditis who underwent valve replacement or repair procedures showed the following clinically important findings [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17718/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Valvular specimens from patients undergoing surgery before the completion of a standard course of antimicrobial therapy show microorganisms by Gram stain or histologic examination in the majority of cases. Gram stain of resected vegetations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      valves showed organisms in 231 of 285 cases (81 percent) and histolopathologic examination showed microorganisms in 140 of 208 specimens (67 percent).",
"     </li>",
"     <li>",
"      The presence of microorganisms using Gram stain or histopathologic staining of resected specimens does not imply treatment failure in patients undergoing surgery before completion of antimicrobial therapy. The only reliable method to determine the efficacy of treatment in such cases is culture of the excised tissue because it may take months for dead bacteria in a vegetation to be removed via the process of bacterial cell lysis or phagocytosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1168016718\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The endothelial lining of the heart and its valves is normally resistant to infection with bacteria and fungi. Experiments in animal models have demonstrated that a sequence of interrelated events must occur before microbes can establish an infective nidus or vegetation on the endocardium:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Although a few highly virulent organisms such as Staphylococcus aureus are capable of infecting normal human heart valves, the initial step in the establishment of a vegetation is injury to the endocardium, followed by focal adherence of platelets and fibrin.",
"     </li>",
"     <li>",
"      The initially sterile platelet-fibrin nidus then becomes infected by microorganisms circulating in the bloodstream, either from a distant source of focal infection, or as a result of transient bacteremia from a mucosal or skin source.",
"     </li>",
"     <li>",
"      Following colonization of the platelet-fibrin aggregate, microbial growth results in the secondary accumulation of more platelets and fibrin and the further activation of the coagulation system via the extrinsic clotting pathway, until a macroscopic excrescence or vegetation is present. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vegetations tend to occur when blood travels from an area of high pressure through a narrow orifice into an area of lower pressure. Vegetations in patients with preexisting valvular lesions are usually located on the atrial surface of incompetent atrioventricular valves or the ventricular surface of incompetent semilunar valves. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Location of vegetations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The culmination of this pathogenic process is a mature vegetation consisting of an amorphous collection of fibrin, platelets, leukocytes, red blood cell debris, and dense clusters of bacteria. The surface of most vegetations consists of fibrin and varying numbers of leukocytes. Clumps of bacteria, histiocytes, and monocytes are usually found deep within the vegetation. Extremely high concentrations of bacteria may accumulate deep within vegetations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathology of vegetations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vegetations often prevent proper valvular leaflet or cusp coaptation, thereby causing valvular incompetence. A number of other complications may result from valvular infection, including congestive heart failure, leaflet perforation, chordal rupture, extension into surrounding structures, or formation of a diverticulum, aneurysm, or fistula. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical consequences of valvular infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with large vegetations (&gt;10 mm) have been considered by some experts to be at higher risk of complications, such as embolism, and some consider this as an indication for surgery in patients with left-side endocarditis. (See",
"      <a class=\"local\" href=\"#H2926042\">",
"       'Significance of vegetation size'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac vegetations may disappear or persist following therapy for infective endocarditis. Echocardiography may reveal persistent vegetations for months or years after successful treatment of endocarditis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Impact of antimicrobial therapy on vegetations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/1\">",
"      Garrison PK, Freedman LR. Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart. Yale J Biol Med 1970; 42:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/2\">",
"      Durack DT, Beeson PB. Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. Br J Exp Pathol 1972; 53:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/3\">",
"      Gould K, Ramirez-Ronda CH, Holmes RK, Sanford JP. Adherence of bacteria to heart valves in vitro. J Clin Invest 1975; 56:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/4\">",
"      Freedman LR, Valone J Jr. Experimental infective endocarditis. Prog Cardiovasc Dis 1979; 22:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/5\">",
"      Scheld WM, Valone JA, Sande MA. Bacterial adherence in the pathogenesis of endocarditis. Interaction of bacterial dextran, platelets, and fibrin. J Clin Invest 1978; 61:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/6\">",
"      Kuypers JM, Proctor RA. Reduced adherence to traumatized rat heart valves by a low-fibronectin-binding mutant of Staphylococcus aureus. Infect Immun 1989; 57:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/7\">",
"      Yeh CY, Chen JY, Chia JS. Glucosyltransferases of viridans group streptococci modulate interleukin-6 and adhesion molecule expression in endothelial cells and augment monocytic cell adherence. Infect Immun 2006; 74:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/8\">",
"      Kupferwasser LI, Yeaman MR, Shapiro SM, et al. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation 1999; 99:2791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/9\">",
"      Mair, W. Pneumococcal endocarditis in rabbits. J Pathol Bacteriol 1923; 26:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/10\">",
"      Durack DT, Gilliland BC, Petersdorf RG. Effect of immunization on susceptibility to experimental Streptococcus mutans and Streptococcus sanguis endocarditis. Infect Immun 1978; 22:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/11\">",
"      RODBARD S. Blood velocity and endocarditis. Circulation 1963; 27:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/12\">",
"      Bansal RC. Infective endocarditis. Med Clin North Am 1995; 79:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/13\">",
"      Lepidi H, Casalta JP, Fournier PE, et al. Quantitative histological examination of bioprosthetic heart valves. Clin Infect Dis 2006; 42:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/14\">",
"      Lang S, Watkin RW, Lambert PA, et al. Detection of bacterial DNA in cardiac vegetations by PCR after the completion of antimicrobial treatment for endocarditis. Clin Microbiol Infect 2004; 10:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/15\">",
"      Weinstein L. Life-threatening complications of infective endocarditis and their management. Arch Intern Med 1986; 146:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/16\">",
"      Yvorchuk KJ, Chan KL. Application of transthoracic and transesophageal echocardiography in the diagnosis and management of infective endocarditis. J Am Soc Echocardiogr 1994; 7:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/17\">",
"      De Castro S, d'Amati G, Cartoni D, et al. Valvular perforation in left-sided infective endocarditis: a prospective echocardiographic evaluation and clinical outcome. Am Heart J 1997; 134:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/18\">",
"      Karalis DG, Bansal RC, Hauck AJ, et al. Transesophageal echocardiographic recognition of subaortic complications in aortic valve endocarditis. Clinical and surgical implications. Circulation 1992; 86:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/19\">",
"      M&uuml;gge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. J Am Coll Cardiol 1989; 14:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/20\">",
"      Luaces M, Vilacosta I, Fern&aacute;ndez C, et al. Vegetation size at diagnosis in infective endocarditis: influencing factors and prognostic implications. Int J Cardiol 2009; 137:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17718/abstract/21\">",
"      Morris AJ, Drinkovic D, Pottumarthy S, et al. Gram stain, culture, and histopathological examination findings for heart valves removed because of infective endocarditis. Clin Infect Dis 2003; 36:697.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2140 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17718=[""].join("\n");
var outline_f17_19_17718=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1168016718\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1168016430\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Endocardial injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Microbial adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Source of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Location of vegetations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY OF VEGETATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL CONSEQUENCES OF VALVULAR INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2926042\">",
"      SIGNIFICANCE OF VEGETATION SIZE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IMPACT OF ANTIMICROBIAL THERAPY ON VEGETATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1168016718\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=related_link\">",
"      Infective endocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40215?source=related_link\">",
"      Infective endocarditis in injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=related_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_19_17719="Arrhythmic complications of mitral valve prolapse";
var content_f17_19_17719=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Arrhythmic complications of mitral valve prolapse",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17719/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17719/contributors\">",
"     Matthew J Sorrentino, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17719/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17719/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17719/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17719/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17719/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/19/17719/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 18, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral valve prolapse (MVP) is the most common cause of primary mitral regurgitation (MR) in developed countries. The diagnosis is usually suspected from cardiac auscultation and then confirmed by echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=see_link\">",
"     \"Definition and diagnosis of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the correlation between certain nonspecific symptoms and MVP remains unclear, many patients with this disorder present with palpitations and atrial or ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Some studies suggest that these patients are at increased risk of sudden cardiac death (SCD) compared with the general population, but the exact incidence is unknown. Furthermore, since atrial and ventricular arrhythmias are common in the general population, it is not clearly established that the incidence of arrhythmias and SCD are in fact increased in patients with MVP.",
"   </p>",
"   <p>",
"    This topic will review the incidence of arrhythmias, the risk of SCD, the electrocardiographic abnormalities that can be seen, and the treatment of arrhythmias in patients with MVP. The nonarrhythmic complications of MVP, including nonspecific symptoms and major complications, such as infective endocarditis, MR, transient ischemic attacks, and cerebrovascular accidents, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=see_link\">",
"     \"Nonarrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3476?source=see_link\">",
"     \"Mitral valve prolapse syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE OF ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies report a broad range in incidence of the arrhythmias in patients with mitral valve prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrial premature beats &mdash; 35 to 90 percent",
"     </li>",
"     <li>",
"      Paroxysmal supraventricular tachycardia &mdash; 3 to 32 percent",
"     </li>",
"     <li>",
"      Ventricular premature beats &mdash; 58 to 89 percent",
"     </li>",
"     <li>",
"      Complex ventricular ectopy &mdash; 30 to 56 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This wide variability is most likely due to selection bias and to the heterogeneity of the populations studied. Most studies have been performed in adults, but ventricular arrhythmias have also been reported in children with MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    What remains unclear is whether the incidence of one or more of these arrhythmias in adults with MVP is higher than in controls. Some well-controlled studies do not show an increased incidence of arrhythmias in MVP. The Framingham Heart Study compared 84 patients with MVP, based upon current two-dimensional echocardiographic criteria, with 3403 control subjects without MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/8\">",
"     8",
"    </a>",
"    ]. On average, the patients in this study had trace to mild mitral regurgitation (MR). The prevalence of atrial ectopy (3.2 versus 1.6 percent), atrial fibrillation (1.2 versus 1.7 percent), and ventricular ectopy (2.6 versus 1.4) was equivalent in the two groups. This study suggests that MVP without significant MR is not associated with excess risk of atrial or ventricular arrhythmias.",
"   </p>",
"   <p>",
"    Arrhythmias may be more common in patients with MVP who develop MR, a population that may be overrepresented in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients with MR and MVP have more ventricular arrhythmias than those with MVP alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/10\">",
"     10",
"    </a>",
"    ]. The presence of moderate to severe MR is an independent predictor of ventricular arrhythmias in patients with MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/11\">",
"     11",
"    </a>",
"    ]. Atrial arrhythmias are also more common in those with MVP and MR than in those with MVP alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/10\">",
"     10",
"    </a>",
"    ]. The presence of moderate to severe MR is an independent predictor of atrial arrhythmias in patients with MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In echocardiographic series of patients with MVP, the observed frequency of atrial fibrillation (AF) has varied from 1 to 25 percent or more [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/13\">",
"     13",
"    </a>",
"    ]. In a study of 246 patients with MVP with MR undergoing mitral valve surgery, the frequency of chronic AF was 15 percent, and paroxysmal AF occurred in 13 percent. Risk factors for development of AF were evaluated in 89 patients with moderate to severe MR and simple mitral valve prolapse and 360 patients with flail mitral leaflets [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/14\">",
"     14",
"    </a>",
"    ]. In both groups, the predictors of AF were age and left atrial diameter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SUDDEN CARDIAC DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac death (SCD) in patients with MVP is usually due to ventricular fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the relation between MVP and SCD is uncertain. Consistent with a causative role for MVP is the observation that MVP is the only cardiac abnormality in some patients at autopsy and in certain survivors of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/15-21\">",
"     15-21",
"    </a>",
"    ]. MVP is also the only cardiac abnormality found in 8 to 16 percent of patients with refractory ventricular tachycardia (VT) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. On the other hand, both SCD and VT can occur in patients without apparent structural heart disease, and it is not clear that other causes of SCD and VT were excluded in the above reports. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of SCD in patients with MVP is not clearly established. One estimate of the risk of SCD in patients with MVP without MR was 1.9 per 10,000 patients per year [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/1\">",
"     1",
"    </a>",
"    ]. The risk was estimated to be 50 to 100 times higher (0.9 to 1.9 percent per year) if significant MR is present; this is the rate that was later observed in patients with flail mitral leaflet. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Flail mitral leaflet'",
"    </a>",
"    below.) In series including patients with MVP with a spectrum of MR severity, an intermediate risk of SCD has been observed. Two such series of 237 and 300 patients, both with mean follow-up of six years, found that SCD occurred in 2.5 and 1.0 percent (0.4 and 0.2 percent per year), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early small series of patients with MVP suggested an association between the following factors and increased risk of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/1-3,17,22\">",
"     1-3,17,22",
"    </a>",
"    ]: history of syncope or near syncope, symptoms such as palpitations, chest pain, and dyspnea, prolonged QT interval or inferolateral repolarization abnormalities, frequent or complex ventricular premature beats, prolapse of both the anterior and posterior mitral valve leaflets, hemodynamically significant mitral regurgitation, and flail mitral leaflet. The increased risk of SCD associated with flail mitral leaflet was confirmed in a large series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Flail mitral leaflet'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A study of 237 patients found a higher incidence of SCD (approximately 1.6 percent per year) in patients with redundant (defined as thickness of 5 mm or more) mitral valve leaflets as compared with the rate (approximately 0.1 percent per year) for those without redundant leaflets [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased risk of SCD associated with MR may be directly related to the valvular regurgitation, rather than MVP itself. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonarrhythmic complications of mitral valve prolapse\", section on 'Mitral regurgitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;As for other patient populations, prior cardiac arrest or sustained VT are strong predictors of SCD in individuals with MVP. While other clinical risk factors for sudden death, such as the presence of flail leaflet or the presence of significant mitral regurgitation, have been proposed, no specific recommendations for risk stratification of patients with MVP have been defined.",
"   </p>",
"   <p>",
"    The 2006 American College of Cardiology",
"    <span class=\"nowrap\">",
"     /American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     /European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for ventricular arrhythmias and sudden cardiac death recommended that patients with valvular heart disease and ventricular arrhythmias should be evaluated and treated following current recommendations for each disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/24\">",
"     24",
"    </a>",
"    ]. No specific risk stratification of patients with MVP for SCD was recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Flail mitral leaflet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with MVP, SCD appears be more common in patients with chordal rupture resulting in a flail mitral leaflet, particularly those treated conservatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted in a retrospective report of 348 patients with flail mitral leaflet who were followed for a mean of four years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated sudden death rate at 5 and 10 years was 8.6 and 18.8 percent, respectively. The linearized rate was 1.8 percent per year.",
"     </li>",
"     <li>",
"      Independent predictors of sudden death were NYHA class III and IV (7.8 versus 1.0 and 3.1 percent per year in class I and II, respectively), LVEF less than 50 percent (12.7 versus about 1.2 percent with LVEF above 50 percent), and AF (4.9 versus 1.3 percent per year with sinus rhythm).",
"     </li>",
"     <li>",
"      Twenty percent of patients with sudden death had none of these risk factors; the yearly rate of sudden death in this setting was 0.8 percent. Other comorbidities prevalent in these patients may have been important.",
"     </li>",
"     <li>",
"      Surgical correction of the flail leaflet reduced the incidence of sudden death (adjusted hazard ratio 0.29).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Causes of sudden cardiac arrest generally are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ELECTROCARDIOGRAPHIC ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several electrocardiographic abnormalities have been reported in patients with MVP, including QT interval prolongation, repolarization abnormalities, and evidence for accessory pathways. These findings, however, are not supported by all surveys of patients with MVP. As an example, some studies report that as many as 75 percent of patients with MVP have QT interval prolongation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, at least two series found no increase in QT prolongation compared with control populations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. The Framingham Heart Study found no difference in the prevalence of left ventricular hypertrophy or left atrial enlargement between those with and without MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also no evidence to indicate an increased prevalence of accessory pathways in patients with MVP. In addition, the claim that ST segment and T wave abnormalities are more common in MVP is controversial, as is the possible link between repolarization abnormalities and arrhythmias. One study noted greater dispersion of refractoriness in 32 patients with MVP and documented ventricular arrhythmias, although the QT interval was not prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/26\">",
"     26",
"    </a>",
"    ]. This raises the possibility that regional shortening and lengthening of repolarization times may be a mechanism for arrhythmias and SCD in MVP.",
"   </p>",
"   <p>",
"    The role of the signal-averaged ECG for the evaluation of ventricular arrhythmias is also unclear. Although late potentials have been identified in patients with MVP, the sensitivity of late potentials as a predictor of ventricular tachycardia appears to be low (eg, sensitivity of 52 percent and specificity of 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/4,7,27\">",
"     4,7,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21325375\">",
"    <span class=\"h1\">",
"     CMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a cardiovascular magnetic resonance (CMR) imaging report, focal late gadolinium enhancement in the papillary muscles was observed in patients with MVP, particularly in those with complex ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/28\">",
"     28",
"    </a>",
"    ]. The clinical significance of this observation has not been determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiologic (EP) testing has been used in an attempt to understand the role of arrhythmias in patients with MVP. Unfortunately, the data are again conflicting. It has been suggested that patients with symptoms or documented arrhythmias are more likely to have inducible ventricular tachycardia. However, an analysis of six fairly rigorous studies found that only 6 out of 100 patients with symptomatic or asymptomatic nonsustained ventricular tachycardia had inducible sustained monomorphic ventricular tachycardia; as a result, the association between inducibility and clinical symptoms is unlikely to be valid [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to its role in other patient groups, EP testing is not generally performed in survivors of SCD or sustained VT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link&amp;anchor=H18#H18\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\", section on 'EP study'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of arrhythmias in patients with MVP varies with the clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Survivors of SCD or sustained VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of SCD or sustained VT with structural heart disease are considered to be at high risk for subsequent SCD. An implantable cardioverter-defibrillator (ICD) is recommended in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H20#H20\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'ICD therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Very symptomatic palpitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type and presence of arrhythmias in patients with marked symptoms due to palpitations should be documented by either 24-hour Holter or transtelephonic monitoring. Treatment is then initiated based upon both the arrhythmia and the severity of symptoms. The benefit derived from the relief of symptoms with treatment must be weighed against the possible proarrhythmic and other side effects of many antiarrhythmic drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=see_link\">",
"     \"Overview of palpitations in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mild palpitations from atrial or ventricular premature beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with mild palpitations from premature beats can be treated conservatively with reassurance, abstinence from alcohol or stimulants such as caffeine or nicotine, and participation in an exercise program. Beta blockers can occasionally be used; they are particularly effective in patients with inappropriate heart rate responses to stress, anxiety, or activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link\">",
"     \"Clinical significance and treatment of ventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, it is not clear if the incidence of atrial fibrillation (AF) is increased in patients with MVP who have no or mild MR [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/8\">",
"     8",
"    </a>",
"    ]. The risk of atrial fibrillation is related to MR, age, and atrial size.",
"   </p>",
"   <p>",
"    The role of antithrombotic therapy in patients with MVP with and without AF is presented separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=see_link&amp;anchor=H13#H13\">",
"     \"Nonarrhythmic complications of mitral valve prolapse\", section on 'Recommendations for antithrombotic therapy'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, the development of new-onset AF in patients with MVP and severe MR is an indication for corrective surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Asymptomatic patients without evidence of sustained arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that therapy will offer any survival advantage to asymptomatic patients without evidence of sustained arrhythmias. The prognosis in asymptomatic patients with nonsustained arrhythmias and structurally normal hearts is quite good. Thus, the potential deleterious effects of drug therapy probably outweigh any risk from the arrhythmia in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mitral valve surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is a risk of SCD in patients with MVP, particularly among those with flail mitral leaflet treated conservatively, the efficacy of mitral valve repair or replacement in reducing the risk of sudden death in patients with severe MR and ventricular arrhythmias is not well established [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for surgery in patients with mitral valve prolapse and MR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link\">",
"     \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Participation in sports",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular exercise is encouraged in most patients with MVP, particularly those who are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/30\">",
"     30",
"    </a>",
"    ]. An athlete with MVP in sinus rhythm with mild to moderate or less MR, sinus rhythm, normal left ventricular size and function, and normal pulmonary artery pressures can participate in all competitive sports and high-dynamic training unless there are features that may indicate an increased risk for sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. High-risk features include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of syncope associated with documented arrhythmia",
"     </li>",
"     <li>",
"      A family history of MVP-related SCD",
"     </li>",
"     <li>",
"      Sustained or repetitive and nonsustained supraventricular tachycardia or frequent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complex ventricular tachyarrhythmias on ambulatory Holter monitoring",
"     </li>",
"     <li>",
"      Severe mitral valve regurgitation",
"     </li>",
"     <li>",
"      A prior embolic event",
"     </li>",
"     <li>",
"      Left ventricular systolic dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If any of these is present, activity should be restricted to low-intensity competitive sports (class 1A) only (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17719/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31318?source=see_link\">",
"     \"Screening to prevent sudden cardiac death in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sports recommendations for patients with mild or greater MR (of any cause) are detailed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the management of chronic mitral regurgitation\", section on 'Physical activity and exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the potential for worsening of MR and rupture of myxomatous chordae due to the greatly increased systemic vascular resistance occurring with isometric exercise, sports with vigorous isometric components (eg, weight lifting) should be avoided when MVP is associated with marked valvular abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21043120\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial and ventricular arrhythmias have been observed in patients with MVP. However, there is evidence that the prevalence of these arrhythmias is similar to that in the general population, at least among those with trace or mild mitral regurgitation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence of arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk for SCD in patients with MVP appears to vary with severity of accompanying mitral regurgitation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Sudden cardiac death'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A role for electrophysiologic testing in patients with MVP has not been established. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Electrophysiologic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survivors of SCD or sustained VT with structural heart disease are considered to be at high risk for subsequent SCD. An implantable cardioverter-defibrillator (ICD) is recommended in such patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Survivors of SCD or sustained VT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the risk of SCD is increased in patients with flail mitral leaflet, the available evidence is insufficient to establish a role for mitral valve surgery in reducing the risk of SCD. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Flail mitral leaflet'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Mitral valve surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An athlete with MVP in sinus rhythm with mild to moderate or less mitral regurgitation, sinus rhythm, normal left ventricular size and function, and normal pulmonary artery pressures can participate in all competitive sports and high-dynamic training unless there are features that may indicate a high risk for sudden death. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Participation in sports'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/1\">",
"      Kligfield P, Levy D, Devereux RB, Savage DD. Arrhythmias and sudden death in mitral valve prolapse. Am Heart J 1987; 113:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/2\">",
"      Schaal SF. Ventricular arrhythmias in patients with mitral valve prolapse. Cardiovasc Clin 1992; 22:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/3\">",
"      Kligfield P, Devereux RB. Is the mitral valve prolapse patient at high risk of sudden death identifiable? Cardiovasc Clin 1990; 21:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/4\">",
"      Babuty D, Cosnay P, Breuillac JC, et al. Ventricular arrhythmia factors in mitral valve prolapse. Pacing Clin Electrophysiol 1994; 17:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/5\">",
"      Zuppiroli A, Mori F, Favilli S, et al. Arrhythmias in mitral valve prolapse: relation to anterior mitral leaflet thickening, clinical variables, and color Doppler echocardiographic parameters. Am Heart J 1994; 128:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/6\">",
"      Kavey RE, Blackman MS, Sondheimer HM, Byrum CJ. Ventricular arrhythmias and mitral valve prolapse in childhood. J Pediatr 1984; 105:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/7\">",
"      Bobkowski W, Siwi��ska A, Zachwieja J, et al. A prospective study to determine the significance of ventricular late potentials in children with mitral valvar prolapse. Cardiol Young 2002; 12:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/8\">",
"      Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999; 341:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/9\">",
"      Kim S, Kuroda T, Nishinaga M, et al. Relationship between severity of mitral regurgitation and prognosis of mitral valve prolapse: echocardiographic follow-up study. Am Heart J 1996; 132:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/10\">",
"      Kligfield P, Hochreiter C, Kramer H, et al. Complex arrhythmias in mitral regurgitation with and without mitral valve prolapse: contrast to arrhythmias in mitral valve prolapse without mitral regurgitation. Am J Cardiol 1985; 55:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/11\">",
"      Turker Y, Ozaydin M, Acar G, et al. Predictors of ventricular arrhythmias in patients with mitral valve prolapse. Int J Cardiovasc Imaging 2010; 26:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/12\">",
"      Turker Y, Ozaydin M, Acar G, et al. Predictors of atrial arrhythmias in patients with mitral valve prolapse. Acta Cardiol 2009; 64:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/13\">",
"      Berbarie RF, Roberts WC. Frequency of atrial fibrillation in patients having mitral valve repair or replacement for pure mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol 2006; 97:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/14\">",
"      Grigioni F, Avierinos JF, Ling LH, et al. Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. J Am Coll Cardiol 2002; 40:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/15\">",
"      Boudoulas H, Schaal SF, Stang JM, et al. Mitral valve prolapse: cardiac arrest with long-term survival. Int J Cardiol 1990; 26:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/16\">",
"      Vohra J, Sathe S, Warren R, et al. Malignant ventricular arrhythmias in patients with mitral valve prolapse and mild mitral regurgitation. Pacing Clin Electrophysiol 1993; 16:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/17\">",
"      Davies MJ, Moore BP, Braimbridge MV. The floppy mitral valve. Study of incidence, pathology, and complications in surgical, necropsy, and forensic material. Br Heart J 1978; 40:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/18\">",
"      Chesler E, King RA, Edwards JE. The myxomatous mitral valve and sudden death. Circulation 1983; 67:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/19\">",
"      Nishimura RA, McGoon MD, Shub C, et al. Echocardiographically documented mitral-valve prolapse. Long-term follow-up of 237 patients. N Engl J Med 1985; 313:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/20\">",
"      D&uuml;ren DR, Becker AE, Dunning AJ. Long-term follow-up of idiopathic mitral valve prolapse in 300 patients: a prospective study. J Am Coll Cardiol 1988; 11:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/21\">",
"      Anders S, Said S, Schulz F, P&uuml;schel K. Mitral valve prolapse syndrome as cause of sudden death in young adults. Forensic Sci Int 2007; 171:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/22\">",
"      Alpert JS. Association between arrhythmias and mitral valve prolapse. Arch Intern Med 1984; 144:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/23\">",
"      Grigioni F, Enriquez-Sarano M, Ling LH, et al. Sudden death in mitral regurgitation due to flail leaflet. J Am Coll Cardiol 1999; 34:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/24\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/25\">",
"      Sniezek-Maciejewska M, Dubiel JP, Piwowarska W, et al. Ventricular arrhythmias and the autonomic tone in patients with mitral valve prolapse. Clin Cardiol 1992; 15:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/26\">",
"      Tieleman RG, Crijns HJ, Wiesfeld AC, et al. Increased dispersion of refractoriness in the absence of QT prolongation in patients with mitral valve prolapse and ventricular arrhythmias. Br Heart J 1995; 73:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/27\">",
"      Jabi H, Burger AJ, Orawiec B, Touchon RC. Late potentials in mitral valve prolapse. Am Heart J 1991; 122:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/28\">",
"      Han Y, Peters DC, Salton CJ, et al. Cardiovascular magnetic resonance characterization of mitral valve prolapse. JACC Cardiovasc Imaging 2008; 1:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/29\">",
"      Kinder C, Tamburro P, Kopp D, et al. The clinical significance of nonsustained ventricular tachycardia: current perspectives. Pacing Clin Electrophysiol 1994; 17:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/30\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/31\">",
"      Bonow RO, Cheitlin MD, Crawford MH, Douglas PS. Task Force 3: valvular heart disease. J Am Coll Cardiol 2005; 45:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17719/abstract/32\">",
"      Maron BJ, Ackerman MJ, Nishimura RA, et al. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 2005; 45:1340.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8169 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-F0BCE44B44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17719=[""].join("\n");
var outline_f17_19_17719=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21043120\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE OF ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SUDDEN CARDIAC DEATH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Flail mitral leaflet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ELECTROCARDIOGRAPHIC ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21325375\">",
"      CMR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ELECTROPHYSIOLOGIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Survivors of SCD or sustained VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Very symptomatic palpitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mild palpitations from atrial or ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Asymptomatic patients without evidence of sustained arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mitral valve surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Participation in sports",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21043120\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8169\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8169|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/51/29489\" title=\"figure 1\">",
"      Classification exercise",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=related_link\">",
"      Definition and diagnosis of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=related_link\">",
"      Evaluation of the survivor of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=related_link\">",
"      Indications for corrective surgery in severe chronic primary mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3476?source=related_link\">",
"      Mitral valve prolapse syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=related_link\">",
"      Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=related_link\">",
"      Nonarrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=related_link\">",
"      Overview of palpitations in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=related_link\">",
"      Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31318?source=related_link\">",
"      Screening to prevent sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_19_17720="Chronic prostatitis/chronic pelvic pain syndrome";
var content_f17_19_17720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic prostatitis/chronic pelvic pain syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17720/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17720/contributors\">",
"     Michel Pontari, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17720/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17720/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17720/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17720/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/19/17720/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome",
"    <span class=\"nowrap\">",
"     (CP/CPPS)",
"    </span>",
"    is a clinical syndrome, defined primarily on the basis of urologic symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pain or discomfort in the pelvic region. Despite the use of the term \"prostatitis,\" it is unclear to what degree the prostate is the source of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, evaluation, and management of",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    will be reviewed here. Acute prostatitis and chronic bacterial prostatitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4776?source=see_link\">",
"     \"Acute bacterial prostatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=see_link\">",
"     \"Chronic bacterial prostatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of terms have been used to describe the syndrome now commonly called chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome",
"    <span class=\"nowrap\">",
"     (CP/CPPS).",
"    </span>",
"    These include prostatodynia (painful prostate) and abacterial prostatitis.",
"   </p>",
"   <p>",
"    A classification approach supported by the National Institutes of Health (NIH) to standardize definitions and facilitate research is the currently accepted categorization of prostate syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/2\">",
"     2",
"    </a>",
"    ]. This schema defines the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      I. Acute prostatitis",
"     </li>",
"     <li>",
"      II. Chronic bacterial prostatitis",
"     </li>",
"     <li>",
"      IIIA. Chronic",
"      <span class=\"nowrap\">",
"       prostatitis/pelvic",
"      </span>",
"      pain syndrome, inflammatory",
"     </li>",
"     <li>",
"      IIIB. Chronic",
"      <span class=\"nowrap\">",
"       prostatitis/pelvic",
"      </span>",
"      pain syndrome, noninflammatory",
"     </li>",
"     <li>",
"      IV. Asymptomatic inflammatory prostatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute and chronic bacterial prostatitis (classes I and II, respectively) are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4776?source=see_link\">",
"     \"Acute bacterial prostatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=see_link\">",
"     \"Chronic bacterial prostatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Research guidelines define",
"    <span 1ff8 c lass=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    as chronic pelvic pain for at least three of the preceding six months in the absence of other identifiable causes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/3\">",
"     3",
"    </a>",
"    ]. The inflammatory subset of",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    (class IIIA) includes patients with inflammatory cells in expressed prostatic secretions, postprostate massage urine, or seminal fluid. The noninflammatory",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    (class IIIB) subset includes the remainder of the patients with chronic prostatitis or pelvic pain. The distinction between inflammatory and noninflammatory",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    is generally for research purposes only, as there is no evidence that patients in the two subgroups have different symptoms or respond differently to therapy.",
"   </p>",
"   <p>",
"    In contrast to the symptomatic patient presenting with",
"    <span class=\"nowrap\">",
"     CP/CPPS,",
"    </span>",
"    asymptomatic inflammatory prostatitis (class IV) is typically diagnosed incidentally during prostate biopsy or an infertility or cancer work-up. This entity is not sufficiently studied to have an adequate understanding of its natural history, need for therapy, or response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic prostatitis is a common condition worldwide, affecting approximately 2 to 10 percent of all adult men [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one United States survey of 58,955 ambulatory visits to physicians by men over the age of 18 years, genitourinary tract symptoms accounted for 5 percent of all complaints, and prostatitis was listed as a diagnosis in nearly two million encounters annually [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/5\">",
"     5",
"    </a>",
"    ]. Most men diagnosed with \"prostatitis\" have",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    rather than acute or chronic bacterial prostatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large population-based Canadian study, 10 percent of the men had complaints compatible with chronic prostatitis, and 7 percent had moderate to severe symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/6\">",
"     6",
"    </a>",
"    ]. The prevalence seems to peak in the fifth decade, but declines thereafter:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      11 percent ages 20 to 39",
"     </li>",
"     <li>",
"      13 percent ages 40 to 49",
"     </li>",
"     <li>",
"      10 percent ages 50 to 59",
"     </li>",
"     <li>",
"      9 percent ages 60 to 69",
"     </li>",
"     <li>",
"      7 percent ages 70 to 74",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome",
"    <span class=\"nowrap\">",
"     (CP/CPPS)",
"    </span>",
"    is unknown. Despite the use of the term \"prostatitis,\" it is unclear to what degree the prostate is the source of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although bacterial infection has been suspected, particularly in the inflammatory subset of",
"    <span class=\"nowrap\">",
"     CP/CPPS,",
"    </span>",
"    a bacterial etiology has not been consistently identified. Most experts believe that inflammatory and noninflammatory",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    are both noninfectious disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Studies of Chlamydia, Mycoplasma, and Ureaplasma, which have all been implicated in chronic prostatitis, have generally concluded that they are not responsible for",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Several investigators have performed polymerase chain reaction (PCR) testing looking for evidence of bacteria in prostatic tissues, but these have yielded negative results [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. One study cultured prostatic biopsy specimens obtained via the transperineal approach from men with",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    and from normal volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/15\">",
"     15",
"    </a>",
"    ]. There was no difference in the number of patients from whom bacteria were cultured (38 versus 36 percent, respectively).",
"   </p>",
"   <p>",
"    Additionally, there appears to be little correlation between histologic prostatic inflammation and presence or absence of",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/16\">",
"     16",
"    </a>",
"    ]. Leukocytes can be found in the prostatic fluid of asymptomatic men, and there appears to be no correlation between the presence of leukocytes and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noninfectious etiologies have been proposed for",
"    <span class=\"nowrap\">",
"     CP/CPPS,",
"    </span>",
"    but none has been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/17\">",
"     17",
"    </a>",
"    ]. These include inflammation due to trauma, autoimmunity, reaction to normal prostate flora or some other factor, neurogenic pain, increased prostate tissue pressure, and the interplay of somatic and psychologic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Psychological stress, including anxiety and fear of severe illness, appears to be common in men with symptoms of",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    and may be a contributing factor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome",
"    <span class=\"nowrap\">",
"     (CP/CPPS)",
"    </span>",
"    include pain (in the perineum, lower abdomen, testicles, penis, and with ejaculation), voiding difficulty (including bladder irritation and bladder outlet obstruction), and sometimes blood in the semen. Chronic prostatitis may also lead to problems with daily activities, depression, and overall quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/22\">",
"     22",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    is also associated with erectile dysfunction and ejaculatory pain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    There is an association of chronic pelvic pain syndromes with other pain syndromes, such as irritable bowel syndrome (IBS), chronic fatigue syndrome, and fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/26\">",
"     26",
"    </a>",
"    ]. Given the overlapping innervation of the bowel and bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/27\">",
"     27",
"    </a>",
"    ], irritation of the bowel can result in lower abdominal pain and urinary symptoms as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"     \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=see_link\">",
"     \"Clinical features and diagnosis of chronic fatigue syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical course of",
"    <span class=\"nowrap\">",
"     CP/CPPS,",
"    </span>",
"    with or without treatment, is not well-defined [",
"    <a 1ff8 class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/28\">",
"     28",
"    </a>",
"    ]. The patient usually will experience a relapsing-remitting pattern where the severity and frequency of flares decreases, usually over many months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334781393\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome",
"    <span class=\"nowrap\">",
"     (CP/CPPS)",
"    </span>",
"    is a diagnosis of exclusion.",
"   </p>",
"   <p>",
"    The clinical presentation of",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    can be similar to that of chronic bacterial prostatitis, as both may present with urinary frequency, dysuria, and perineal pain. However,",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    does not present with low-grade fever, which can occur with chronic bacterial prostatitis. In patients with chronic bacterial prostatitis, the rectal examination may also demonstrate prostatic hypertrophy, tenderness, and edema, which does not occur in",
"    <span class=\"nowrap\">",
"     CP/CPPS.",
"    </span>",
"    The evaluation of chronic bacterial prostatitis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=see_link&amp;anchor=H14689254#H14689254\">",
"     \"Chronic bacterial prostatitis\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=see_link&amp;anchor=H14689261#H14689261\">",
"     \"Chronic bacterial prostatitis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=see_link\">",
"     \"Chronic bacterial prostatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes should also be considered prior to making a diagnosis of",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urethritis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=see_link\">",
"       \"Infectious causes of dysuria in adult men\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Urogenital cancer (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link\">",
"       \"Clinical presentation, diagnosis, and staging of bladder cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10664?source=see_link\">",
"       \"Urethral cancer in men\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Urinary tract disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=see_link\">",
"       \"Lower urinary tract symptoms in men\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Urethral stricture (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36617?source=see_link\">",
"       \"Treatment of urethral stricture disease in men\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neurologic disease affecting the bladder, such as spinal cord injury and lumbar spinal stenosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link&amp;anchor=H8#H8\">",
"       \"Chronic complications of spinal cord injury\", section on 'Urinary complications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link&amp;anchor=H5#H5\">",
"       \"Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis\", section on 'Clinical presentation'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike patients with these other disorders, patients with",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    are unlikely to have systemic or neurologic symptoms (eg, fever, weight loss, fatigue, incontinence).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome",
"    <span class=\"nowrap\">",
"     (CP/CPPS)",
"    </span>",
"    is a diagnosis of exclusion, the evaluation is designed to rule out identifiable causes of pelvic pain. The evaluation includes the history, physical examination, urinalysis, urine culture, and, in select cases, diagnostic imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H901733\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should ask about pain, urinary complaints, sexual function, depressive symptoms, and overall quality of life. The NIH developed and validated the Chronic Prostatitis Symptom Index (NIH-CPSI) which can be useful in the evaluation of patients presenting to general medicine and urology clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/29\">",
"     29",
"    </a>",
"    ]. The NIH-CPSI specifically assesses pain, voiding, and quality of life. The maximum possible symptom score is 43, where higher numbers indicate more severe symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76624028\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The focused examination should evaluate areas of pain, search for unexpected masses, and assess for possible urinary tract abnormalities (including urinary retention).",
"   </p>",
"   <p>",
"    The evaluation consists of an examination of the abdomen, including careful palpation of the groin, spermatic cord, epididymis, and testes. Clinicians should specifically search for hernias, testicular masses, and hemorrhoids.",
"   </p>",
"   <p>",
"    On digital rectal examination, the prostate is usually not tender but may sometimes be mildly tender; severe tenderness suggests acute prostatitis. In addition to the prostate, the digital rectal examination should also assess for rectal masses and muscle spasm or myofascial tenderness by palpation of the perineum, pelvic floor, and pelvic sidewalls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76624035\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A urinalysis should be performed in any patient suspected of prostatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/30\">",
"     30",
"    </a>",
"    ]. A urine culture is also required to rule out urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients with recurrent urinary tract infections should be evaluated for chronic bacterial prostatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=see_link&amp;anchor=H14689261#H14689261\">",
"     \"Chronic bacterial prostatitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with hematuria should have an evaluation that includes urine cytology (looking for carcinoma in situ of the bladder), cystoscopy, and possibly upper tract imaging with intravenous pyelography or CT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prostate specific antigen (PSA) test is not indicated for the assessment of",
"    <span class=\"nowrap\">",
"     CP/CPPS,",
"    </span>",
"    and if a PSA is measured and found to be elevated, the elevation should not be ascribed to",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=see_link\">",
"     \"Measurement of prostate specific antigen\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The classic \"four glass test\" (examining and culturing the first void, midstream, and post-massage urine samples along with expressed prostatic secretions) is no longer routinely performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76624042\">",
"    <span class=\"h2\">",
"     Diagnostic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are appropriate in certain patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with concomitant abdominal pain may require imaging with CT to exclude an intra-abdominal process. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"       \"Diagnostic approach to abdominal pain in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testicular pain should be evaluated with a scrotal ultrasound. (Se",
"1ff8",
"e",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5942?source=see_link\">",
"       \"Evaluation of nonacute scrotal pathology in adult men\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A bladder ultrasound or catheterization may be performed to check a post-void residual in patients who report a sensation of incomplete bladder emptying. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"       \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lumbar radiculopathy can produce pelvic pain, so patients with signs and symptoms suggesting radiculopathy (eg, lower extremity paresthesias or weakness) may require imaging of the spine with MRI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12633?source=see_link\">",
"       \"Diagnostic testing for low back pain\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of therapies are available for chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome",
"    <span class=\"nowrap\">",
"     (CP/CPPS);",
"    </span>",
"    however, there is no uniformly-accepted treatment regimen. Alpha blockers and antibiotics are the main first-line agents for treatment of",
"    <span class=\"nowrap\">",
"     CP/CPPS,",
"    </span>",
"    and can be used in combination. Physical therapy and psychological support are also used in certain cases of",
"    <span class=\"nowrap\">",
"     CP/CPPS.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    NIH chronic prostatitis symptoms index (NIH-CPSI) can be used to follow symptoms (ie, pain, voiding, and quality of life) and measure response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In primary care practice, patients suspected of having acute or chronic bacterial prostatitis will frequently receive an empiric trial of an antibiotic (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ), and the diagnosis of",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    will only be entertained in those patients who relapse or do not respond to such therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=see_link&amp;anchor=H14689289#H14689289\">",
"     \"Chronic bacterial prostatitis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6553842\">",
"    <span class=\"h2\">",
"     Medical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha blockers, antibiotics, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    (a 5-alpha-reductase inhibitor) are the most efficacious medications for treatment of",
"    <span class=\"nowrap\">",
"     CP/CPPS.",
"    </span>",
"    &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    In a meta-analysis including 23 randomized trials of patients with",
"    <span class=\"nowrap\">",
"     CP/CPPS,",
"    </span>",
"    several treatments were found to reduce NIH-CPSI scores compared to placebo, including alpha blockers (-11.0, 95% CI -13.9 to -8.1), antibiotics (-9.8, 95% CI -15.1 to -4.6), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    (-4.6, 95% CI -8.7 to -0.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/33\">",
"     33",
"    </a>",
"    ]. The overall decrease in symptom scores was relatively small for each of the medications and likely of modest clinical significance. The greatest improvement in NIH-CPSI score occurred with combination alpha blocker and antibiotic treatment compared with placebo (-13.8, 95% CI -17.5 to -10.2). Symptomatic improvement with combination alpha blocker and antibiotic treatment was significantly greater than for each of the other treatments alone.",
"   </p>",
"   <p>",
"    The choice of treatment in clinical practice may vary based on etiology of",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    and specific symptoms (eg, alpha blockers for those with pain and voiding symptoms, antibiotics for those with a history of urinary tract infection). However, given these data, we suggest the use of combination alpha blocker and antibiotic as initial treatment. An alpha blocker (either receptor specific or non-specific) plus a quinolone for six weeks initially is a reasonable option (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    0.4 mg daily and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 mg twice daily). If initial treatment is not effective, patients should be referred to a urologist for further evaluation and management.",
"   </p>",
"   <p>",
"    Some clinicians decide to continue initial treatment despite lack of response. It is reasonable to continue an alpha blocker in patients with continued pain and voiding symptoms. Patients should be reevaluated after three months of continued alpha blocker therapy. We suggest not administering further antibiotics if the first course is ineffective and subsequent urine cultures are negative. Several antibiotic classes such as quinolones and tetracyclines (two of the most commonly-used antibiotics for",
"    <span class=\"nowrap\">",
"     CP/CPPS)",
"    </span>",
"    are considered anti-inflammatory drugs and may improve symptoms regardless of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, in the absence of fever and positive urine culture, the patient does not likely have an infection, particularly if a patient feels better on antibiotics and feels worse the day after stopping them.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    , anti-inflammatory medications, and phytotherapies may have modest, but lesser, benefits in patients with",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/33\">",
"     33",
"    </a>",
"    ]. Finasteride is common treatment for older men with urinary symptoms, but is not recommended in young men who are still trying to have children given the effects on semen volume. Most of the anti-inflammatory medications studied for",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    treatment include cyclooxygenase-2 inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    ) and glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ). Anti-inflammatory medications are generally given when pain is not controlled with initial therapy. Other medications found to be effective include phytotherapies and medication for neuropathic pain (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ). Specific phytotherapies found to be effective include cernilton (pollen extract) and quercetin (bioflavonoid) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small randomized trial suggested some benefits with mepartricin, an antifungal agent that lowers estrogen levels in the prostate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/37\">",
"     37",
"    </a>",
"    ]. Mepartricin is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76624206\">",
"    <span class=\"h2\">",
"     Psychological support",
"    </span>",
"    &nbsp;&mdash;&nbsp;As",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    is associated with depression and a poor quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/38\">",
"     38",
"    </a>",
"    ], behavioral counseling may be beneficial in select patients with concomitant psychosocial problems. A cognitive behavioral program specifically targeting",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    can improve both symptoms and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/39\">",
"     39",
"    </a>",
"    ]. This approach addresses approaches to pain, urinary difficulties, depressive symptoms, social support, sexual functioning, and overall quality of life issues. Prio",
"1ff8",
"r to widespread use of behavioral counseling, further studies are needed to determine which patients with",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    might benefit from this type of program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334782121\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few other treatments may be helpful in managing",
"    <span class=\"nowrap\">",
"     CP/CPPS:",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small",
"      randomized trials have found that acupuncture is more effective than sham acupuncture [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Physical therapy aimed at achieving myofascial trigger point release may have benefit in patients with pelvic floor muscle spasm [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. This therapy is usually performed by a physical therapist, rather than a urologist or primary care clinician. (See",
"      <a class=\"local\" href=\"#H76624028\">",
"       'Physical examination'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Small randomized trials have found that transurethral microwave thermotherapy of the prostate may be effective in reducing symptoms of",
"      <span class=\"nowrap\">",
"       CP/CPPS",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Further trials are needed to document long-term efficacy and safety of thermotherapy, in comparison to medical therapy.",
"     </li>",
"     <li>",
"      Sitz baths have anecdotally been reported to provide some relief, although there have been no studies on efficacy for chronic symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical intervention for",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    is reserved only for those patients with a specific indication (eg, urethral stricture, bladder neck obstruction) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transurethral needle ablation of the prostate is not more effective compared to sham treatment in patients with",
"    <span class=\"nowrap\">",
"     CP/CPPS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17720/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76624145\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose symptoms persist despite initial treatment, or who are found to have abnormalities such as hematuria or an elevated PSA, should be referred to a urologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29873?source=see_link\">",
"       \"Patient information: Prostatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic",
"      <span class=\"nowrap\">",
"       prostatitis/chronic",
"      </span>",
"      pelvic pain syndrome",
"      <span class=\"nowrap\">",
"       (CP/CPPS)",
"      </span>",
"      is a clinical syndrome, defined primarily on the basis of urologic symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pelvic pain. It is the most common diagnosis in men presenting with prostatitis; acute and chronic bacterial prostatitis are less common. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4776?source=see_link\">",
"       \"Acute bacterial prostatitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=see_link\">",
"       \"Chronic bacterial prostatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The etiology of",
"      <span class=\"nowrap\">",
"       CP/CPPS",
"      </span>",
"      is unknown. Despite the use of the term \"prostatitis,\" it is unclear to what degree the prostate is the source of symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       CP/CPPS",
"      </span>",
"      is a diagnosis of exclusion. Patients should have a physical examination directed at identifying other etiologies of pelvic pain. Any patient suspected of prostatitis should also have a urinalysis and urine culture. Diagnostic imaging is used in selected patients. (See",
"      <a class=\"local\" href=\"#H334781393\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with",
"      <span class=\"nowrap\">",
"       CP/CPPS,",
"      </span>",
"      we suggest initial treatment with combination alpha-blocker and antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"       tamsulosin",
"      </a>",
"      0.4 mg daily and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      500 mg twice daily. After initial treatment, we suggest NOT repeating a course of antibiotics unless there is a subsequent positive urine culture (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6553842\">",
"       'Medical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anti-inflammatory medications,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      , and phytotherapies also appear to have modest, but lesser, effects on symptoms. Physical therapy aimed at myofascial release may have benefit in patients with pelvic floor muscle spasm. A cognitive behavioral treatment program may be beneficial in some patients with concomitant psychosocial problems. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients whose symptoms persist despite these initial treatments, or who are found to have abnormalities such as hematuria or an elevated PSA, should be referred to a urologist. (See",
"      <a class=\"local\" href=\"#H76624145\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/1\">",
"      Potts JM. Chronic pelvic pain syndrome: a non-prostatocentric perspective. World J Urol 2003; 21:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/2\">",
"      Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 282:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/3\">",
"      Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology 1999; 54:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/4\">",
"      Krieger JN, Riley DE, Cheah PY, et al. Epidemiology of prostatitis: new evidence for a wor",
"1ff8",
"ld-wide problem. World J Urol 2003; 21:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/5\">",
"      Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol 1998; 159:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/6\">",
"      Nickel JC, Downey J, Hunter D, Clark J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol 2001; 165:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/7\">",
"      Krieger JN, Egan KJ. Comprehensive evaluation and treatment of 75 men referred to chronic prostatitis clinic. Urology 1991; 38:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/8\">",
"      Schaeffer AJ. Editorial: Emerging concepts in the management of prostatitis/chronic pelvic pain syndrome. J Urol 2003; 169:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/9\">",
"      Ohkawa M, Yamaguchi K, Tokunaga S, et al. Ureaplasma urealyticum in the urogenital tract of patients with chronic prostatitis or related symptomatology. Br J Urol 1993; 72:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/10\">",
"      Shortliffe LM, Sellers RG, Schachter J. The characterization of nonbacterial prostatitis: search for an etiology. J Urol 1992; 148:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/11\">",
"      Berger RE, Krieger JN, Kessler D, et al. Case-control study of men with suspected chronic idiopathic prostatitis. J Urol 1989; 141:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/12\">",
"      Doble A, Thomas BJ, Walker MM, et al. The role of Chlamydia trachomatis in chronic abacterial prostatitis: a study using ultrasound guided biopsy. J Urol 1989; 141:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/13\">",
"      Hochreiter WW, Duncan JL, Schaeffer AJ. Evaluation of the bacterial flora of the prostate using a 16S rRNA gene based polymerase chain reaction. J Urol 2000; 163:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/14\">",
"      Leskinen MJ, Rantakokko-Jalava K, Manninen R, et al. Negative bacterial polymerase chain reaction (PCR) findings in prostate tissue from patients with symptoms of chronic pelvic pain syndrome (CPPS) and localized prostate cancer. Prostate 2003; 55:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/15\">",
"      Lee JC, Muller CH, Rothman I, et al. Prostate biopsy culture findings of men with chronic pelvic pain syndrome do not differ from those of healthy controls. J Urol 2003; 169:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/16\">",
"      Nickel JC, Roehrborn CG, O'leary MP, et al. Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol 2007; 178:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/17\">",
"      Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol 2004; 172:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/18\">",
"      Mehik A, Hellstr&ouml;m P, Nickel JC, et al. The chronic prostatitis-chronic pelvic pain syndrome can be characterized by prostatic tissue pressure measurements. J Urol 2002; 167:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/19\">",
"      Mehik A, Leskinen MJ, Hellstr&ouml;m P. Mechanisms of pain in chronic pelvic pain syndrome: influence of prostatic inflammation. World J Urol 2003; 21:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/20\">",
"      Mehik A, Hellstr&ouml;m P, Sarpola A, et al. Fears, sexual disturbances and personality features in men with prostatitis: a population-based cross-sectional study in Finland. BJU Int 2001; 88:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/21\">",
"      Anderson RU, Orenberg EK, Morey A, et al. Stress induced hypothalamus-pituitary-adrenal axis responses and disturbances in psychological profiles in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol 2009; 182:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/22\">",
"      Walz J, Perrotte P, Hutterer G, et al. Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men. BJU Int 2007; 100:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/23\">",
"      S&ouml;nmez NC, Kiremit MC, G&uuml;ney S, et al. Sexual dysfunction in type III chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS) observed in Turkish patients. Int Urol Nephrol 2011; 43:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/24\">",
"      M&uuml;ller A, Mulhall JP. Sexual dysfunction in the patient with prostatitis. Curr Urol Rep 2006; 7:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/25\">",
"      Trinchieri A, Magri V, Cariani L, et al. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome. Arch Ital Urol Androl 2007; 79:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/26\">",
"      Rodr&iacute;guez MA, Afari N, Buchwald DS, National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Urological Chronic Pelvic Pain. Evidence for overlap between urological and nonurological unexplained clinical conditions. J Urol 2009; 182:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/27\">",
"      Ustinova EE, Gutkin DW, Pezzone MA. Sensitization of pelvic nerve afferents and mast cell infiltration in the urinary bladder following chronic colonic irritation is mediated by neuropeptides. Am J Physiol Renal Physiol 2007; 292:F123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/28\">",
"      Erickson BA, Schaeffer AJ, Van Le B. Chronic prostatitis. Clin Evid (Online) 2008; 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/29\">",
"      Turner JA, Ciol MA, Von Korff M, Berger R. Validity and responsiveness of the national institutes of health chronic prostatitis symptom index. J Urol 2003; 169:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/30\">",
"      Schaeffer AJ. Etiology and management of chronic pelvic pain syndrome in men. Urology 2004; 63:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/31\">",
"      Nickel JC. Clinical evaluation of the man with chronic prostatitis/chronic pelvic pain syndrome. Urology 2002; 60:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/32\">",
"      Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Res",
"1ff8",
"earch Network. J Urol 1999; 162:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/33\">",
"      Anothaisintawee T, Attia J, Nickel JC, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 2011; 305:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/34\">",
"      Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003; 3:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/35\">",
"      Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999; 54:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/36\">",
"      Wagenlehner FM, Schneider H, Ludwig M, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol 2009; 56:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/37\">",
"      De Rose AF, Gallo F, Giglio M, Carmignani G. Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial. Urology 2004; 63:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/38\">",
"      Wu LX, Liang CZ, Hao ZY, et al. [Epidemiological study of chronic prostatitis patients with depression symptoms]. Zhonghua Nan Ke Xue 2006; 12:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/39\">",
"      Nickel JC, Mullins C, Tripp DA. Development of an evidence-based cognitive behavioral treatment program for men with chronic prostatitis/chronic pelvic pain syndrome. World J Urol 2008; 26:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/40\">",
"      Lee SH, Lee BC. Use of acupuncture as a treatment method for chronic prostatitis/chronic pelvic pain syndromes. Curr Urol Rep 2011; 12:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/41\">",
"      Anderson RU, Wise D, Sawyer T, Chan C. Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. J Urol 2005; 174:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/42\">",
"      Anderson RU, Wise D, Sawyer T, et al. 6-day intensive treatment protocol for refractory chronic prostatitis/chronic pelvic pain syndrome using myofascial release and paradoxical relaxation training. J Urol 2011; 185:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/43\">",
"      Kastner C, Hochreiter W, Huidobro C, et al. Cooled transurethral microwave thermotherapy for intractable chronic prostatitis--results of a pilot study after 1 year. Urology 2004; 64:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/44\">",
"      Nickel JC, Sorensen R. Transurethral microwave thermotherapy for nonbacterial prostatitis: a randomized double-blind sham controlled study using new prostatitis specific assessment questionnaires. J Urol 1996; 155:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/45\">",
"      Touma NJ, Nickel JC. Prostatitis and chronic pelvic pain syndrome in men. Med Clin North Am 2011; 95:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17720/abstract/46\">",
"      Leskinen MJ, Kilponen A, Lukkarinen O, Tammela TL. Transurethral needle ablation for the treatment of chronic pelvic pain syndrome (category III prostatitis): a randomized, sham-controlled study. Urology 2002; 60:300.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6880 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-322217C268-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17720=[""].join("\n");
var outline_f17_19_17720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H334781393\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H901733\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76624028\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76624035\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76624042\">",
"      Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6553842\">",
"      Medical treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76624206\">",
"      Psychological support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H334782121\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76624145\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4776?source=related_link\">",
"      Acute bacterial prostatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23496?source=related_link\">",
"      Chronic bacterial prostatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=related_link\">",
"      Clinical features and diagnosis of chronic fatigue syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./c",
"1218",
"linical-manifestations-and-diagnosis-of-irritable-bowel-syndrome?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12633?source=related_link\">",
"      Diagnostic testing for low back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5942?source=related_link\">",
"      Evaluation of nonacute scrotal pathology in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=related_link\">",
"      Infectious causes of dysuria in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=related_link\">",
"      Lower urinary tract symptoms in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=related_link\">",
"      Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29873?source=related_link\">",
"      Patient information: Prostatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36617?source=related_link\">",
"      Treatment of urethral stricture disease in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10664?source=related_link\">",
"      Urethral cancer in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_19_17721="Light micrograph showing collapsing FGS";
var content_f17_19_17721=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing collapsing FGS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADzAXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwBxurqOR/s8crOjcBDkLHzy2eBgd/oK7dUu7/RLe5mG1ZFG5j1wRkZGPpWfcaHHr1uZ/IjVSpQrJmMyrnkZH0FXUuZbfw6+k3KyC4togpEeD8oxgg/TArOpJSty7rcmzuZb2lxFfQxQ4YkExkLyDWsmnPY6hCl3Ju85eSVHyuOnTrnJrftYVjEEryb5MDn0465H86j1NRNcRSfu3MRBGOuc8Vj7Zydhqo72K86JPbmC5jWWRhwAAQ65Gf1p0ulCMyfOgGQcKOSe3NWzbNMrXCr5asP9XnJ//XUkbtcQmJtpDDac+/v3rPmfQzd+hSs5GiVXYHCsVXK8nPtWm9vM0MCyuksqFSXK7dxH6Uy9to0hXglVcE+2P6VV13XbbRbVnnJuLhxuit0XczenA/h9zU2c2uRais5tcu5xt5qklzeX4uiZT5ywwQgDjqRx1IBwc+9aei6bDY6e13c5MudsaEnaCONx/Gszw1YT2l7NcamkazzEEBvmEYPPGepHTNVL6e6k1O6tId/lnOHZ8hFz1+pr0nFN8sXoelGnyr2cfmylrmragJpLTR0DzOcPKDwmTzkZxWnF4Z1rUYYlunMURHEacg8DqSOp5rt9B0C00+xjEUUZmKgmQAHd7Z9PerrXttZW7FmJRSQFTnn0rGWKfw0lsZvFcsn7Fanm8RhtWAUyb0JDD3HUkfhXQWt0Le0L6bDEwA3PLu37B9P73rj1rnNQunuryaYqA0z79ic9TXTaJp15FBHOI1dAN5Qjqa2qpct5HfiIpQTkNvL3z50luFZRH87IMjdz0z61WXUFjGWeWKHdnYoySuMYPv06VW8Q3m5lhJD78MHXGeeoP0rCuXe7mzFvCxkwhWOACO3B96dOkmtTzqNFVKnLtY0YlM91NMAkMMz5X5dx6cYrV12WS006CG2SJb65cRxljtC8E7s59sfjWXDbSWcdu8+ZmdNxJ+bZkgjHpjrVrxJqllNA0l0wcqBGAq/OzdiD2ptc0lbVHbVpOpaFMztJ1SKZJX1OP7PJbzmKSQjIcZ5Kj0qLUfFlrHA9ppsT3rtIC7oAo2gjjd0HT64+tVYtIi1Ly/7VP2SwTbiJARyckbm/znFdhpvgazntYPLndYhglRjBwe2KucqVN3n/AMAU69OirN80l9xw9tceItcmksLCFisjb5IoRuWMc4yzAL+ea6vSfhtFJpsY8SXWovNJJgQRTZjj5OMgDH4nivSNNs7ewtUt7RFSJeeMZPuatck9c1w1cdJ+7TXKvxOCpmFWT9129Diovhh4WiyG0/zVZcMHbr78YNdZp1haabaLbafbw21uvIjiQKM+v196tZ6A0E8561yzqzn8TbOOdSU3eTuJ0GOn1pMc5z+FCqqghAAMk4A9eaMc1mQKenGK5jx74tt/B2n2Fzc2s92b2+jsYo4mRD5jhiCWcqoHynknjNdM2SPl6/XFch8SfBzeMtM0y1S9hs2sNQi1BTPai4jkKKw2Mm5cqd3PPQY7042vqNWvqRaX8R9Bu/DNrrd7LLp0FzK8EcVwu6RnQkNtCbtwGCcjIxWlceL/AA8kLzyavarElot95gbI8hm2iUccjdx9a5DTPhXNpUFhPpmuiDV7O8urtJjZK1uv2hQskaQbhtUbQVAbg56g4pZ/hFp7W3ha1jvphaaRF9nuYnj3fb4vMWXY5yNo8xA3friqtDuV7p11/wCNfDtglw11rFrCtvJFFKzE4RpV3ICfdRmoNH+IHhXWbyG00zW7W4uZo3lSNchiE+91HDADO0845xiuY0X4Urpmg6dYHWpLq4tdat9We6kt/mlEACpFjdwNqgbsnucc1PafDJ7e6064GtSRyWt5qN2DFBtfN2jLhW3cFM5zg5x0FFodwtE3oPiB4Wuba9uY9XhEVlGs0xkV49iMcK+GAJUnAyMisrWNd8PeLdNlTSbaLxEyXUFnOtuCGtxI23zM7c7VyWz0wCc8GuYX4KStYanBc+IY3mvtNTTzMlgQSVmEnmvmUl2OMHkfpivRdI8ODTfF/iLXhdeb/a6Wy+QIseV5KMv3s/NndnoMY707xg7xeo4y5HeL1PK21jTvDWuTW+ianFqMCboixDFrdlI3APja5HQ9SKv2viqxE8t3HOwM9wWliBDBVxnIGOnTv3qe++GVzpF3fa1a3iXrFmkXToITbxSuzg7pRvZWI7bVTPeuf1jwBf3tzc32m2qWixojqFO5WJ65Ht+Neth50qkb1Hr3PUw+IjU92WjfXp8zspv7L1eW0+xSXEdxvEkscmUJU8ggHqPenalYSpC0MU0iQTuHZZhlGIPRT6c8Z6YrnvAeq319qMOl67MkN3bvvilPyl8DGPTHGDXbahbyT6nEl4qpGqHakZHXP3vT0rOpelNRv+o5KcX7OqeRfEdNU0vW4I9MXba3PzOyqH5HGemABz+Rru/CUF1N4VtpLt4BJIrTPjPzY44/KpvF+gxX2wXhuGiQY/dNtDnIPI/AdKzdY1mWG403TNFDeUxw3y4xgjgHGQBx0roVT21KMI79zGFBx99O6Ol8L3guIXjWZAZC33efl6Afp1ou7BvKa7DAKF2bzzjbnP5/rXn3iKbVPBmtWrPco1pdHYDgYjXk+nI681t+E/FkPiCykjZyYY5VDFeQe5wPTrUSoSt7WD91m0G1LRq/5nZaBqQs7eW3uFIWQbkKqM9Ofw/wq3DHCltBPCFMxkGVZjwDnGefao9QjWa8hvLVkKQttZUA28dj29M1i2+mzm1n1C6u7YPDl1ROpyx+/wBOg6DmuRcsve2uYVGn7667nfxyhUy3yjORjJ4pl1dCGElsg54IUn1POOnA6msDwtqZliWC8LMWXzITLwSPStHVAsphSIygbTgBCF6dzjpXLKnyz5WcainKzIYpHmthMXUSBcHgHBpVs5No/eydPUf4VIkol0qCQjMrY3KR0OcZI/z2p583PD5H0/8ArVT1NW9TL8wbRA0bABeFA4x0A4qC80iW4k85iimRfKbZ2HY1oSqJNrEhJFOQR6VRGseZOIikiuj4OehHrSi5LWJnFyesF6k0Nvc29uBcSGbb8qnBJ56Zq+llhXYH96eeOlRzzmJA/T3PQVYV2wDkbevFRKTIc5WuN+2Qw27vdukCRjLtIwVQO5+lPn8tbfzFKgKM5GMVS1XTbfVbN7W7XzIJMblPQ4Ocf561y3j/AF1oIrbSLG9EeoXR2yO3Kxx4OWNXSp+0mlEqjTdaajAn17xdAkcsFsTLdkFFUcKp9T9KZ4W0CW8T7deSyESEMWJJ3jqB6Y9ulco9npp8qBJZBbA/PNyTMwxnj+lWry5vNOkWPTLu4hkZC20SsVJGcgDp0/U16Hsko8lPRs9CcqdKHJSevVnZa81nA/lQFEnKdCwViQffkn/Cud0EvMkD3cwaW9Zi3mHJfbwPyrg9Jsze6i2uXWozXBjkKmPduBIGfvdducdK0NCkDXUkttdzPJFPGZS6EbJCchU9BjOfr71t9XUIuNzLnlCivNntKahtsI22rj7pYE4BH/6sVyetTqkkszAneoVFIK8ng8Dp/Wt/TEkjhO+VnjJyq47nqc/XNYer3Km8iupIwsUUykkH73PPHpXDRSUtCsLZT0RreGfDcFssNzcxF5yOUcAgZ5BHvXVN8p2qg27epPSq6nB3Ke3BFU9a1AWNlJOzAFRxmuSU5VZanFUqzrzvI4HxzE8usXEEAZYZoXCsjbCjbgcg9eo9PXFUvD1uz3cNmw8sMWYyE4KjPJzjr/jTtS8UNeyTfZntC8TeSqMuZSf6AZzjvWbp8t/qmqPZWHEjgJLKc4jXAJGfXivahGSp8stLHpYKHPz1E7K1rm94k1+2tb+PT9EtUnlKgFEX7319sd6j0nSlluTf6qcTl90cK/6uM49PWs+7t7PQpw0MsLTyY8yWXJz2GCM8kkgZ9qnu5Ly9V2iu2iVDtjRMEvjpnjg5P5VKSUUoaLuRUxihH2dH7+rO1TQ7bUbRGKx7t+R5iBirevvjPpXU2sSW8CW8QO2JQvPX6n3rK0YiDS4ppS3mBAWIHU+2KiHiS0iYx4mdVAAfZwT0PpXlz56jstUjzpRb2Og4we3v6VHcTpDGXIyO/Nc6dfhubmNU8yEE4yxXntk81BvubrWxFERHFEAzseRk8D6mlGi/taFxov7WhrT67bKqCIFpJPuDqDxWklyjIjqOG9TjH4Vzt3FGZreKNY18mQnei4ycdMD+dXlmjAEzscMM7QuT07CqlCNlYqUIWXKV/FPiuw0LTROzrNM+REgbqQD19ulM0DUtb1Kzt7u6sI7SKZdyRgkuPQtnGAevSsiW3tdS0+5aRMTBidojDKAOR+Nb3hu9vLm0WS8lhkBUY2DB+v8A9YVpOMIU9Fr5jdNQXMtfUtaNqa3aFJmCXAZl8puHwCRnHpjFch8ZPE2peGdIsJtJurS0M1wVmeYorlApOIzJ+73dPvHntXQeJbK1lU3UoMcyKI1lDkEqT096iub6GOHelwpeMgbickGsuRSalFB7OM7Sj16HkV/8UddWA+VqyWdwNIgvbWC604Ca9uGkYeVsBP3gB936jFaesfEfXLf4jWGnQ3CQQvqVnY3OnXESBlEqoHZMZdgCSQ5IHQYPU+laTHpEuoTa/bGMX8tultNKZGH7tcsBtJwMEntmnf8ACUW9zIy6eryoMr5h+UEgZ4HX8afLrZRIcbO1jzC3+IXiE+GNU1FNSgn8RQwys/h37Cd9kFmVN7EfMdqEsc8N26V2fwg8Sal4httVGpahZalHbyx+RcW5QttZSSrhBtBBHbnB5rq4ry5hDNeKm3qpUZOOtaUUodQQScgms5NJbETViQgHoP1peMU0PkD+tG4ZxnpWZmIVLAfeU5BpwTk8cYwRTC2DwRinE880XA4bx54OTUUa+sR5d2nzrjgh/wC8Pr3rnNG8RXN8bSG7jSDULQeRIzHIJHIYj0Ir1ksrcZ69vWvJ/iZ4fe1jOpWAJAPzBBgsoIJH6ZH4134Wsp2pT+R6uDxCkvZVFfsa+veLLcWUMUpNteCZY1MYDhm5wv40zwxF9k1aOSaLMjoWJIwVYnqAa57RLWHxDrDRaZep5ElusoBjK7JBjr7+9d7ZW6SaH524/bbPIdpDkZXrx06elaVOSkuRdf1DnioWS3PJfib4X1PWNQtYrKBTFLM0xDk4PGB24GK2vhV4PuPC+k3Z1R4R5riQqvG1P9nHHPrXT2esTOGuyVMw4iDqQu0nH0x1OazL+21h5BAmo2kEOVLSgZ3oDllC47jpzW/tpun7FuyCpdT5ramxbItvZyzwyAxOf9Uf488g8jj3rTnmtNY0e2spRFHeXLCPZnlV7n8q8q8fXPiXVNY03+wpRDZ2x2SgN8rAYHI6Y/PJNdha4S6tlUNLK21SqjOGwD8v5/hWUqK5VJvX8inFzk1JWtqasOjp4YuoI7Qsylv3bOSdo6kfjXawziSCJ2wS4HC+9cbq8187RpesYow25SwB2Y7nHX6Uttqc+nxrJNvmsZDzJ/COOgP4Vy1Iuok27s550XKK2udPNbx27ZiUAuepOM56j9acHAGBDwPf/wCvWbc6pb3tmpWUqSNwDEAHA65+uKjXVI9o/dr07KTWShK2xjyStqtSfDAEIg7n6n/Oaz7i2Pm+Y2AO+R6Zq87xRAtKwUKfvE1wHir4jaNDL9gtbpZZAcyFCQAo9/rinQpVKjtBXMoXTXmd1arM1qofbgZXDCrEG4bvmHHYn7v/ANavNtK8TaxqLtD4espJoupmum2Rjj1I+lUPFR8SWcBfWb1XhaMEpaLhQf7vPJ6/St1hJOXJKSR2xwU5y5JNK/8AWx1Pi3xtHp5a00j99c8iSRWyE/HpmuUtNK+1O+o3zmW5ZSykHcAT0z61kaHppu/LnmMRIIZYmbcWP+36n2xXa2UY2BNwZlGBt42t3GPxrrcY4dcsN+rNpuOHj7Oj13fcxrwXGqaDJp93FLa3UBWSK6DdCvOffqB7102n2E1zpP2nahEGUWNl3B+ACSe5zU0ehNL5JlkPluoJG0nnrj2rq7S1WGAR7AmRgKDkCuatXSVonBdUtTzy52OojFsqRovSKMKoPXt171R8Jo8yrDvwEuMMWUYHHTPTPUV0NxAYpLq3jljKq+9/l5cY6A+xI/Kqvhu2VLK6GwIROWJPIPatVP3HY7Hb2T9Tq7JnaN7eABEXq4P3ueue5pNUtTLaC3uoVWM5AkU55weT364q7p9itraom7PHLD/D1pbgiWRraRei7ty9TyevpXBz+9dHHGpaV10MzTNQurKHyLuN50j4Eq8n6MP61k+L7m4NxACCEIHmRAjLIDkgn3/pWxc6nZWDbt0ZYv8AvFL859cflXC+JtVmuLuY22TLcsFjiABwAK66FNynzWsdVOHtJ6RtcxtSvLnU9cunjSN1iZpWYJ8sQIwDxwWxgVtafp/2KzT+z5JHu5JGWWNnBZpN2N6EdsYOfrWf4atWSdbdUk8pA0sruAqdc5znk4wPx9q9BstK+zzwxxWaW4uOkoOW24JbJ9frXVXqqHuomtUTXs6ekV+PmVNWtrW6to4btk+0xhWHQjdkHGD155pdE0f/AE1pnRrlY8yYJ9RztHrnFdd/Z9mYfKe0jaLbjlck/U/rVW3RdLjHmFjDnIIPT8K89V24uMTm51ujnfEXiOYNPBp9nNJZWoVrqQgoUB6ADHXGax49fsZw6fvQuNvm7dyM3XH5Y6+9bmi6vaWeq3Ud6Ykg1CdpYp27nONjnp/unvnHXr51GmpReI9U0i3eF7aW7d9vl7hECcgj0GGz26GuyhTi7xatbX/M9PDUac7pq1ut9+5n+NNWnS5juLWIgQukQUfey+TlfyA+ldDoOq3k+jwF0eRyQw+cjPGTnHY1JF4OBmdrto7rcTJgZG3ngLzxx3PNdF4U0a0t76NJ1BQKfL3MMA8cDAx3repVp+zstbDnUpxk2rtFa01uZpEBQLMoyVZvXsMf55rctLh7vWbdI2aKKRCzgHgnPT2/+tWRr8EMPiCHyl++yll4znOKFylwVgDiaMeYxSTbhRjg/X+lcslFpNaXRFSEWlKOlzorS3g03UbuOWUNZy7CrZJIbGNvTBzXNeKdaurPR207TX2MGdiA2HZMnaM9hj8a7ZybywmtniESFCi5AJXI4bHTI4qvF4esbmAy3UStcMoUuvGCBgf/AKq54VIxfNPU5XKP2zi/h3czTyXQ1mNJPNjAUSOzgn/YJPA61oX+oZiu7NzG9vEdpkUhG78E9M4HWjVLaAeROpEaozqHDDGASCcVj61pgntLiaOQSW6uUGG4JzjkepzXV7s5870ubQp8r0GW928kaL5RSJ+NoIAZQAAT3J5z6Gui0eOEWMksriHyn3lwduO9cPpWs6juj0kANbTXBxL5YZkcAcAnoD/Q11Gu6NqOjaW088tvdWww8qpEwwFOTnJOR/hmqqwSai3a+xdejJW5t3sbei61NrKXkaW6KYGVNzkgsSM5Ix6fzrSt7+TS7iSO/K/ZMZWVG3BMdQR1xXIaBHBoOoT6iftUlpqCRmYl/OBYLxIuOx5FZHifxmmv6tBonhid4eGNxfumfJXAJEYbrJgjA7ZBPYHnnSvK0V7pyRi2rSWh6PpnizRtUvZ7XTruOeeHb5gUH5cjIBPY47dR3rcceZG24Aow6Z4IryiytLDw9CLDToEMDKyq3mESFuTvz1JJbJPfmrXg7xReWuqQ6ZqgaS2uWCxM42vGT0z6g1nLCNxcoEToW1iemqRtUfdB6f0p56/h1pMAr3A9M9KCo9K4TmEJIHAXA9TUUimVCsiI8bcMG9Pp3qYKAOnTmkZRsJwc47mkM8n0Vf8AhEfiMbCd4xZ3KFYmbgDcQfoMHH4Gu2u5P7ELMo3wTsZH3c7s9QBXNfEvwybizivLJZWu4pfOdg27Pboe3aoND1u98SWa2piizGrR71ByCBwxH0/XNeo4+2iqt/J/Lqeu4+3iqq9H+jNFdtn4a/tC7mSKwXlBt/hJxj8T2rlrDxJHrd3cOluVZwwjEiHaVXHAPqMiqWvLd3No+kTXEiwRyfJg55DZ7fzNV9L042irJCjgrnDsxAwSQcevOea6oUoqLcnq9jTknGafQ7LwrLZqQLlEcI3mAt/Fnrn6VrJqFsuppdR+SttAuFK8FmJ547fWvMNXkfEaQvIVKsMqSqn0z6/Sun8LwxW0X2rWJ/KgDhkt1bfv9Bjnj2rOrQVnNvfoTWvzvRs3/FfjexttLlNrZz3Z6AlfLX82696j0zxPY3emW32uyuYIZvnMZw4AA6gjnpjtWLreqzarqrCW2QaZECLeMoVYkgcvn6dKZbOCJpJ4UeFO3m+WfYDrk+3es40IKFmtfUiFCMY3lp/Xc0jqFqlzHawzgi4z5SMpzx79uorXBtABuQ7u/SuLvb+11G4imsI/szQ4O2Xnnucfh2reh1DEMe+JmfaMn1OKc6TstAnCUrOOxzWo3niDW9yyRLZW5UkG4ZgSP90dz25qfw94O0bSnW6u4BeXScpuICpnso6e+TnpVbW9UhjuS9g0AmRj8pJzgE53A49Og571VlvpbxWd57iKOYY/dAhlPT5e+QMf4V0KEnGy0RdR8kLwVl/XU6S38VDTrK9isNMnY2jDJZNqfN0CnvzWMuqTa7qMUOrQzpcRROQiciR8EKoA6EH+daPgIDVNHuYbu2mEca/KZ5Ru6nn5fvc561JpNqi6huV0fYhU7owqgk9R+XWsvcpuSS1XU5otO80VfC+nXkV3LcXIK232WOBFkTazSDlgQfT1rsbHT4VjFz5im4znYDwK5jUL25axm1L5xaxD5S4Ziyjv7AjBH5VveFpJi7Spllzgr9RnP61lX5mudnLF6aHRXgeSyCQP5bYG1l6j3qjq+rNaaak6t+9xtPoDxzWjG5M7EkAEYYg5GfQVz3iWNpHijfcYyT8wOOcf4VyUoqUkmKmk9Dk49Zt2di2ZCSV3ZJbfn6evvTp9STTTcW3lT3V5LJhYI/cAk8ntzwKbHYW8V9B5Kja7lvmOcnv+uaPF2iuuoRahbpG2P9axBYI2eSMc4IH516aUOZLudihJ0rLd/obPgbxRN4ke9t7eBoJ7Rtp3AjnPH19OKy5/FOoRXrbYY/Nidgw3EfKDzg89KraJew2YnFk80kjDaPLBBPOMFj6Vk3VhJclriaMKuSQqjqeep+vtinCjDnd1oKnhZzVno/M3NUvY5YhexfeCh3wfl6dz1zn+dUfDdncanLJqlw37tUxDheTjq2PwIFZek2N54g1iDSImEcBAluyOFjjz0PuentXrnhzTLRLbEK5RDiMjsvb6Uq9RUI8q3/Q6a8lhafIt3+RHZ2KTBnjEfKKcYzz6N6fStGO/tbi/soo51Z/3hZA2SuF7/nWZrk9zpEEs8ONgXJYtjP4euawPA9kdV0+6vpZ5DqST4DR/KYRjgj19/Xn1rjVNTg6jehyRo88HUb0R6XtGzG7AP41xnivxjYWBaxiElzIDh2jGQvtWL4i8Qa3d2ljbWqtDHOzQyTQZ3MwO0jP8I61zktnNYtFbzW7gSNgMBu3Y+8c1ph8Gk+ao/kdOEy+L96q/kWLu4a+1O0t5hJHZOpMgY43nsDjtx681z/w51Z7Lx3PBdLtaaaQbXzs2sMrk9+/NddqljYz2NslneAXVxKsQFypUqNvJI4PYc9OaydJ0v7Neaj9tHk39rHt2bMkNnBO7uNpyK74yj7OUX1X9M6pQpVIJQduXoR/ETxq2kpDb6XcxiSQvufbkIoHYnjj69sVFpN14gvbONtYgmdZYhNCzbVkaIj5ZAAcYyenavYdI0nTr3w5YwXllaXUaRAYmhVxnHJwRXnPje4tP+Ehe1aQwWljH9nhhUEKOMkE+mQOKxoVoz/dRhqupyYOTlWcUtEZ1tqU96WSdohPbMsKzRE7Cc9SfXIrvvBmo21yt487bpZJQVMgGWAxz6Vxd6lnpGki4aIpExX5VI2sOuSMc4roNEZ/MhmhaNVaX5yy9QRnj0pV4qcHZaGNebqtySstrHfSRwkAByHY4GOCa4u/1q7sIjZSSzOkkjRpLt2u+3O4gjAA9+35V3ojjdV3IGO0Dkda8w8YaRJfa9NaqZEgiXCgPjAfBLD3OCK4cKoylaRlh5Rbs/wATM1E3114cdrNrOLTLYYVIpgdp6/McZJOetYEHieCGwkS4uvMYMCyoCfM9D25FaepfD+904yJpU97c2VxEIzaPOflZTngEcjr1IrhfEnh3WNJ1NIrmxWG4cCSNF5DEfxdSD34/OvZoqlPRP/M9ihUUqTuk3vZf8HU6fStSsVubi7sbiRZonLGCRSBIOPmB7MOcjpXU+I/iHbX/AIfktbY+TcyRkPNuwiDHJOen0rzO9Se1DRS6bLAt184kdSCXB+Yjtg9MCsm78Na54nvl0bRY1BuMNPMx2pEgIByep7Zx29qVajTt7SWtjedGFWj7arF3WxWi8XyyQwro2oXHleWVmkxtaBc/dXP8RwcemRn0PXi0jfwVp8nh9nkSxkkuNgPmMwY4fnAJOSOtVNE+HeneGpnjkEup3UbBZpYmKDPHCjIyuSOSPxr2XQvB0+neHZorS+FnPMhZ0iRHC5ycByM/j+NZzrxhGM5fF+B5VRTir1JKz+85Xwfcm+iX7SoeUgbFPUggdPcdDzXT6lZW/wBq0+6hCpOkil4255zjHsB1qh4N0OaKd2kcgxMAmRxuwRnn1NdPqFkbeQvcMGjVMl2X1HIwB7frXJWqR9p7rFWlH2nLFnSwOskasrgg985p46cHIrltFuJ7Cci4QpZzN+65+6T/AA/T0rqHAaMqpK5GAV7fSvMqQ5XuebOPKxT0OCBTVBAwGzxxxxSjPljdy2Ohpc5HFZEDcBj83zEcEGvJbLZ4Y+JV1aSEiynBnjXdgYI4APtzXrhIFeT/ABrC2Wp+HtRJ2Rl5LaV/9kgEDj8fyrswTvUdN7STX6noZdK9R0ntJW/yG/EqW1Gp29/aSrgkJJGBjL9d31xjNcvfaizJuTccIfmBwQufama1PJqRtXlMjIoKICu5Qf8AP+NUtIt1jjgfVVZEVA/3CVznIUnvmvYpUlCCT1senCpTpuFKSubEFy7afau7IySAu7E5ZccZP86teKJD4eSyezvLa7e4TcQFw6Djr7VU8UajZ38qTadZQwQzAIMMN6sODkA9Dmud1i0fTbp7adU8/HOwhh+dOEOZpvTfT+ux3woRk03p5f12Ln/CRXrHcyJ14wMD/wCvXWXenJZ+GE1a41G2eQbXMCDDAnpt3ck+ox0rk/CutRaRqkd3Parc7FYKjDgHHB+ta3jbxcfEVvHCLOKFEfeXcDeTjoD2FKrTk5qMFZdWRXw7lOMIRtHq/wBCnYara3N0js6rKC33xzyMEemO9aihGUML7aCM7fNxj2qPwHr2j6CZ21GyYzStkXCqGIX+7jsO9dQfH3hViS2mysx5LfZk59+azrSnCVoQbRxV6Eqc+WjB2Oj0/R9M05MQWsSTMBukIyzeuSa5bXooZ9YI09B5dtEHneFhtznHA9Rj3/Sus1G/hh0i7ulljaOKFnDHoMA9fxryL4W3kt5Pd3KxEW010BhXypxwQR0IPUVxYaEnGVVvY8rDTbqPm1Z2NpaXMXlNb7lST5CznoueeBjI60mpWw0nUYQ0jPb3AKGTkBiQAe9dEWg+z4lmjR5V3fIeQM/oaxNfvIvP0+FWSXzEZfnGCoXoQOx561UJuUtjohUT0tZGMiLbW7RW8ks1tBMf3fmHaz46KnQ4GM9q7Lwprmm3egJdxyxRW6na2RswRxz71xXkTadezJZ3EPlXMi3DmVQylsYx344/StK2gENmCkkc8kz7fMCAhfoOwxWlaEZrU5J0JR0ktDo9Q1WGZPL0yQAIM5HAOR2xVC6nM9pHDg+YZA2T1Awf8e9VDAIWSRnwyn5mUYzShFeJkkkGBknfz9KzjCMVoaQhFO62ICV8syAkIjFFJQgqR1yD756VYuGji0ZJJm2ZO1mYhRsOM89c1WiK3IlEESBQ/wA6lvlTgZx/9areqaPFqVrLDcXv2e3gUMCCMsR2we3HSruk1zHU/dSRvJreh2+lxm1ubcx2y/LGjc8cdOv1rPbSLTUNKivpZdjTuZTj3Occ9xzzXmUOnQwXcGpRCRW3OoDkKkg78Ae/U11virXY4NN/s6wgEl2yrHHODlAxGcrjr/8Arp/VuSSVNvUmlQmpJK6bffoYXgm7+x65dOJP3eoySKgKZ/cqcA7h0OePxrv7qW60q4F1YIbhWRd1rvChxnsT93APWuK0uH7OmmWoLLEqrHDEcKZ5jjcx9Fyc++BWv4o1W703UILO7t0aSQf6xstE6gZKgnoe34VrVj7SenUmdOeKqOS67eiF8b67Lf6fll8mNc4jjfcx453NxwfauAfxJ4ij1iRrMz2ltfoisIeO+Mj0I9q7y+msbvSrY2enTwWkjeWsx4HmHoPfBHX61UlWGRktJI5rW6VhvWYfuyeDlT1AOeOK0ouMI8vKd2Fpxp0uSa1vqWfCja9qC/2fc2KDT/KLRSrwSQ2N3Jzk9T19qz/Hck40eTTb1FXVIplCFXx5kZX9M5zn1Fd74H1W0OnvGziGWDKOjkHHzHoePY1558S7PUNe8VJJpjSfZfLEbMhABwSeT6Z/lWdGTlXakrJGXOpVZRnC0fI5N7u7tLP+y9R3izEm63ZifNRAchQxOevua2/iZcarZ3XhzWrBLh4L4bLlcZJfbg5HHUD6cUltoN6Z7dpIriWC1+Zy5J3njIA7Dg9Olek+KlW58AG70ryfsohUhCuSMkAqfcHAroq1lCpBpXu9fmViKEKXs40na+l/0Zs/D/UV1HwvbzxDcqkrx7Yz/Ouf13Gq+Kr3TjDCtra24uX3Jl93HXnkYOfwrG8FeO9F8Jx2PhrWnktbiT50cxNsVmPKsexz36fSp/ihe3XhvxJZ6pp0Upe6VomlR0QAY6Etx2yM1wQoyjXaSte9jljy0sTUTdt7M2fEfgqw8Q6O7RytYTRZRntV2pKoHO5eh69etY3gjTWSR7OItJaW5AXzDlmIHQH8vzrH0HxPqtxoUNiI5lXc0ttOXDuvUlW5+YAHjj+Vd34St5LXSUWEHzF5K9WJ4/Orn7SjBwk79h1Ieyg3J3b29O52NqJPITzvv45+tZWsLFHqltJOFETxPGzM2BwMj29avaTei8s4Z0DgSIG+YYIz2I9awfiFOBp9rCMgmYMxx90bWG788V59KLdSx5kbqRy3hfxnqXiPxxq+jXDWWmpZBWgJBkNwmT8wyR25/Guf+K+pzMyWdtNFfLZ/vpLiGPa0Tc8bskdOcVt2+nWOq6rZXzWcPmxQiDzYmwW6DHv160eO7i2tfB97pukwwxSXDlFIIGGHzHk9TwBz616kOSNWLjH5frc9PBSiqikld9v+Cef2V3qWuaVbRXcuI7U4jeRcjaRwOPTFVNJ0+7OsWtnZSSwXcjcvE/VWbue461q6BHqfh/TrmTUGhuluEJit2kBm68fKo698dOK5zwjq2sD4kJJaWsm91+WJVySOhxxxXorXm5bWPVVROmqnK1/wb7+R6V4+8K3lvb2Rt5nEMRUGQyBdxz3J6nPOK9B2raaFDa3JZrlECbhwSeuM+nauWvLuO4sfIucCOGXzGaXLSRvn5sE9D24pYfFEL29xA7mSQAeWHyGX2IIzz2ryZxqVIJPWzPMnRnJX3d9TpYIZDJDukVZjIJI052kkEnP0xWxEjyXTfaHDrjGwfdzjk4/OuPubuN7a2ayYnUFw5Ac4B9T+NXv+Eiv9NuUj1rTSrbCwe0VpVfpzwMjHuK5J0pPY5Z0ZtaG94hhR9KlZo/M8sblXOOe2PxxXLeGNb1Bdj38m+zZjFuI+ZWz/ABE1Z1PxXa3kJt7RmRySMyqVwfxHP/1qz7HWLe10eexaxeRmY7WDAK7H15yKdOnKNNxlEhUpQjaaPQU5QE5ORQnAx1A4qrpt5Fd2qPA24AYwRggj1FW8iuGSs7M5WrOzEIBBHX1rhPjJpg1LwnFAuPN+0xhGb+HOQTXd9TnnANUdd02PV9LuLOV2jEi/K69UPY1dGp7Oop9mXSm4TUl0PBtMupprS50+7z9qiLlmXqeAD+vNW7ECS28uSJY+T8rqRwM96pzi+8OeOJ4tTjWOOUiPzOquOgOff8/rXVnS31KeM2+xlkVsk9AwB4P4D9a9+copJ9HqfSSlCrGNVaJ/n1ObuNLSWNZbSEA7QXKngnsRXO3Cs+5mXL57Cumu57nT5IrO+DW5c7MyjAUjtz71zV8Ggu5YzJExDEHyZBIv4EVvSbZ0YbEpT9jN69CsAcnHGO5qXzTjBXheuTnNG8M3IJ9KmcABcDn0A4+prU9AiViVVSG+ueKQxrk/vFFP2jbggnA4+lSAAgGmT6Hq/h/Txe6XOHOS/wArK5ODkYIx0/Sua0ZLOJVh0uHyGiOHiHRRk9P89qfBrFzaXT6cbuJZUcB4o1zzjGzf9PSr+mWL2E0sy3HlqVIROCwGfu579c15Ci43u99j5dS96TTTudPYxxT2hMzeWyqOdvBwPT3rE1O1F/dodrKsGMsBz1z069a0rORlOZFcQ43gkfMSOMGpbqUTySu7KBjblR94Y+nWuaLcZaGMbpsztTSyLqrRRNKBndwB7jFc3Ms9ndYguAhboFPA/H+tacURmUb3+baSFzwPr9PSm3SwwWbJcvHuHRcYx6A11U1y6bndHlpxs3cuaPY2V2JX1TVTujA3I0oVV/pWddzwtP5GnytJbE7TKRjqeo9eO9YdlaxXLGSaQDOSVVR+fT2oNyAVX7M0QAO5w2QAPX0HFbKl7zd7kxlTjP4vl0Okt57eB3tbUnyuCwJwXbvyOB1qvPPp63cWnSWmJblSfPJYhSOvzdD9Kqo0ZDlfLGOxPU+menFdFp0dpJq9tHc7QyJuMWc/McnJJ9v1rOVoamlT3VzI53VsPbWEcRwsYO4qgHBGTk/hjHvWZ4GsTea+ke1jBaqcBjyM55JP410WsyWU2tamqzxW6RW5eBUACysOGX9eTVf4d2ssWi3V6zH7TcTEMR32joCa057Un/W5TnGFGUktf8x3j2TE63EIVZIR8ikYJXgnHvx+lVNd8crqOkWUMVtDHcggNLId5HHJUY6n/Oaj8WSiF5JtRtvPjliBWcSD92/QKVxx04Oa4gMsU1rcmO2FlAGUNJkK7leM4HXn8a0oUYyhFyW2xnhfeoOdruGx3Xgq8ghuI2u3MygF0m3nbHnjO3oD17d6f8QbK71DQ11jSYwTBKYicDcwPTB9ecfjWDpWp/2Voj3DywCJ4/sMryR7/MXOd+B05Bxn0rodIhsbjw+uqWF4HjaXC7zgI/TBHQZ9cDP4USi4VPaLvYqfLVam5Wk7f15GJ4StrzV9Pm1G/s3ge0O6W2jkYCdcYJ3Z59cVQ0TxTdW2rRSWqN9i8/5UJ+RI9wByPfnn1IFdfoOvrplzrtpqltscplELA7WC/L3+62Rg15VqlnPp/jQPZJHJDdTxywrj5JFY8rj1DH9K3pr2kpKS06diW9fZTbdmvmj28a3ZyMr2jtLEzkJHGN7gdMnHT/PWsldPuXvEgtsxw3l0gW2lJCs3LZZc9Bt/HFSzajNoVs0d/JbolznbsjOEPfDdR27UWmt2UviDSrqOXbHETJmTCK4EbAYPqc9T6VxKLim4rQqSqQ0hH3X19Cl8TfCdnJLBJ4gupZJxH/oc9vANzOpB8tl54ORg5/GrXjbVLvUvDNpavbo07lVkijUEg9xzzwB+dWPG2vaXrtujRl/Jj+QTY+42eoPp0ya831M3trrMMKoQ2MpuYgr05/8A11ph6cqkY8+jRcMI6lJSqR169zpPh3aTyaiLdbeZUgJEayL/AKtSwUZPfAx0r0zSZnstSuBLKNg4IU+gAGPyrlfAeoPLbXdxcrsZQUDc9R0GPbjmuqkkgmhiS3CmRZRl1QDuOTx7Vz4puVRpo83GU3TqcltFoN1m+kMU9wJnRfuxJC4j4B5Y5IPH1rDhvbx5RMri7kkXaucTAsGwMema3fEeknVNOmkt44rhDGyPGBy4OCSueh4xWVpyQRWqQQolu5YYSMcxqAAp+o25PvWdNxUDlSbehYuVg0a3lub+Fba6YMRsAC5x2AP8qxfC2m2PiW0vJb+3R5LkF1ZhkxDOF2+g/nW74p0X+0ba3SK/864kkBdpCGG1Qc8DHY9K5rxlo19pPh/7bYXckuqMFEX2Z/IJbI+TrjGM9aum1KNk7SZ6OGcOSydpP9Czo1lHaaalxa2kEd2jI24kluMDA56E88Vi6xq2m+EvFEF7prpdX8wYPA3yeWzHoT0CnmufW/1zRb5I79j5jIrPGSG2bh3I6nr0qjZeH9S17WLrVoBIUtyDOYow0iA9doJ+9iu2NFXcqkvd/M7quGnGEqqd7rvo/W56X4Z1HR9ahu7/AFSXy9QuroqIAzKUOBwADn2ye9UbdYNE8RXtlfxzJbXBUxPJwxQ9CM9cH8eK5nwjqT3Ul08NgLc25jCxsCXIBOMt/EcgE+5NReJ9WXW9Ymk2PE5CmNd25kHPUjpyD78VH1dqo49Py7HPQkpLmbtF6ej6WO9t/E2haNryQXcM5JbAnIXAzg7tvDEd8gVreK/FunWnlwadOt1qU37qCOEgj5h3I/A15PqtnazX0+l6n9qi1CytvNhm3/6xeD5YzyQR6/pXPaexmureYyFZXnwxBAwpJ5U+3GaSwNOpabb0/Ewp0oSq3qS5leyPebmKysfD/maxCZ76VCGhTn5iP8/0pPDzW9pY2a3MCyXEmEeVsfLjtj6d8dqxL2XSUEcf9qPMxjBXM3m5PTk4JHPY1cvRHHaPI65VUyPY45HvzXG6elnfUqcPds7/AJfcdbNpcclzHNpEsdrJESJDEo2t6Bh3NW7Sa5jIjvkTJGNyd6foVslro9lEg2gRLnvkkc/rViYBkfkDAyD6GvNlL7O6PKcrvlY5vukkA4pdvGAOOvNQ2Ts8WX5IJHXJxVjI4561m1YhqzsYHirwxZeIrUrdxA3CIwhkBIKkjv6jNeY/DzVAl+2m6puS4sZij+/XGTXtuBkHvXhXjk23h/4kXUpbyo7qNJvubl3lhnI98/pXo4GTmnRfbQ9TAVU4TpT2tc73xhZW/iTSnSKNrgDgSFcBCO+7vzz+FeUatappckemzyrLbpveFkQKCT94eue9evwa208FtviX7JJGGjWIZDd8HHbmvM/G9he32lSahZhpBbylpLcRblCbuSrdQenODXTgm4P2ctEVSqRopKotFscb5uJGCqWwcZ9KtQSyEqPLwTxxUuopD5MV1HPHscbkII6ehx361VUxhVaORixHI6Y/GvVTuj6OnVjVV0ywYjlScbfbtTHuQGI29/Wo9xP3iVB/2qrMsm47ZFx2+U/40GiR39xp1rpWs3t/Jp4e7uTvQAZ5z2qSwubxbSe7e3LLuXaYl27WI5469cVsBtRsnh/dWs8cUedyjbn69qks7+bTNV8/ULVTZXGWLKoIicnjBHUf415XtG13Z8nCmo3lB3IrTV70wxCe3ELAbZA/Dc+n/wCqthLi0ltYsMJCM703HAGOPrUPinV9ITRZ9TQx3M9ohdYkbDlcZww64rzbwf44n1eM3UFhBbEttKPIWRxngKR93HOQfb1qYUXVhzpWsJzg0rqzPRTar9mW5hMRJYhkzllye/0qjrGnl7hZHdjjDMNuRn0FT2F7Z6rZm9t7WdG2Nkqu4KynBHHuKa0009orRboo43BORnIz39iO1Ebpm3M7cyGNbWhhRDBGs+CM8fT86Ynhy3udqSXTIuBvhXHvkE9R+FXpdn39qqzDJLdPx9ulUxrVq+rbLwIPkMkdt0LdiQe9NOdvdORRlJlG8tF0ySVEU3BzlAp29ehx9OK6u00ZNN0e5urt45Li4j3E7eQTk4B/GubiuTc6mgb942Qqq47AcA1taxLcx6fDY3LrHhdrMjHIXHBz+n40VOZ8sb+p6FXntGN/U4TW7GzuPD63NxmTUo5jJDGrYCr05wf0PtXYeC49vhiyYKPNUSO3HAJOPzIGa5nXE3WNvbR7syv5Z3Yx16+tdxpEbRaSytHtCYDDGMccGtaz/dpeYYubVFRe7dxI9Ne5yoEMlvdR+Wyy9Pfg9fp71geK9C0yOGDTY/IiinlJZlXCgrjBPp1I/Gr19p/2q9WMx+epkBwGwV4/PGQPzp91p7yaZb28nzTxl9zbuTnPy7j14/Os4PlafMceFqunVTeiOe8S6Zodx4ftrZL1dlqQ5igjP3sYyxH9T1rkbuwtbMiwtWJFxEHAdmbLY4BAwN2fr1713N54au5bf7PBdpBeTvuA3fKxQbgTx+ea4DU476W+nm3Ri9kcRvskztI2gMOwIIFd+GaaspHoKCacsO7yb1fU7OWR/EOiaQDam2vTCEhnL43IpIOTjoMZ5qDxBAbnRla5iSDUrTkSoNvm4ORwOAep9810HhXUreHSLTQZ5nS9hdxJCV6YywIPTnrViTThf3Vxb9SUCGJhlpQRndnrjtn1rmU+SVrWSGqro1uVxsl18v8AJnmup6/Lq9rAimUS21kNu35vNkaQAliemOMAcnrXb6mLzXRpBtLNIrVgBiLa2wgjLNgcAgNweelefzWVxp19METy3trgwSocM0TZ/dv1yQRjnGAa9I8G6xcwywrLby3eqXEYaaGIZyVyM56AYA5rfEJRipQWxNSfPKTpa21XS3l/WhneKtNsNJuWUTq9veRM+JTt8th8obj8a5TxTdT+IbHS5Yp0mmgRIDJGw3SKrDGQOp75+lM+Jms6heaxM01n9nlDhBDtLAFewxwTkn2yPeuW0aQxXTXE6/ZoQpedQfLDYzt2hc4z34Fb4ei+RTk9TaeIlRUVVi3pq137dtdjuxqv9gzmGSRRAXVpAJCxJYA5UgdMFea1PB9zeJFqd4A02lxOigFxuJxuZseoB/Gs3Q44fEXg+2tbmW2W9ABhYlSX25Gw8ZAGRjvUkOm33ht7WKC6sp7uZWZ1DnGCAcY/Dr61nNRacPtHBL2tWo1U0vqr/ke5aE0U+lwS20heFxuUkYP0PuOlYHj3TFktIZoFaKTzAu9DjGTXOfDHV7uwu5bDUWeSyun3wSyDGyTHI9s4zjt+Nd14utGvdEuI1baQA6leuQf8M14soOhXSvoear8xg6beWNjJJDK8MiIgzggsWH3sj9ao6tp15q2pWs+jzwtGjsy7juRRt4bjqck4Fc/p9too0vyNQWWbUULSSmOPaWJyAocdgCDnnNdN4Utn8NafFbznEQjAVF5II7H3Gf510ziqbcovXz6nRSqzjLnW55F8R/Duqaf4k3XV691GNjvMFKgxtnAYA8DIIOPrXb/CnzLS8voVkJt5N2NrZVypHIPoORmtbxM9vL4gsJ72NUgkVraaOQY82PBYA59yakur6xtb+A6HHF9hsrJ0Kxn5U+cZ/wDQh+NbSrSqUVTa3R6EpSrJN9Y28tP+GNxvBOnySTzpNeWz3Ay6Qy4Xkc9s1514v8Hf2Jam6ivvMEkixNHIoGVzwQeuRjn2Nek6L4i/tiNYVhe2uUUbwxHT1HHQ1B4u8Pf8JHp32G4lEGHDRSKM7Wwc59Rgkdq5KVepRqWqPQ5qdapCfJWenmePSeI7O9ik+0JbBraJRJJ1e52jC445HbnNYX2C7mii1GXTontDIFAnBAIzyAe3HcdKtWXh508US6WAZp7SYxyuz7hhT1Ge1XbAzprb3V3Y3Vxdec8aNKcQW8XQspB5OPy9zXtrlj8B6GKny0FBxT5n0voHhtY49bLxobiwUZYgY8pSP4sdSMflXo2tSmK1uYiJPLZfNE6ldojIwMflXn+jak9vPczQwsdOeTcyoAdueB09Rziuw01BrulL9nmlZfnjjCP91TyoOeMc1yYhe8pPYzx1OdOEdbtHomjX4v8ASLW8gkBSVAGCtnDAYIrQjdmO0pkg4DZrl/Bvhu601JluXlhQsCsav8pHuBx+VdMls0T8yfLnIJPU+9eJWjBSai7njaWsyKZhDdRpGVjd2Pvng5z+Oa0FOe4OOpFZNyRLq9uQpOzKyHBx0/n0rXQttBYYPpWU1oiaiskVLax8nULu6+0XMhuAg8p5MxxbQfuL2znn1rxD4zTQS+OYgpYta24eXYRkqQeOeOBzXvdeC/FSwSHxU8p/d+e4WSUD5jv+X8sV25bb2132OrL9ayj3uvvR2HwyuhqOhrcW8qvEreXhgQyrj09KTxJZWlvN9o1S3uWtZTm4ezlZEi+bAZlGc545xVfwlaT6XcyG9uRlXVPM6JtQfzI/nXS6y0cMRu7WWQzSqQ2z5hJk88elXVaVZuOzG4yk0pbs848QeFYtG099Q8MoJdLnU+YkiBxHls8f571x15YtCBNEqiFudqsTt/rivoDwobAeHEtokjWKAMkkUgAAy2eh7V55440caTtutORBp8zM6KV3FDjqfVT2rpw+KfO6ct+/c6sJiFQm3JarTyf/AATi/Dth/aepC0/dl3RiAz7e3b1PtWzLoekRSvH9qmOwlc7OuKqaNbPcysmEnuPuo0MXliVjjgAn3Oe3FdevhjU9oz5YOOm7p+S11VZpS1lY9GeO5vei7LzLd5a6rZaO9la2qzRqwZJlOWXGM5z1zzWg19Be2ASaHAG1ZQy/LwOc10trGIYRD8zkDrtxnn8qp6ppK3MM32UrDPIPmJB2v9a8VV4t2l9587GcG7beZyEtlp0149rexs4kXbBKTksmOYznuOo9ce1YF/FYLZTeHDbW0EFvdZieJBG6nAwxUY4OeelbHlS2PmW+qwExFvl28lOw2nr9MdKz4khvNTvYEu2S7liKs04+a4XHygkjh1yckdRivRpu2ren9a/1+R0yTk+V6/1uanhux1Hw5HcxS77qwnkafzokx5bNjoP7vX863ZbOR4FZ1PkuBs+bHQde1U9N1y0s/D8emXqSwX8LeS0bDOTu6g9xis3xN4iZtZg0iAhY5kBh4O+T8u+OeaytOpN6fP8AUp3jo1Zbf5GjGn264CSy+QqqBzzn8K5zxFp15qWrPpd3p4ggEw26iAAPJ4+cHs2eMfpWy1tqP2qPepAhjxuA5k9MY+la0V0txE8EcElzIUBYFc7F9fx5xVKbpvmj/wAMa1ItWtsWdBt4bS8knht3ckhFfOT5fA3fXgGue8Y6o2oarK1pGFhgHlbzjLN9PwP0rQU3n2nbZxnIyhwpYAHjOO1c+tlNLrSG2WcJEWDDAzIRgHA7E80qUYqbnJ9DNq9RO+pBprGbxJGl2DM0bfKEHA44A/Lk16DEgksHKSKWYjCA43Y/rXnfhRol8asl1uAhJckHO04OAffqK7TSLsRalcW6MZIY8sARgqe2arErXTokPMZ2qqPZL/Mle3mju0wFEncHOR+nWrEk0z28rxxrK0A344ycZ796TUdSSwsb69W2urloF3SSQR+YRjBOB3wOTjJxnFZkeqRajpol06eO6ieJvLkg537ueveudXkcsdWkyPSRc3tld6rJKw+ySq67QcsoPz9egHIx7V5nrMAs9TnnhE3l3L4cKAQFPc+/Tj29q67WfEV7H4WtdH8PyR291LCn2m5SPc2WBJUKenA5J9eBTrLTzb+Ebk68La41MqXiyuw/MQA23uRnOO9ehSbpNyl1drdTvp4hqpLlVmnZGPHqi2NvbXVnJBI8UylyBuLsmckn0wWH+Nej6xcyWxstUhVFkt1DMGwS4JAKrjnoentXkmmaW2kbj+8MBLK0UiYGOx9xxnv1P4eg6Rq0uo+HpoZUQmCNjG4XlsdMZ5yPWliYK6lHVf5lzUqtONaS1vZ+jM/4jyWFx9l1yGMQXbt5RnONsgKnIKtjkAcHORUvhWG+mt7HxDpc0DNs8nyV6lQcbSM9cYNdRfaDaeIPCoikG+KSIM8YOQWHG4ehGOtc7oFg+i3OLJVWEshyR90ADOfwzWUakZUuRbrv27CoySjNQ9NfyNSB9F1K9u5tUt7WTUJA6NFcKD/wEZ5GPzrxGawS28R3ltdQyfZRKTsc/Mq44/DmvbNFtrbxDquqvuEkEc0jg/8APQ5x+Vea+KBpmseLXjS6MUe5QMfdYheOe3I/St8JPlk467fcdVGSUnHVtJO36L5GhqT6daLax+XGkYTeGjIAUKMjBHrXJandOni/TWFzO0BVZ1V1wYwW6sfTJ/pV6e0Eemu+3JVhFkcgqc89c5NXr7w5ea9qWmXUc+QB5M28lcIpEgyRnpggj6dK64OMNZPuZY2LnThOC0TOw0tL2a6tlS7t4bWGVjPEYsvMTwOf4Vwf0FetXyRjTLkBUA8pgQPpXlPhHUY1v44ryAKlxMkkUjsMrhsH8MdD7V6jrMiJp1xxvZoyioOrMQQBivDxl+dI8rF0PY1XFbXOA1BLCyS1iglSRXVQzSJnOF5wfema14H1bxDYiay8U6ho7bAYvs6q4GfXo+enRgKx4dOkk1ILLJOQiqqRg9DySVI5U9ARXZjVH0nQLiOSTy7ox7oQRk7mOAoHft/kVrXi0koO7M480vdjueF6V8JPEFv8Qp01LXnulWLL30bFpeQCu4OG4zwcE16LHqum2+nWfh2GUXFyGaS5nKqiyYO8oT1J56e1Zdt4huNK8QWrLOCBEwuGk53AkADJ7g81LqHgm+NhJq9neKbKKd7z7PIjKwUvywx/sg8HqD610RpqFo1Hp09T069KdCmo+he+HGqXes+NZ7u5kRYriNkjijHyoEbgKe/C5J9a9VuLLEO9Z/LkTJVjkqv4V5b4f8NHRrPz7NyLhdzxyo+4bPvcdPfJ9q7e1udQ1ixjtyzGN8rLPGoXcvoPQnue1cmLSlPmg9DzuSTSk3tueS+GLufTvHc9zcFJt5drhjk7/m65+prt9DGmXOgahcXtqHeIyhlkPyoCxxjtjBFcH4/0afQ9UklTdGrx7UkL7cOpyQcDkkAHH613Sw3Vl4YZdCkt9WRo0kmkjYSMmR82UB+b8+3SuyvyyjGSe9vLY9jEuPs04J9LP8f1OT8O+I9H1i5l0XRdKmMsB/dEgbZY/wCMk/h171r+Cp7PS/EN9FYXUT2JKyiIZIj5BIHsCQQemDXOWmvzaTcajcW1nBFczwGBr3aEKDtiP156n0rH8I2cmj60L66uJjHcQ+QPlC+ao5GRu9hzW06KkpLZW9bs5aWGxEoucldO977+R9E3OoIZUaBklXIAjXkk5657Y5qvd3E9zEVTKjcQRjBx6g/qK5u31+a4s4Rb2qxJvWNlUqWUngbh2zXQ2Fy0iOFUmQceg6df5/WvElS9nujgXLHYigtpoLiWSIPJJngk+2MnitqxnZ441l/1hX5gcZH+NTgrGihsLnj8ayricfb18jCiNjuxnnjoR/ntWLftOhm3zvU1JXZcBVJY9DjgfWvG/i1a+fdajOkeZI0hctnGQOP6gV6pEtxI8vDbCCN2fm+nPArzv4n6fPapBKskkiSSKJfNIJC7hgZHXkCunA2jWWp14CKWIjqVY/FVpoSCzMQme5ZEaPqqhgOCfqR9K6X/AISjRry/jQTLGYlznIIV/wC7xWfL4e0S9uLfUNSjZ7j/AFiW8b4UkgYJx3Bya5rWtBv9PuwkUlj/AGW77Q8kBRw3QNkcHA+ma6lGjVdndMK7qObkkdx4kc2+j3E0dpJgoojPyspPrkHPrXj1leavc6zHH5sixqxjNuVb7oPXJPp3zXtf2WbSdFjtTfLcWxAUusY3A9emelTXhtLNYylnEVZeXPJz3z9azoYlUrpK9/66mavOxzmnw3NtpfnFFEwYqVdhnGOp9KmTUb/Yv749P7gNJf2Mt7ex2tnbeUWYyGX+4R/CfQe1bCaLfRoqLrLBVGADDHn/ANBqZ1IrWVtf68zadopczVzWlB2MFxuI4ycU7adqBiNx9OOaaGyzDB+U4yRjPfIoctuGOqnseorzkeaY/i/SpNT0aZbUf6RGN8eD1xzj8SBXnHh6JdQuJp9St/PlMLRszJtKPuyDwB24yMHj617FHJl3UKR5eM5BA5HY9/wrn9T06yXUUmkAtlmPMqkLhh6+xrtw2I5YuDNqUrtLqtjE0y6W0Z7bUIfNtpAI4bqTBETY+47HkA9j+FUbPRxbawbvMbkrhWlCsUYrg89eB0HSpVu0S1e0uLaG5gkDNtJwNmT94/rjNPsbmWxu47S7t0lWYLFDP0yO2454POOevH0rqV1e3U76bVS6e6E1XX0sJIrC5uXtyQA0nl8t7DHWor+9u49IjTRZDbJIP3sqgBpAe4zznnrUmoaTa3xH29EMKyfK0hbevuMcgVkzaLcahd2CmdrKytTIHh3bTM3G0jPJGMnmrgqdl+JNR8qtumb3gif+xbeUSpLc+ZwGTLZwe5P4itnUPMYS6gAtvcbQhjPJ2nI/769qreEtLU6eViVYN7PtXrg7slv89ajkmeS5GneU7X8cpZZn5VsZOMf/AF+lc8rSqNrfqTTSUrpa9fQ8/wBCmW28WayMOjoElxKDvLKccetem+FESeaa7lZQ0nIQ5zj6+uea4+5+0an8QjLZIIrqe3ESMRhcjOWI9Rz3r0bTdIbSlWMXEkoC/OxO0Fj1IHb3rTFzXLro2kGOu5qUt2kVdbmCQSxQq2zOyRE4LKRg59uteb6rYz+Ep49R0IxpoLMHu9MjBkaE8gyxDvwAWQHnkgZ6+rahZpq1pNbu7RP0BB6cHr7V52WuBcrbywSeY0jKHjBEfHQEZIwcdenGKzw9pK3VHJ1ui94ensSI9Q09YHSdf9fCN4KkZ4z0/TrWT8Q4Z2svtCEfZztVW28Bjn/6/P6Vyvie4ufAdxHqNpdtFpc0xe4tYsbUc9XjB4yTnK98ZHfKad4z/wCEw0eG4ld/3ZJa0JyPOGQowPVcH05+tdlKP7xSuerhaDnKLm73XzsQabczCVDbzme2ydsU026UArg8EdM89a77T9JvNPWynVvKtGmRTI/CjcefoO3PrXmsEEcqxWzWNzPqaykLIzkwYBJAK5xgAjPfitzXtVvn0ibQ7DUrq5SLa8iYDsCRwAuARyfpXZWg5tKJdJzpU5U56RT69V5f1Y9juYp7W3uJtOjWCN1aXy2+4TjnB7E/lmvO/DTm81U6XqsjtBdKYyxfG5myR06cgj8ay7bxBqM+nxW95i7traJdwd3Ct1wpA4yMd6xLbUIp9RSw093gllYsCCzMmFLnPrggdORxxXNSwzhGSf3lwj9WpOTkmn1/I9IOj6v4YMxs5lurSUFMYCOqEYPPAJHrXnaaWLjVLueBWSQRloYygJJVRkYyewOD7Vr33jm51rRjPfsyxJCsbuxwN+PmKjofX8faudPiRVvLbUNESRtEjKx3BCjMeWIy3GVzkc59a2oU6qTctzWVaGHalXs5vt+bJIbiCKC0g+0yXNx9y48zdh++VHsTjj3rV0jXHtdTmtlkjmtWcNtJB2Z+XOB357Vhw2zDxPBYuWRIP9XhQVZCCQ+epJ4B/wDr10tlptrb3PmQCON7g7SyjA3Dpz25xxWtTltZ9TDD0qnIlJ7N6fqd3p3huK7eA3WH/dfK/CsFyOR710V4U02OKOSbzoIxnEhwRwTxgZ/GsnQbiU6LavIpMoLIG6FuSCPf2qr4sv73S7SSWK2k1FhKYo41XALMMEseAuOCOvpXjNSqVOVs83Ezlzvm6Nm5pDRyEXcQjZnfg4HDc9+/SuI+K6Xl0Vitg6XAbG7PIPYfQjua67THg0i5liubgGVYllwZVKxyHOV/l+FZXijV9Plt7uSaeCWeRcRRK25+OOAOhHWqpNxqqUVdDw6cpKy30PL7S+NrdWV1q9ilzcQXCRmNZPvp0Yj6sR+Xeuv8ba3rOjSxWN6FEt2w3MScfMcbR7dAfrXE3Fo8sqLYxzTM2xmKAheDkZJHJBz0716/qujy33hPd4xgguTCnmMwUl4wMY5H5mu7EShCcJSV/Lr8jsr88YWbWjsu9lb+mcfNfT2XgtLlJx85aAIgOR1JBOfYg16l4V1jTLzQra4tLiCNWTLxvIAyN3BHYg15Fol5p+uFbRLd4I7c+Sq5OwDorccHPI/Gs/xDZf2Rei2tbpQZUJcK/IXPUn9PWsquHjW9x6O9zoeGjioqM3Z7tmr8S9Sj8T+KYYtHUzw2ieXIVbAlbJyAfXHANYPg3SbvT/F1nHoOqva3E0hGHXJWM/3geGAweMdafbacml2dhqzTLHuJfaTgDGTyO/rWVqGqRajqNzcvcXP2zzM27xDZGE7NkfMGzzzgfyrqpw5Yeyhtaw61LksqabUdO9/kdp448KXGnXFt5V1LcpISWLkBWkLEscdBz+VbenaTotx4LuL06bA8rW7SMz/KyE/dwR3+lYt/4ukuPCsWlXUwv5cq32ooQQvdT79Rmrnh9rm00mTT1VnMi/Oqg/ID7enOM1yyVT2aUnqn96NZqs6MVUdmn96HajZ2+n6XHc3l3KdrAeQFbEpAGORye+PpXU+GPMlZLfzGI8vzI5Q2C0Z4AYEZ3VnfaNO+wJa3U0kZiQEhMHaw+6fqPasPxXrmr6BBpqeFrL+0NU1OYRSTrGWEQJ9BwM9vTmsWpVVydX32PCqRtJuJ2+qi5t3mWa8dlPyokZ+djj1/Ose5uY7SyjljvrltVLYkUceWOc5BH071uyRMPEscRclFjGSWB+bqcVz/AI2sGS9nMbE+aNxGRwT6flXPSabUWb0oxclFneaJcG70iyuG5MsKux6ZJHJxXJ/FlWOj2Hl4aVryNFB785P/AKDXU+HY3g0DTo5B8626AgfQVxfxCuXuPFeiWKMDHbA3cigZychQD+ZNc9BXxGnRsxwq/wBoVujNPQD/AGZEiyNukZVDtwOff8629V8u7tHgkQeU68ggHt6dutZV8qxut1EN8JKgqwxxnA6/1q612Jbd5IVDOp27WGAAD/eon70lMuquaSmVZ7uOfSnXaiRxny3L9TjuMV5N8SPEOp6jpUdhpEknnAjzWXAOAOgPpkCtf4i+IprVo7G2bBlXJxnpn7x/z2rzT+1jBlYg7Fv4sH1/T/61ephMNZKo16HpYfBKVNuR2Hw08Xaxo+mG08QJ5kivuSQtuKgjpXXnxVZOd370557V5LDqLM2XVSAcYznj1NWxcIRkoufqa6KmGhObk1q+xqsuUVaKPo6VA42guoPdTjFKijezZbLAD8P8mnOWBweFAye+evT9Kdn5QR0HrxXzfQ+XuLtJXDbuPSszxDE82lSCNS7BlLBRzgdcVqD7uD0I/Sn5weuB60RlytMqEuWSZ43cRRfbLwXUIlgkt9q28sgQFsjjPQcGr+rTxy6I4jjeLyvLLKw5QcdPUd66nxVpTm5Se3gZ4H4uAuCVORzjtx6VzsVnBE0kcgdbRhhkxnKnjoK9eFVTSkd0LKaqo6S48rTEtLqW5hNvKVH71x39O2Oawp/EEWp6gUt4oXjhuDGl1G+7aD64PTmo59OGp2c+mF1WaAK9vcAFGZedre5HQ+tcbrOk+JLLRJrawtYZ7yVGhRrdQu4u2WdiT2HHrzVUaMHvLUc4yjK+6PTBem2ngjs5V80MQseC2cjn5R16UkN6P7QSLULOSGRFEgjCkMc8bvz/ACrJ+FTyRTE69LbvqvkgebFjaWJOcehxt9K6XU3j1LXIZLRj5UUTQmYfdck5IHqBjr6msZrkm4W6bm7aUuW3Tc5s3VnpPi7TL+Z2WJ0eOTeCCjsQMHPp6+9ehrf2nmKiyoN3youe/bNeZ+NrOF2ji3PJ57glz97r3FZWuQa1oWv6cLG7a5sFhP2mOeQZYY+R1HBPp7VcsPGuou+tjHGJNQn8vxPT0Ec3iWeyMsmBGJGEUpThicDIIPY1y+ukQeJPLs0C20CKJI09CcdO/Genp71f8Jt9omkuZbfyAzCR5WTJUgY2hsdOtVry6tp9UIVCLmUs24HooHoTyM/X2rOnHkm15HLpuir480m3uvB8tvqNtbzpOI4ow6B/KYckg9QcZ5GK8pX4az+E5m1KwvYLjT7iNRNbFx5iZGQyEE5Abg8g4J6mvQPizrsGm6XYae4FwwkBX5/kJxjBA5Oc1zunGK+8MSyrbyG7imeK5iK7fKYEdD1xjjmu2hTlyRqPuenhfZOmozdnf529TB0y4htLkypCltPC252Wc+XJGAONuevrVq3m+2X9zPbyXEcFx82ImAdvlKsD6rwR7Vg3KPaT3MhgjumnjVgBLt2KTyckdCcdCK1PCsosUMUFwksoj8wIuHGCpL544HXj3/GvSlHTm6nVQUJuWFavHo29eh2mlaa+l+GllKpcoH3SKHLAhVy236Y6muXvNKms/EihIrplLma2WIkYLcllPGM5/IVreDdQ1W7kOlwny7a7yryKvOw9Rz0/D1r0K/0wolu8Qcm3AQlTlgoXjH4VxSqujNqXUrFUoxfsar0ex5De/ZIIja3VpcqbfORFNsUALlup5z6Ywa1dL8QWuiW1xFpGlxG2uYzPcBsGRhj5sqeCPQf412F7oFhrFw8s8Eck6Ku4LlQ+Tx06Hn9TWXr/AIDuImdw8ttMgzbup+VBjByfoTxVe3pTSjM5JXTlezk3pe2hzPg+dNX1aI2wkG1HG2RSHORjGOxweK6eeBbSzkCGITNcqFUnDnPGAO4GM8Vy2ivfaPqjanO6yT7wrPIcZxgLyO3GAauXSX9742XVZxbLFvVolU4RMOOFB9SevtV1I3ne+lj0a0qi5HJauydvXU9Z0S0lOjzy22YblJnaJnA2lSBwAemf61bgsY7l3eaOR4Tgkfd5AGevHrVwahbQ6dG95dR2xKBSWYDnPPPrx+VPuruIWcl3IQsMa7jE4+9np+Y6V4TlK70PAqOU5Ntbs8t1VrC/u9Qto4J1KqZBnajccllGcjHBz7UzSpf7Q0uO1t42jhlb/WMoG5Qc/KRyffHeube6tLn4gL5Vvcy3tyVgd4j8kcTHG7GDk4GMn1r1PUfsdpDY6PZKiC1G91yMoOignuTXqVf3ajG2r1O+nU0dJLW9l5W6nQQeGoJrExXzP8+0iOI+WsWOgXHcYHPrVC81mTRppNK8TIbq1uFZYLtUGJEIwVlHQEeveurspxcW6OCCSoJ2niqXiLS7XWbFrS5HIUuuDgj0968iNS8rVNvyPNp1Up8tXb8jy/wdo0VrYGXTrZjFJI8dwXkzhQ3ytgnjIx+Vcx4o0CbTddFxe2MptZFHleSquCoBJ5yMNnbn2zXovhtyZHtbdI4nmDRqCSUGOpGTnI6YqTxnZC30m6tNS8uW3mjMkcxJBSVBkY9M9Px/CvTjiJRq27/edcsRGrJwfwv7zy5tNmvdE0mEOt5duGRYYiT5WDjDD3wfwrpdM0FND0qWSeK3k1FflRJV3Lg8ZGOuB2rt/h1pcMdhPcokazuSgk28gc/1rzHxH4M1m01lrmOAKrSH545MDH/fXHr05rSNdVZum3a34nZWzFqfsILRM6bwr4buvEWpNe6zbRW1vBjEKDIz24Pfvz613Vz4VgbzDb3VzbSOCNwIOKg8IzGBYLR2LyzRmZ8/w9q6a4yABGR9e1eZiK9R1LLRHnYvFVJ1bXsuhwWheGLcajdjVZftecAIY/u7ep3d88VtXMK+H2FzZKEtWH72PPA9/pW9bWyYZ1LK0hJJznNc98QNXn0TRXa30C81jzAVZLYx4AHZtzBj/wABVqzdaU5JM5lNc1iCK3g1fTlvLKUC8LmRZ/L53k8gj+72rF8RPLMsgus7xhHCA4Q5xjPp3z3zXmuk/GXxPN400nQx4VOnwSyiJ7N0P2lxjopkMag/UD616HqKXcniydbiC7tYbwQmMT4wGCAEZBK5HTgnpXRSvz6+qO2lLmk10Wx6cuEjAPygAZ56CvOoY21jxBeanDH/AK8tBbFgQpEfRs+5rY8ca35NodM09i91cRkuyHPlxDhmJ7dab4b091t0jkdvKiQiPDbQueTx15z+lY0ounBzfUihTdKm6r6nLaDe6nH4t1GGRnutMmVpAZXJMT5+6R6+/pitPS9INpBfyx3pjhmkdhFu3Fj/ABY54HtU91ZltRRLeUeS2FZ2bPTqfftXQWNtFJZOqNE+Adqhfu9gT3zW1WokrrS9i/dopNdT5y8RXclzrN3Mysz527jzhR2/KqlvbD5SVP4dyK3dXtLddUl0/KJcs5bawIGewz0ycfSspm8kEMArLkEmvbi/dVj6LDTjKNk9iui7JWQbSpOewI9ulaq2ilQQpwR6GspLkO7bQFYHqP51E9xPvb5c8+hquVnRufVDKxIK8AZ/H60AkjC9ajWeOWd4o3y6AFhjpmpvc4x9a+RsfAPTcXkAgAemKVC2zB6jnApBkHB6ev8ASlAOSGP5GkIMHcO2eK5rWNMdopZUXcy5LIO/GQePpXTD69KfGm8kcdPTrWlOo6bujWnUcHoebRRXd8shtxFJdQbShzgqOuSMcjnH1FT2PjC1tNThtNSj8q5vCYY2I3p5ikcZHTPFZni1bvS/E15JGmy3mI8to+PlI5H86xNf0pdV0JFRmjuA5l3jO5GHQj0PevYjThUSctmd9uaKj93+R1UlhZWrPKbVIZpX3EQqcsOmf0Pt1o12Ri1v5ODbMyLvChOMdOOnYfiay/AWv309k1nqcLG8hGxmXCGb65HBz1H9K6dltrrS7bbuZkyksbnGWx0P1OMVEuanO0+hq02knsc5qt0C6k+X5kTAIrSAsyAAk468c/lXZvHY+IH03z7dJI44d5KnoflAHHbqa818R6C3/CTNcRS3CoUU2kMAGOg3mQn0+bHHeuj8HT6gYCdNiMssQbepIw654B9x2p1aacFKD/TczS9pRs94v8z0JrYQWeGRIRFnYUOAB7/n71xOthN8M8qhrV43t3O0NgZyCR+n410uo3017pnkXFvLayzDa6NkDA5ODjv6dawtAkjvNPm+0B51kBZF4DA5OOD3GDXLQTinJnF/dZx3iKzjuNEsW1SFX+zM67CSnDdDkY4wOee1czcXhur19J0CYeSU80QxpggHG4k8Ege5rvtWQzLbpPcAWzMA4ZicsOMcDOMf56VyFvosfgzWrpJGV1n2MqwjdKcElVDe+ck+gr1qM1a3Xoj1sDTcqbgtW/yMaDSDOZJL/wAy2igcbYpXUMc9Bx2P+TWnJot3a6dbLcoIYba0aIsu3DZbLEEdRwOvqa6Y6zbXV0n/AAkWnrHYqAkpY4Oc5wCO33eO9c/ea7pt1qcGipNcpYtLmOXyTtETP9zqewx/OtPaVJO1jslQjCcJyVnHrvf59WejeAbVbOzka3h2OI1ZRt/gHAIyOma1bLU7fTzLLf8AMLsFZweATwRj86hvbm0kkt00+QC3mXYgjPPy8kY9Ogqa502TVrKPyDl4mBEbnAB/i5xXkzak+aelzzaklUqc9TRSODl1f7H4hgNteeZp8SrKSnzjjnaT1z/Kl1T4nX0us6jZvaLLaqrqlvHE4mQ4IVt3QHvyMc1eu9J02CaRdTtWs7rr+8wu8LzkMOo61wEz3mnSXFwXW5td2d5fh1JwqtnnI6da9GnTpVdWr6G2LoRnFTgm7f5f8Au+FV1TUPDOsx63EZbiJRIqyAbgnOScemB/Wupl0WG2NpJbyIIpIg481wCAOh756Vl6PqmoaFqV7aeTDHceU0VzFK4deccHGNp+YAevPtWN4j1BNOhtmF55SeUCf3ZPln7pyM/qPyq2pznps/8AI3p1LUueL0Xf7tTsxrOoy3EMVzaJcm0kYEHlCSo6fhiub1nxHq4mj06zUQ6WrNkuu5kAGcEjnHUDNbPhptc1XTksbO2tktghk88ZRpRnsxHcn0qOXwjfyxSxwQ3KrKVWXzCCc5GRx1H1rGPs4StO39dTWUIJWTSa+f8AwxB4e8SaDZ6XNLPDFFqa4W2mU7yATwpPquDz9Oag/wCEuskttRslJuTeSbpJZMKc54w7Hj0qRPh/dLIzstwDKd2JQABjgkAe2K6JPhRYzaWr3l9IskwBbZGMAEfrTnPDxd29xRq0IQcqj95lrwR4pjdTHLLHCIwFaPzQ2Tj+Ed66a21m1nubydpHaRSFjgxjdt6H/vomvIL/AMJRaRfWlzbtLLCLny3ONpZRkjK++Diu2kvNF/4RmMFPJuUy8U8YBfPOM456YyK5q9CEpc0Opz4jCKdpx3l2G6DfnRSsuqxpBcm+nl2geYdhO3blcnk5Oe1YPjrXNR8amS30+GO1srMhnWSTBlz68e3Tt39s/VNbudVvbdYbJUeH/WzQDc7dvmx0HsPxNbnhUwaVeX2tzB5tLVAgKg7C59R6dOo71t7NU37Vr3ug6WCjQi3NXlb+rFnw7eahpUFulpaTSBE5IIYcYHUHpW19tvNVma41eGKK2gTZDCgZQzkjJJPsOO1bfhXWIPENlJfW8cKbW8jYpyeOenbrVa5njaC4JDsckKsg+Qt/s1yTneTvGzOerUvJpwtJaehk6fpdzZeJJ9QsZmkQfuvJf7nl9Rg9myTyPcfTqLeU6nEHkh8kIccHqR2rGgN1Bbu4kiMmQMx/eAI6Ad63dJt53SSW3uI445AAf3eTkDGcdBWVVt6vc5JJJcz3HQ6vbQW6xzy4nUAGMnLeg+ucVnhH1bVTcXSSRW1vwisThwecj2xWVrekzW2sNNZzSSSlg8rysDjJ5wMADiuhlDLEI9szKWwZE4/D+lZuMY2lHqUoxj70Xq/wNJ1gcxGREKIcoWA+VvXmq2rwxnSrkzBPLiQzI/8AdZeQaWBf3mDt2McHPsen8q5z4nakU0yDQ7SXbfao4hX5sbUz8xz9OPzrKnBymooypUnOooLqcnZLdavZ3erIFW51BmxnqkQ+4o9Bxnmuwe5ksbSJJCPNmhG9s4xjGMfgf0rLtNKgsovsyyu4jAj3q2BgDGM9+9WLq3W5mWSTc6KAiqxxkdT9K7ajjJ26Hp1VGUrfZM9ZUguVSdo/KncmNGPzEj0GQcHNdJbKWcXOmNKkBGCkmTuOcFeenr+FcNr+g3U0rW1tHKFmKkThtikZzknr9Mc8V2N+b7R9Dih09Ypr1mCAMSxYfxHbkc5qaqTS5XqzhqVpTexia74Ig1rUnv8A/V6hGoyhwQwByCfoRXn3jTwvqcdo9xZ2kc8kTgyoHAO3nJHr6V63Dd6lDFZm4S1W9ZCZFV8KvqOTz2/Ks+PxHYas6+c8aTsQmUzhjngA+vWtKNetB6apG9KtUgtNL/eeGaxaNaNEWURFYkbb356/rmqH2wDjcB7bhXv3izwdba9aLBdTFJUBEM5jG9R6ZHUfWvNJPhRqgkYJqliVBOCWYEivQo42lOPvOzPXw2PpSjab1PbhaC2tQBI+0MHOGIOQQeo7ccj8Kuh98XmISw64FZUWpoIkt9Rj2SuwVDn5XJ6D69a2IVCwgKDsIB6f59a+dmmviPlakWleW4fxHO3gZOT0605clyB1z0pw+VscZB5zzTgBuDnOegrMzQFCCARx9c1IibRyRj17CgguuAXHPUfWns+1C209OfagZz/iq2jlSFpliZQeVbjHv789q525SyNwdufJICyIhBU4/wDrd63NYurfUNMJjcPJnKfPheO+a5y2tC8ZcYkKg/cye/X2HSvRoJqGp1pPlSfQpJNFb38YRiQ+fLbBwQM8fXA71Gt9JFJcpLse2n+V8jJTvuH5D9afcW+yaLy1C7EO7p8ue38qgitIp55IwjNJIOQGOOnXHTNdiSerPToTuvfJ4bo22qPNIkN2PsjQxnGSGOcHqOCDg/SpPBdxJoc9wty5dGQmSIAkMW5GOMnk4yayfOhkS0jLyReYjyiRULBUB24Zvx/zitG9ml0yWAFJUu4HEgGfldTjH06Zpyhdcr6ihTpVXLk15t0dBJcNe6jd3k0syW89ssBtJ8qkTZG5gOvH86u+HNT0OBLazaSNbqXEYaXAEjDsPWsJ7231GykngicNIQp+fcxYnByc8DP+FcX468CPrt5aHTBbxagZkVp3lYeUinIdMfxD5vr71jGjCfuTfKcWIUX7qVmj0rxp4fhaSJ7Z0tzNkkY4Drzx6ZGc15beaV9kvruK5umnvonVIUd87lYbgV+nI6+leqajNJcrb73ciNFixnncBy2enPFeaa/dQ32sM9tEI54ZBG0n3mZlJ2jH1/QCtsG525WellE53cOhy2ualO6eQzQ3KMoaSLlVjA9D3I9fXFGnzj7XF/o6/Z42yIeQexyO+eM9KtajAbHWiJo4owSCrzcKQzEvkbTnGenWr1yGv7CW60/R7oW8eFW7VcqpwN270GT1x37V6XMlFHUn7bEuMl7i+X/Dnc+HBJreqST2kSwJG6CTcfmwSeMH+letQQJBCiRLhFFeAfDrxSNOvLlLxeZowit5mNjKSOO3p1r1IeNLVkj3zRQttKyRyZzuxwQcV4mNo1HOyWh52Z4Wqqlor3Te16xtLzRrqPUIYpYgjP8AOOAQMgj0PvXgWu6rDMJo7rT0iskCx5jiy5B+6SemOgrt/GfxBD6TKlvbMLTb++kIznHO38eK4Lw9fJ4iFy95bjBIWNI2JBPOAx9utdWBoTpQcprQihSqUYqDdpN6Ly8yiIpzfx3FrbyJIFCiUSbSpbJ3SepwQO/bFdjZaIviTWiksMc9rbklufvYPcdQOlZ/l2umlILYlXiffMm07XYE4B7H867v4OCFYtRbYonlfee3Gc/5FbYms4wc49Dd040KU6qactn2+47TQ7SK1tmWC1jgUfLhBjOOM/nXOX19rtv41S3t3sTpcqZeKb5ZFx1dMfeHQY4xXYXV/b2SO9w6oqr8xz0B7mqeo3WnRWX9pStG2QFjkX5jJn+FSOucV4cJvmbavc8eLcntuQPNI0S/OFZODhckg+35U3ToYbe6RSCkTJiPzHwAc9Bn6VlvPqmryhLOFtPjwP3zKGbb+PHaua+Imk3sGkl38Q3YlZiFWVthIA9Vx+X61tCkpSUG7XOrkfw31fQsfFi7ih0+SCBULGRJDjrkdP51554a/wCJuk0OoOfJiXf5akKGY4wM9x1rJ1W7uV0uxWQTziCM5kEhBdsnDEg8AEnHWk8NwzTmSzjdXlJUmQ8qo7tXsUqPsqXLf5n0GDpyp0XTkrNdTXt7qLQLieF4RAocyRrnG7GT1749K7X4na1aXXge0/sNokS8lDy26gKzJtLEj6HGSK5HXZ9IlmsrN9QefyFaMmBdwUHgsSc4zxnHSrGp6XJc6d5pha4sLdSkYQlWiVj94Hvz/SplCM5QnLSxm5Qr1FUv8P4s3PAGgtrFva3VncNFtCFt2M8cEDjJ78V6Nqlutxbsl0QrR/KhViFZsYXp744968s8LwajFqcdjDOIniXcsmCQFPK9Oeea7GS51K1vLZr68tZ3ifeFj7t0+bHfmuLEwcqmjODHxbqXlJeR0d1oscSxzvue6ACvhsBzjHJ7Uun2F/bM88VwH3tloCvDe49D/Oki1GO9u4FYMgI5Ge/+QK3sBQd3t+NefOUo6SPIqTktJHGX95bf2vZwXflRXM0yooL4aQg5OB3/ABq7ea1Y2Upgu7hQ2dpUEHB9SOuOtc34nk+zeIItYkEb28Em1XVSfLXGG3HB28464rG8RRxRyrqtrtlNxOTMpYjzQcDCsDwecV1xoRny3/pjak3ZHcX+v6dbWD3kcyvjCqixnfIx+6oBHc15ZrPgzX/EPjA6nq0yKkK+aTHKGWIDqgHdgBjt3restEeGRb/WDbQHAjSEkkRADjnPLEfxGumSS3eWWPSYpbmUpskhQkAdMFuQOfrWkP8AZ3enq+52RouMLd93+hS1e/aK6jt7KzmuJyAYod4RSAQCXYnC8sPzq1p0slrpWzV47ddQ3uDFbMXjQ5yME4JHTrWbd6TEbmyknikhudkvmu8hHlICN4HOCSQOfpSQ6iIlF3YrDJp7zCETRnc0Zzjc2ecE9eKnlTikhVakYWTZfm1GQ7Q1pMwIIB5Kj/dBHFSWV3aXsM0AMZuGySs3B9+v51ZKIzxtiaGRBlWPKkY6Z/Hrx+dZt7p9pfzYePbKT/rVkCMee2cZNZrlfkEakdpK3mM8SWsEGkLdWsIkcMqygFj5akYJ2jnAPp/KspvD19BpdpqEGBK6+ZNZvEHQnrlc8jI6jk5NbGktd6XqhtZ9xi6MG46jg1b1O9lF39kWyaBI496ytIcPz2q1OUHyx16/IKsWpJN3RrWsMGo6Va3FoVjJQbTn7rDGQR+Y7VjyW+orIwXRy4BIDC6QA+/36WWwR28y3vDlwDJtfaWJPfHU1KdAbJ/0+QfVz/jWFlHqQoqP2vwKmk3iazaxfLmRfmyEBx7jPT+ddVDlQqk4KDHHevIdH16z0i6njePUoJEY7YIhuZGI5Dqeoz3Hr+Nehz+Ikh0FdQii88S48tcgdfXHSjEUJKSSWj2MKsG3ymo7sNUjTedgGWA5A47++a0fL4BTJB4APTFeZ+E/G0mp6udPuY4/MnXfFKn8Rz0J+mOnSu5E0lpKv2h3CH7ruRj6HHSsqtCUHyy3M3G+xrj7ueSD36VmeIZVTTmzIUDYU844PvTdX1qDS9ONwU3YIGwdfyrhLya510tJckjcSREWwFx0p0KLk+Z6IdOHVmfqmrrbXCWsKf6Mp5VPu9OB7YGOvXNW7LVDZq0kmYyz+WIAfmIwAO/vVbxBo15GQ9vPHFA4RbhXGQwB5ORyG6fWks7f7a8UrJ+6g+ROOSB3x6n1r1LQcbo6cPSdWTc9kMsL6K5v5oZXLXLMWSLbjcoIGAT6V0OgaWs99LKJISDlTGDlgRwQPcV55rXha+i8U2+q6VC7xvIMQMQhhIwSyk9ie3ua9V8L2kFrcNqLy7yEbevACu2CxHfn3PepxDjGN4PdG1StUUWlGxnxaamnA2N/ayXmmszYVdoYLwQhGQcZ5z7Vm6vbFNDM/k3A2BgoALFUP3Vz/s1peOJNQ1DRzc6G6wXUE4MisBl0x6Z9xWbpuvCTEGpWMrRsAWu4kwu4ccA9AcZ/Opp8zip/ev67mFCfsaqkzJh0260qCOS2m+YjerRg7WGQefzqxNfXJuPMvYlt5XYN5hQ4UjqR+GeK6PwpfWsmlvbSwkzlmWE43A+gB7YweKm1u1j02SKBLgTRTDeUuolcIcgD6delW63v8slqd2IcZzcauj7kVj4lSRboGKOeQkbPs6MzHA4JHRR65I61y03haR76W/ur+ewe5m8yaCAg9+oJ4B/Cpbn+1ri0ht9IzCknBjhfYpA68Dv07EVS0DSLu5e5tPEM17FeIQTe5LQyBwcHnlcHGe1XCCppyi7fix0ZvDTcV167m9Z+F/DF3cg3MWpXzbflea4diPQHGAMmtPVvD98LKTTtMu5oNNkQgwTRZAB6jcOe1cppovrGOXT5TA8ZbzjbxOMkKCMqQecE7gO/1rf0nxXqWm2axahbNqcEYJWaQeVKybevPBYdCPcc1E41E7xdzGti6sJp6tbq/wDkee69p66PrKST2hmVITmRFKrJjnt3GME4/wAapa/qKWWvrp08D+UyJJHIyB1fcMkEDHTPrivYZY9B8QxwTpBLJFL86R4wyNyD/npUOraX4d1KYvfrHczwABnWQMV5zs45HTpWsMWk0pxfmOpiq1d2b0dtLHmnhC6h1XUv7JurK8gWF9kov4gqtnpznBGP05r0Gfwr/ZtrI1hHGlunz7I1xzjqMYrnNT0TUT517ZefPYhywKoCYcnjjJ4Ax/Ou/wDCevLrGgwwXqCK4ZTE2Dw2DjI/nUYipJJTht1NHWqRUWtbbnnU1oiNM4R3uHy0cknVQDyAPTpxWVoGrajZ38MlvIhaePcEhOWXH8JGcZOPrnjmug+IVlei+s7HSJIxcxsTgkAFc9Tx79KqwsbBpZ5YYptRkdYoogu3OTy2OuB1xW8ZKULvW5soObvDROzfn/XUrap4g8S319LZ3QWJ3yjqsAlYqRjA5GBzXYeF7VdB0W2vvETOy2yFYUbBxjqQOm49c/QZrJ0DfZ6hf32sx7ZZ5FSMlBkqBg46YHPWk8davGXjt5Y3KxrhCD8pXPJx6+1YzXO1SirLy/QhUqVSt7Cmrd3f8ES3nxB1fVLphokENtbmOSTfKQXMaDqFx1OePrXI+JtWv9et1E8l1HNjduLdcgdgBt7n35rN0qyF0wKJMqC4zEySAbBxzg5PQdK6bTdBP9pQRgSTs3zBWIACAcE47g/4V0KnSo6pbHW8IsPV53bkS26/eUvCnhOW/ukVZ7jykLiWSMkhwFB2nPfkDrXVafYWVrb3ejrol/FfzJgNvjJcHIDZzxVp9E12zZYtEHDA7o2OEXPJ+bOfete0a30iCafUUcag5w4LeYy45wCT9fwrlq13LVO/kYYrGqUXZ6dEclbeB59LtUvdbuLaOygBVbeJck4JJWRsZ5IycfnXZEW97Yb44Ejs72NQUz8pyvUdsVi20k7vcRXVtIi7QzOZA0bo2dwznrzyKfqV3Howg09t0G2DckStvODngfiCaio51Hq7s8qFSPJfZpldNK+zXcTyX0kknlLHGf8AVsyIDhOO/bNE8NwJrW1t4Z7tpJDIdxVTEDggAdWAGOetb3hjT5tTZ57mGeKwI/d+dxLJ7n0rpbPw5Y2c0c9qsiSKQRI8hbHbGT0HbFZTxCg7PVmNWrKq+aTKWiWwkiuVuEEbKfmxxg9RwelYWs69eW1wIy3+hElACRu/pU3iDxXa2M8llYobvUppR+5QZJxx8x7Lx1rnRYvqii41dzNbxyHclvgRrnPyD+8SerHpU0qevPUWh0xw02vaVHyx/H5Ip22sa5Lq1zHpjme0uCyy+ZF+6WMjHHPJByc96txeH4LqRJLi93zwP+7gUDJOf7o4A+gNdJpjNeQLY2tmiRs5+ZRwi8dTU1xptxpczzCFZIx8okXsMdfUc1pKtZ2jox+1UE401v33MG4FvEZ21MvMSTzM+Np5wPc1f8Oa5Fo1v5DWMzGZ2cvH1Ixx19veqmo6Ul7Y3L3KPPa5WRoc5DMDkEY5GP6VX0aW9ub8TXxESE5itwNoTbwCc+1DUZwaZEas5Pkqapm9Ij3mp6m140cEOzy3Mj4VFYdM9mPFU4PDS20aStdy31s2FR1KlQQTgkgZxmq/iyzur2OO5tFTZcSKzxowG4rwRzx6EfQ07wjoup6V/aDXlvFZ2txnybKOYtk7gQ+ecH2zULSF1K3kZ1f4iVux2gtlhsCuVVtnO5cgE+3bNec3+lXEywyLZtJqiSMCXjbAXpndwB+feux1yC6muGne4I0+BV2IGBLyA5+Ye3GPp7VSspl1APIyTJJu2M6SYD59s4JycelZUZOHvLUhxutWZUNrqGqasLW+KQqUG2aNuX4+Ynv1FaFrp081umn3t5Ktxby7o2Zt4MY6jJ5PWrPhqFH1+8D7GFvCqcDA3MSTkeuAK1dRW2vLy3t4hHKQx8xCeMe5H4U51fe5V2N3Nq1N9F9xk2unmayMsMmbgEupRuoz/wDWqk2vCNijWlwWU4OLeQjP1rSvAunavE0afZw6FBt5XP8ATrWglzJtHzRHjutTfrumOc+r2Z5z4i0uXVZkuLiyjju41wJIpBuPsfUVlzzSQwLDcqwKZUIVC57cHp+g+td9qcyQxm5ldBGFDNwQFz0/z6VRSfTtUtHhuVQrxhiMMuemD7+vtXRTrNRV1oXHExtacTzY6Lfieyu9LimRreYSDyWBLtncBgcgnGCR27V6brPiOLVNHihihnimlCtIGT/U4/nzmoLfwsIZWe2uvIkTG1lJO4Hv7fhTdOhlvLwWV0UBhOWdBlmHqe2OaqrUjVak/sidKjK8oX0KgJa2U3N2lwIgFUsNpJI5J9Oc0Pfw22UbIQKCrKM7j3Gfaq+sulpbzSjymXgq2f4efmIHOO3auVfVoGfFs8d28zYVYwFUZ6EN259e9a06POrh+6TXNJnT3d8b9Y1iileMH7gHAPXJxRJqsdvHFb2SAbSQdmNzHvnuaWOa4sbC2soImt7qcHIJ3Mi+hx0yKt22nw2ohWFFaeTGCBk+vy+9L3V0OyVWlTitNOn/AAStLPezCMMGyBw3TH4d6vGS/S38kTQmMtlmxyvrj1rTsrCRmikA83zm2jB6HpzjnHeujm8PW5tmjhJVmGWJPXg/1OawnXjGyZy1MZ2SXyOLkmmEUZXZc2roVAjfLIR2I7VnRXNxfac2jRwW8Xlbm+0bssqqM7QD0PB/Gu7t/D0emWF7cRSGSVI3cZxnIGcc9a4LRA2qWdvJLcx21yyZikA25bsjfmRV0pxkm10M4VadR2qff/mbUlxZwaKPLMYhiQCJuFPXjPvnvWVDfw6ltl1hbh2xs3bcnpjC89On19arWFsNUnjnu3XbDHjZgBQcn8+nX0q3p0NzPqBeUJtlK4Vuij2x9MVryqN+56Fb2dH3Zav8ivo9jd6TFcRf2h59kSTFG8fzQ+wbPr/Orj3jTafIk0vlzElHXPUEY6fnVC6t72e6ubj7RP5g/drZKqhQdxPmepyMdc+taU1jJLaQzyRhJnGXUHkHJHOM+lOVr3kzDDVqbny6qxxt3pF1/asMEbOxdtoyO3qOK09akks9BhRwN8d09plsttxznj/Z+lae7zhtEwWZAAPLPzbs46++P51o6VfyWVnc2JgtZ45v3m2aPeFYjBIz1/HvWkqjdna9j0cVKdenaDVyr4KnOpxC1kVbIINhEZ3HaQeOMYJ9uapaboU+j3Oo2VhawhoZv32XZpZgw3RuSfr+YNUrLXJtO1+NYoxHiTBRQAkmOOQOlY93Fq1/rkMaTTSxmQosnmlWX6kDJGD6/wA6apy5nrZNHkVFWhJNLVeh0viXRB4k0MzG5vdL1Ap5aXcEhQBhwUcDkjt9KwFhn8G2lra6zqsd7Kwz5sUbLjsBn+tddb2etLp8Vqg2OigIXOVd/UnPOf1q2rahfQLbeIdEs9QgjT5Jol2kAEHHtg+9ZxqOPuvWPyN4uVGSmrXe/Yb4BsrbXbm9urq8kFyoEcacKVXnDe/Nct4kupdC8W20pWa6ntJ3WYuGIYFTg5xj7uPxqa18KWlnqZvLbVry33ybTHg5TPZSCP60k2oLJBBfSfZZLVpdhjdy84UPt+fvuxz0qopc7kndPpsRUrSjW9pPRdultmddJdaX4lVLnTnVLgsjTwy/eUbhyM9RyOlbXjDwzpJ8L3MsltvaCFnVk4Yt16/hXM2+h6TMWQ3MEc6dJhKYzGT91gw4BHTB49jUt74wfSNQt9E8TXunT2t4vy3WMlfTzgOAPcVyOEuZeyb06df+CROioz58PL/P5M4PTdOvEjt5nghsWkKEwiRZDDnaAVI65yCe/BFeheD7aOG686cES8mR26n3x6fStPTvh/bzSG5l1Hz7ZyXhjhACAnvkde1dNp2h21rYLB5ccoDHnH+f508Ti4SVkZzxk5Q9nUdzNv8AVpLaZV06D7RO/AXPU9M/T/Cn6L4ZVAbzVpxcajIxd3HCqT2A9skfSt2G0ihYmJIkK8Yx2/z2rM17xRY6OCjyI1x3jBOF5wMnt1FcKlKXu00cbltylmPTrWxj8qGCPy+hAUEkY71LY6dYrIzxwRbwfv7eR7VxGneP2nvZ01ERRxwu5VYjud1UkdOck8kduOtQ+IfHOpRf8g7T5bGNxkTXq4LD2UA4+tafVqzfKzWFCrUjp9+x6HeXFvZxSS3MiJCnzHdxivJ/F/xIgvrwaToc/lxs4SS7Vc7fXA9frWFeHUNTmUa/q11dSyAtbwgYjX6jt1781u2/g3Trm4v20lPJsbaEhy7n53UZz6D+IcV1UsNSovmqu/5HXDDrDx55Wb/Bf5mbqlmfD8Mdtp9xvvL+3Msty4zIU7j2z0xXWeBrMav9pt2lLaXanaFQ43Of4QfRcfma5bTtNudTltWc7rqZV2kDARewHoAK9c8O6bLpul21sGRUjTLBR95icnmjFVFGFr3kZ4ypOUuZy2Ltpp1taRslsnloxyQoHJqw6Bl25xn09etPVQBgAAe1IMn2NeS23uea5Nu7My60oTIVErpzvB7AjocdK563s7N1vbC5b/T0JJZ1AZhglSO5HWu0ZS2c42+nrXk3xQtJZvGenSmaaO1FvhjCuWyH/DFdOGTqS5G7f8A2p1JHSWghu/DN3E2DLFGxUkdCOR+tUdLgWW4SSeSQQMu5UDZzjrx9Kq+EbkW/hu4e8lcOAYQzj73J/pUul3yR2ipuxyWVj2Ht+ldEoOLkl3PRlTdpOK6mjOROLk277dpXYpbg578/jVbVbqV4FSGFRMMFSOx9/T9aTzJLiFEhjOARlz3x1qe9lutORXtRG90YzzKmUGOnPr+NSo2epkoctnL7jGtJbXw9b3Caory3NzMSssa5cnufpWzo1rZXdq0u2VDKQ+9cgsvbt+NcLBYajrGvvq2vGQSqmyO2tSESEd23c5OcdK6prq+iiijtPJ8lAVA8wqF7AZHTr6dq2qQ7PV79i25zbk9L+ZNq9lO5f7NfiVfLbasyHap7ZNeYDWPiSg2pDbFF4GAMY/Out8USa+bcSaddWkBcF2EfJxwcZxmuXFz4zYAxyW7IeVPlR8iujDx5Y3fK/U2jh1Uiv3iXzt+h25u41it7O+tPtMKu25XxtdMYUnPYf1+tdBcafZtDcTWxjkMgCiQj93GFGAAAaba6fFPb7ZY/NYjYN/Rcev41JH4fs3hVSmxQ25lDELz7ZxXmyqRezseZOzdzHtbaTyrxLc+asRxFjJyMZIGfQnH0rDkcNrFtLh8yYjcMSCPUV6NaWcdqFijQJGo4AU9+9ZPiTQYZLWa7gUCX7zlDzjsR7jr+FXTxC5rM6MPWjB8sjBexhOryTpPCsSspZNyAfdxjPXHtnFLdaHpavHPJDDFa7C0nlHaGYDPas3SLyK1vtTj1WyE1yylldIxtYbRgEHOM+o96yV1i0Y2ugNNnUJIi5jDcqWb5fwAzx9K61Cd9GOnBKpZ/1c7bwppAOqvd3UIAaMSRoTnYCTtyPcZPFdTNpNrKeE2YPG0YxWHoVwYtbmj3F/MjjXJbngHjFdPJcQQ3ltaSTKJ7kMYkwckLjJ+nI5968+vOfPc5q9SUp8xFZ2ENq2Y1LSYwCT/SrqKSCduB160vl4XJdfXk1PFGyDqOmMVztt6swb7kEsIZWAVumD7574ryDWNLvLBEsYd1tmYtvVsBgBx25zgntivaFUruLNnOB6Vznj2zE2gFiVDRyIQ7HkZYLn34NdOFrOErdzSk02os8osYpJFgiVdsOEdi5OCCCTx35PfitrQ4LuLTZkzl0Yyljwqr0+X1yen51D4VufMjaSRyMxxR/d4UBSccc4ya3brTDPZpMpDPIMnB3A8AhR9Aa9KpPXlZ7VZRqYi8jOkunX5mGCBwCOcdvzqe2u1kdonIUt1OMAn/ACadeQ3UswFzGFKp24OAT39aqRLhm85SVUkHI/LuP8ikkpI6nRpzjsZWp6Pewwq9vEC27dlDncRjPToTj/61LA0sjpBIrNPtCndztyfQ9s5610+nP9q86Zm8w8bgFwQT3AHbpXM+IYlV2mAIRCfMwOgHTPfHU/jVwm5PlZz4dSoc0XrYstpC3BjSC3O4KQMk5Y98Z7nn8TWJp2rS6bEbuSD7SGzGkKr8qnOF6cj69Diu80NHksrUFXDKWZGcBS+O+Oe/r2q5Domi2/mG5svKeYsJfNJdD1zgevTt9Kz9uo3Ulc5sTXq1ElB2RgaPJfJfR22oSG5+0RGWBoyqmJlIyCAc4we/NbU9/HaQxNOszJjy0jhH32+91NVYofD/AIXs7mWwsI7eMqZJpJGcbcnJJzng9wKZNaWHiuwBnaRTE6yR/ZSVKkZCt79eRx1H4ZSak7tWRzRlKMeV79CKx1WPVWaGTTngk2YEbHLcd/Y9K5zxDo32fUo57K2iaRn3SMUCiUHjkkY3ZA/Gt9lg0MyPElxf6s8RMUBYRIuQT1JPLEH3zWRqepPc6e6XFl5NyG8sqrFij4DY/I1vTupXhsb4dKs/Y1OpzOiXdzZeIp7QWXnxRhpDBuyUj3ABQcc8ZOT6cdK0r1jb+Cri71BIri+ad4rISIDIy7s4bgA/Lx064NegaLapYWFw1wkCm5KiQ7MnPbntya2bTRbB7nzZAn2gKGCKoAGT14qamLipXa/4Ip01Si4qTsjitCsLpLC3bTrq90jVHQSTwWAMkOSM5KMCAPpWrb6x4miWRBd6ddMhBy0Zjk+pXpW5c2d3o2pvdaVAsmQBKsrHDZ6BT2P+eaivxNq8DrfQQxDtHjJT/ayMH9awdRTd2k1+P+f4nTzxqNOSTXna/wDmZlxr3ixoFKW2ljzPlDKzsQT06cVy+u+Etdv7G5lsNQY6pM4NzBI5EbD+IALgZyF49q7G/uI9Hmhnj8tpHXJ4IU++OPzp2m+MNNWJY44WkuQvzAKCxbv+uacZyh71KJMovlvTpr+vUr+B/A8umaMj6rNF/aG8O7wJtGB2yeTx611MOr6HrhazS4t7shiGjznBHrXE+MPGOrQW11EtolinlbneZsnYerAD+Vcd4X06bT4o76znlJuVBM8S/K6ZJ7d85o9hKsnUqSs+hzrDzr2c5q/rdnruuabpc2n3MEVvAk6x5UqgBOOgB/IVzMk1zp3hK8+/Ikmy3LsMF2cjcenYcVlp4gnDRLcSh2OV/eDr7foKveN5xP4X02CwnNtNLcRyI+MqNpyCfxxSjSlBqEtU2buhUox5N7knw6vEl129s5Z4p5oTlZIV+XaOMZ6d69MC4xkdBiuD8HaNBZa09x5ge4mjJmkUkKxY7uB2rvgrZ61zYppzvE8qsnpcTt0OaRe5wafim4wCwPB54rnsZWEPXgE+vtXHeNFMmr6dIiEpGkgcg54yOCPwrsJ3SGJpZHCIoLEk4FcTrN9BPZzX3nooJES7WBxk85H6eta0E+a6N8PF86t10GeFtK/tOGVrrckMcrFUA+8xxkn/AD3qTWvD6WipNCGZdw+Ucj8qv+DZFh08LNJhny+SOpz60/XdWiQBd+5U/eEocg+g9zW7nU9q1HY7ZVKv1hqOxj6HHFZ2E11fMyRTSfu2J6qOOB781l6bq9z4m1i7s4RIttE2cEYyo4yT3rltWuNX1nUbaBpFt9PjY5kjX7g/ufXFdp4VeHR48RKBGU2iSV8E89R6nJronT5E5PWT28jrrwjRi5Sd5y28jYk0NogqW6hpApG3ouOvNaMeiwNH/pCFmIxgZAU+1W9KljuFZ0lSR1ba23t1x/Srm0lcuQMZ7da8+VSWzPFqVJJ2e5zeueHre8sxHAGiuFwyOckZHqKwRourgAGzgOO4m4P6V37REvlmB9M0zyE7sPxNVCvKKtuCrtKz1Mizhjjt43RAG45/GrUoG0HAySM8e9FFYv4mS9yRifbpjpSyorRSIyjZ5Z4/CiimgW55TqRMN3ps8Xyymfyyw7rzxUl9pdjHeWVylpCtx50Q8wL8xG8Dk9+poor102rWPYjtH0f6nR6cqnxDZSbRvKSAnH1rvI40by5WRDKEwH2jIBxkA+nA/KiivMxG69DxqvQkdFkQq6hlPUEdacAAxwB1oorAyFi+ZASBk1zfxCdk8OAqR81xEDx/tUUVvQ+OJ1YZfv4+p5R4QkZLpChwRFEwx67etd0HaLVRbRsRA0/Kdvuj/GiivSxHxv0PVWteoW5AJC0T8x7Gfb2zzXMoM2sjHljnJP1X/E/nRRUUevyOmht9xJpn/HwW7qpI/MVr6yi/alfau75znHpyKKKdX4xVf4qFt7mVZ8BukgUZAOAQOP1rcu5GWOLB6M2OM+lFFYVEuZHLWS50ZOpwRTaZdeaiuDjIYZBycHIqnoEEUdheBEAEedo6gcj/ABNFFNN8rXmclX418iXXQBr+mMFUFrPe2BwWBOCR3xWBoMKXkUVxdDzZrmV2ldicuen8gKKK0g7QTX9bhhf4t/Jmx4nAtJLkW42BpkBA6dq6Hww7fZrR8/M4CscfeGe9FFY1P4Sf9bG023FX7HTSxJOiLKoZd54/OueiYzXNrHKSyCfy8eq4JwT3oormp7MwpbM4zxNDHc3VzBMu6I7E29ON68fqafJbxR2UrxxqrpPJGpA5C4HH6UUV6N/dijbGN+76F/xtp9rqPh6xkvYEleRYWZjwSQhI6e9Zvw7do7OKNMBCjIVxxgcAUUVEXeg15/5nFS+I5zxrbxf2hCAuA0oBAJH8R/wFXNRdkFuisdvl9Dz0Y4/kKKK6o/Aj6HD/AAI9L8GIoF38o4kIB74GP8a6WiivHqfEz52puK3G76UgoorMjqcL8S3ZrnTLUn/R5SxkTs2Omaw9Q0+1tzp1tBCqQIuVQdMhjj+VFFehRdoxt5nZhf4y9P0ZdsppPtc/zHjDD67ayfGrM1hYoThXuIg2OM5Jz0ooraC/eL5HqwX72P8AXQleNYxFZrn7Ol9LGFJJO3d0z1rTsAJpru1lVXgi+dFYA7TkDIPWiis57Hm4l3rL5fmaXgVFhvr9IxhXRXOTnn8frXZgA44oorkr/Gc2L1qXfZCSADGBTSBk8D8qKK53ucktz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph showing collapsing glomerulosclerosis with few open loops in the sclerotic areas (long arrows); these findings are characteristic of HIV nephropathy but can also be seen in idiopathic disease. The degree of collapse can be appreciated by the openness of Bowman's space. Vacuolization and crowding of the glomerular epithelial cells (short arrows) is also frequently seen and reflects the primary epithelial cell injury in this disorder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17721=[""].join("\n");
var outline_f17_19_17721=null;
var title_f17_19_17722="Cardiac sarcoidosis";
var content_f17_19_17722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac sarcoidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17722/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17722/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17722/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17722/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/19/17722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/19/17722/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/19/17722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac sarcoidosis can be a benign, incidentally discovered condition or a life-threatening disorder causing sudden death. Small observational registries and studies have described clinical evidence of myocardial involvement in 5 percent of patients with systemic sarcoidosis, yet autopsy studies indicate that subclinical cardiac involvement is present in up to 70 percent of cases. These observations suggest that the diagnosis of cardiac sarcoidosis is difficult to establish, especially in patients without evidence of sarcoid in other organs and thus cardiac sarcoidosis is often underdiagnosed in every day clinical practice. Furthermore, there is neither a clear-cut understanding of the underlying pathophysiology and progression of this disease, nor a consensus on the optimal methods for disease detection, monitoring, and treatment.",
"   </p>",
"   <p>",
"    There appear to be differences in the presentation of cardiac sarcoidosis among various countries, although comparison among studies is limited by differing methodologies. In the United States, 13 to 25 percent of deaths from sarcoidosis have been attributed to cardiac sarcoidosis while in Japan 47 to 85 percent of deaths from sarcoidosis have been attributed to cardiac involvement. In contrast, a retrospective study from Haifa, Israel reported that only 2 of 120 patients with sarcoidosis died of cardiac involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This report reviews the latest understanding of cardiac sarcoidosis, providing details on the pertinent clinical features, methods used in the diagnosis and monitoring of disease progression and in the management of this condition. General issues related to systemic sarcoidosis are discussed separately. The American Thoracic Society (ATS) statement on sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/2\">",
"     2",
"    </a>",
"    ] can be accessed through the",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/resources/respiratory-disease-adults/sarcoid1-20.pdf\">",
"     ATS web site",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4957536\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is a heterogeneous, non-caseating, granulomatous disorder of unknown etiology that can involve any organ within the body. Cardiac involvement may be detected alone and may precede, follow, or occur concurrently with other organ (eg, lung) involvement. As an example, a German study of 52 patients with evidence of sarcoid heart disease found that one-third had normalized lung changes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are geographic variations in the epidemiology and presentation of cardiac sarcoidosis. Japanese pathologists report cardiac involvement in as many as 50 to 78 percent, whereas in the USA, 13 to 50 percent of all deaths are related to cardiac involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. A retrospective study from Israel interestingly demonstrated that only 2 of 120 patients (2 percent) with sarcoidosis died from cardiac involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have illustrated potential environmental, occupational, and infective disease triggers as well as a possible genetic predisposition in development of cardiac sarcoidosis. The immunological response plays a central role in the development of early disease and in disease progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial involvement with sarcoidosis may be more frequent in patients with sarcoidosis who have cardiac symptoms, but asymptomatic cardiac involvement appears to be common [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/3,11\">",
"     3,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms and signs of cardiac sarcoidosis depend upon the location and extent of granulomatous inflammation. Clinical manifestations include conduction abnormalities (atrioventricular block or bundle-branch block), tachyarrhythmias, cardiomyopathy, congestive cardiac failure, and sudden cardiac death. Clinicians should always consider the possibility of sarcoid heart disease in the evaluation of an otherwise healthy young or middle-aged person with cardiac symptoms, or in a patient with known sarcoidosis who develops arrhythmias, conduction disease, or heart failure.",
"   </p>",
"   <p>",
"    Cardiac involvement may precede, follow, or occur concurrently with involvement of the lungs or other organs. Thus, the course of cardiac sarcoidosis may not be concomitant with that of pulmonary sarcoidosis. In a German study of 52 patients with cardiac sarcoidosis, one-third of the cases cardiac involvement became apparent after the lung changes had normalized [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/12\">",
"     12",
"    </a>",
"    ]. The severity of pulmonary disease does not predict cardiac involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17482569\">",
"    <span class=\"h2\">",
"     Heart block and arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete heart block is the most common finding in patients with clinically evident cardiac sarcoidosis and occurs at a younger age in patients with sarcoidosis than in individuals with complete heart block due to other etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    .) Prolongation of the P-R interval (first-degree heart block) due to disease of the atrioventricular node or bundle of His, and other intraventricular conduction defects, are also common [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/4\">",
"     4",
"    </a>",
"    ]. While these lesions may initially be silent, they can progress to complete heart block and cause syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ventricular arrhythmias (sustained or nonsustained ventricular tachycardia and ventricular premature beats) are the second most common presentation of cardiac sarcoidosis. These arise when sarcoid granulomas within the myocardium become foci for abnormal automaticity, or may disrupt ventricular activation and recovery, causing re-entrant arrhythmias. Electrocardiography reveals ventricular arrhythmias in as many as 22 percent of patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to conduction disease and ventricular arrhythmia, other described arrhythmias include ectopic atrial activity, paroxysmal atrial tachycardia, atrial flutter, atrial fibrillation, and sinus arrest secondary to granulomatous involvement of the sinus node.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17482576\">",
"    <span class=\"h3\">",
"     Sudden death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden death due to ventricular tachyarrhythmias or conduction block accounts for 25 to 65 percent of deaths due to cardiac sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/1,3,12,14\">",
"     1,3,12,14",
"    </a>",
"    ]. Some patients with known systemic sarcoidosis develop symptomatic or electrocardiographically evident arrhythmias or conduction abnormalities prior to sarcoid-related sudden death, assisting diagnosis and therapeutic management. However, sudden death can occur in the absence of symptoms or a previous cardiac event [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .) This presents a diagnostic challenge; it is important to identify at-risk individuals to enable preventative therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17483512\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure, both systolic and diastolic dysfunction, can occur when there is extensive granulomatous infiltration of the myocardium. Patients may present with heart failure or dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/15\">",
"     15",
"    </a>",
"    ]. In various series, progressive heart failure has accounted for 25 to 75 percent of cardiac deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/1,9,16,17\">",
"     1,9,16,17",
"    </a>",
"    ]. It has been suggested that glucocorticoid treatment may convert granulomas to scar tissue, contributing to the development of ventricular aneurysm formation, or dilatation that may mimic arrhythmogenic right ventricular cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17483519\">",
"    <span class=\"h2\">",
"     Valvular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral incompetence may occur with cardiac sarcoidosis due to associated systolic dysfunction and left ventricular dilation or due to papillary muscle involvement by sarcoid granulomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/15\">",
"     15",
"    </a>",
"    ]. Regurgitation due to papillary involvement is usually transient; however, it may occasionally be severe enough to cause pulmonary hypertension and hemodynamic instability, and may require mitral valve replacement. Tricuspid regurgitation with atrioventricular block secondary to infiltration of the tricuspid valve and conduction system by sarcoid granulomas has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link\">",
"     \"Overview of the management of chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, sarcoidosis involves the aortic valve and root, resulting in aortic regurgitation and aneurysm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Even less frequently, aneurysms of the descending thoracic and abdominal aorta have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17483526\">",
"    <span class=\"h2\">",
"     Simulated infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery infiltration with cardiac sarcoid (causing coronary spasm or vasculitis) may produce clinical symptoms (angina), ECG findings (repolarization abnormalities and pathological Q waves), and echocardiographic findings (regional wall motion abnormalities) simulating myocardial infarction. Although the distribution of inflammatory lesions are frequently in a noncoronary distribution, localization similar to myocardial infarction with perfusion defects preferentially affecting the anteroseptal and apical regions are seen in some cases by radionuclide or cardiovascular magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36868?source=see_link\">",
"     \"Pathogenesis and diagnosis of Q waves on the electrocardiogram\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H22303008\">",
"     'Cardiovascular magnetic resonance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17483533\">",
"    <span class=\"h2\">",
"     Pericardial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical pericarditis or cardiac tamponade is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/24\">",
"     24",
"    </a>",
"    ], although clinically silent small pericardial effusions are more common [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17483540\">",
"    <span class=\"h2\">",
"     Cor pulmonale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis occasionally causes cor pulmonale due to advanced fibrotic pulmonary sarcoidosis. However, in most patients who die with inexorable lung disease, death is due to respiratory failure. In some patients with cor pulmonale, right ventricular hypertrophy may regress when the pulmonary disease is improved with glucocorticoid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12703616\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unusual presentations of cardiac sarcoidosis include a left atrial granulomatous mass resembling myxoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/26\">",
"     26",
"    </a>",
"    ] or an increased interventricular septal thickness resembling hypertrophic cardiomyopathy or a septal tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14070583\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17483101\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various definitions and guidelines for diagnosing cardiac sarcoidosis have been proposed (and subsequently revised):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 1993 Japanese Ministry of Health, Labour, and Welfare (MHLW) policy guideline defined cardiac sarcoidosis histologically through the presence of non-caseating granuloma in the heart muscle or histologic diagnosis of extracardiac sarcoid plus the presence of electrocardiographic abnormalities in conjunction with abnormalities in left ventricular function, thallium, or gallium scan abnormalities, or nonspecific findings on endomyocardial biopsy (",
"      <a class=\"graphic graphic_table graphicRef58910 \" href=\"UTD.htm?34/56/35723\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The 1999 Joint Statement of the American Thoracic Society, the European Respiratory Society and the World Association for Sarcoidosis and Other Granulomatous Disorders considers cardiac dysfunction, EKG abnormalities, and thallium-201 imaging defects with or without endomyocardial biopsy as evidence of cardiac sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 1999 multisystem ACCESS study defined &lsquo;definite&rsquo; cardiac sarcoidosis as treatment-responsive cardiomyopathy and a positive thallium scan suggestive of &lsquo;probable&rsquo; sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 2006, the Japanese guidelines were revised by the Japan Society of Sarcoidosis and Other Granulomatous Disorders. These guidelines identify cardiac sarcoidosis by either of two methods [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/28\">",
"       28",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The first is by histological diagnosis (through the presence of noncaseating granuloma on myocardial biopsy) in addition to the histologic or clinical diagnosis of extracardiac sarcoidosis.",
"     </li>",
"     <li>",
"      The second method requires the presence of a histologic or clinical diagnosis of extracardiac sarcoidosis plus a combination of major and minor cardiac criteria. At least three major criteria",
"      <strong>",
"       or",
"      </strong>",
"      at least one major and three minor criteria are required.",
"      <br/>",
"      <br/>",
"      Major criteria include advanced AV block, basal thinning of the interventricular septum, cardiac gallium uptake, and LVEF &lt;50 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Minor criteria include abnormal ECG findings (PVCs or VT, RBBB, axis deviation or abnormal Q wave), abnormal echocardiography (regional wall motion or morphologic abnormality such as ventricular aneurysm or wall thickening), perfusion defect detected by thallium or technetium scintigraphy, late gadolinium enhancement on cardiac magnetic resonance imaging, and more than moderate monocyte infiltration or interstitial fibrosis on endomyocardial biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H925865\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early and accurate diagnosis of cardiac involvement in sarcoidosis is essential to prevent associated morbidity and mortality. (See",
"    <a class=\"local\" href=\"#H22305163\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Since cardiac sarcoidosis may present either as clinically silent, microscopic disease, or with overt symptoms and macroscopic disease, optimal and accurate use of available diagnostic tests is required. Unfortunately, as reflected by the array of definitions and guidelines listed above and the lack of large, prospectively evaluated studies on cardiac sarcoid, there is lack of consensus among sarcoid experts as to which are the key diagnostic and imaging modalities and what their relative sensitivities, specificities, and clinical utility are. A variety of approaches have been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/3,5,28-32\">",
"     3,5,28-32",
"    </a>",
"    ], yet there is no single test that has the sensitivity and specificity to, by itself, accurately detect cardiac sarcoidosis or differentiate between acute and active sarcoid versus chronic and inactive disease. Moreover, there are only scant data available to compare the ability of diagnostic methodologies in risk stratifying patients, evaluating prognosis, guiding therapy, and improving outcomes.",
"   </p>",
"   <p>",
"    A stepwise diagnostic approach is often best utilized in the diagnosis of cardiac sarcoidosis, starting with noninvasive and readily available modalities and progressing to a combination of newer imaging and more invasive techniques with novel techniques being implemented as they become available (",
"    <a class=\"graphic graphic_table graphicRef85756 \" href=\"UTD.htm?33/39/34428\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H926160\">",
"    <span class=\"h2\">",
"     Who to evaluate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cardiac sarcoidosis should be suspected in the following patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Young adults (age &lt;55 years) with unexplained sustained second or third degree atrioventricular block. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=see_link\">",
"       \"Second degree atrioventricular block: Mobitz type II\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=see_link\">",
"       \"Third degree (complete) atrioventricular block\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"       \"Etiology of atrioventricular block\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with sustained monomorphic ventricular tachycardia and dilated cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link\">",
"       \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with histologic (or clinical) diagnosis of extracardiac sarcoidosis, with or without cardiac symptoms, should be fully evaluated to enable detection of subclinical, as well as clinical, cardiac involvement (arrhythmias, conduction disease, heart failure, etc). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14070497\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following initial cardiovascular evaluation should be performed in all patients with sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17483816\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;While",
"    <strong>",
"    </strong>",
"    some patients with cardiac sarcoidosis are asymptomatic with the initial manifestation of cardiac disease being sudden death (see",
"    <a class=\"local\" href=\"#H17482576\">",
"     'Sudden death'",
"    </a>",
"    above), many have symptoms and signs suggestive of cardiac involvement. These include palpitations, syncope, presyncope, bradycardia, dyspnea, orthopnea, chest pain, and peripheral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrocardiogram should be performed in every patient with sarcoidosis (systemic or cardiac) to detect subtle or overt conduction or repolarization abnormalities. (See",
"    <a class=\"local\" href=\"#H17482569\">",
"     'Heart block and arrhythmias'",
"    </a>",
"    above.) As many as 70 percent of the patients with sarcoidosis have one or more ECG abnormalities, although the prevalence of these changes vary with the severity of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19878770\">",
"    <span class=\"h1\">",
"     INITIAL NONINVASIVE TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following initial noninvasive tests should be performed in all patients with suspected cardiac sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22302703\">",
"    <span class=\"h2\">",
"     Holter monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;24-hour ECG monitoring in patients with suspected or known cardiac sarcoidosis should be performed to document and define subclinical rhythm disturbances that may be missed on ECGs and to aid risk estimation of sudden death. In a study of 38 patients with sarcoidosis referred to a cardiology clinic, 7 of 12 patients (67 percent) with confirmed cardiac sarcoidosis had &gt;100 extrasystoles per day as compared to only 8 percent of the 26 patients without cardiac sarcoidosis, and only 5 percent of 58 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Heart rate variability (HRV) analysis obtained during Holter monitoring provides a method to measure autonomic activity. It has been observed that HRV is decreased in patients with systemic sarcoidosis but the decrease is more apparent in patients with cardiac sarcoidosis. The clinical significance of this observation is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=see_link\">",
"     \"Heart rate variability: Uses other than after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22302770\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with known or suspected cardiac sarcoidosis should be assessed by echocardiography, particularly those with any abnormality detected on Holter monitoring or EKG [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities seen on transthoracic echocardiography include septal thinning or segmental or global hypokinesia of the left ventricle, ventricular aneurysms, valvular regurgitation, mitral valve prolapse due to papillary muscle dysfunction, and left ventricular dilatation. Cardiac tissue, particularly the ventricular septum or the left ventricular free wall, appears hyperechogenic when there is granulomatous involvement and scar formation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/17,34,35\">",
"     17,34,35",
"    </a>",
"    ]. Cardiac lesions may also cause an increase in myocardial wall thickness, simulating left ventricular hypertrophy, or increased interventricular septal thickness, resembling hypertrophic cardiomyopathy. Echocardiographic regional wall motion abnormalities are frequently seen in a noncoronary distribution. Patients with severe sarcoid pulmonary disease may develop pulmonary hypertension and secondary right ventricular dysfunction. Furthermore, echocardiography enables estimation of pulmonary artery pressures and left ventricular filling pressures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14378?source=see_link&amp;anchor=H29#H29\">",
"     \"Echocardiographic evaluation of the tricuspid valve\", section on 'Peak velocity of the jet'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link&amp;anchor=H8#H8\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\", section on 'Algorithms for estimating LV filling pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19878795\">",
"    <span class=\"h1\">",
"     ADDITIONAL NONINVASIVE TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular magnetic resonance (CMR) is indicated in patients with abnormalities on Holter monitoring",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    echocardiography. Additional testing with positron emission tomography (PET) may be helpful to assess disease activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22303008\">",
"    <span class=\"h2\">",
"     Cardiovascular magnetic resonance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular magnetic resonance (CMR) imaging enables fast, accurate, high-resolution, and noninvasive diagnosis of subclinical or clinical cardiac sarcoidosis and is currently the technique of choice in the evaluation of sarcoidosis. Sensitivity has been shown to be much higher than with radionucleotide methods. CMR uses T2-weighted imaging and early gadolinium images to detect acute inflammation (edema). T1-weighted (cine) imaging illustrates wall motion abnormalities, hypertrophy due to possible infiltrative disease, wall thinning, or heart failure. Late gadolinium enhancement (also known as delayed enhancement) assesses fibrosis or scar and may represent chronic rather than active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/26,36-40\">",
"     26,36-40",
"    </a>",
"    ]. Preliminary observations also suggest that monitoring gadolinium enhancement may be helpful in the assessment of the efficacy of steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/36,39\">",
"     36,39",
"    </a>",
"    ]. Typical patterns of enhancement on CMR are non-vascular in territory, mid-myocardial, and sub-epicardial, although many patients have patterns in a coronary distribution with subendocardial involvement similar to myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognostic value of CMR was suggested in a study comparing late gadolinium enhancement on CMR to the modified Japanese Ministry of Health and Welfare (JMH) criteria (",
"    <a class=\"graphic graphic_table graphicRef58910 \" href=\"UTD.htm?34/56/35723\">",
"     table 1",
"    </a>",
"    ) in a series of 81 patients with biopsy proven extracardiac sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/11\">",
"     11",
"    </a>",
"    ]. Clinical evaluation included an ECG and at least one non-CMR cardiac imaging study. Late gadolinium enhancement on CMR identified cardiac involvement in 21 patients, while JMH criteria identified cardiac disease in 10 patients, with eight overlapping. Coronary disease was excluded by x-ray angiography in all patients with CMR evidence of myocardial damage. 48 percent of enhanced regions were, however, in a coronary distribution and 52 percent were in a noncoronary distribution. During the mean 21 months follow-up, patients with CMR evidence of myocardial damage had a ninefold higher rate of adverse events (17.2 versus 1.9 percent per year) and 11.5-fold higher rate of cardiac death (11.5 versus 1.0 percent per year) as compared to patients with negative CMR studies. JMH-positive patients had only a 3.5-fold higher rate of adverse events (14.5 versus 4.1 percent per year) and a 3.9-fold higher cardiac death rate (9.7 versus 2.5 percent per year) as compared to JMH-negative patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19879043\">",
"    <span class=\"h2\">",
"     PET",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <sup>",
"     18",
"    </sup>",
"    F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) appears to detect active cardiac sarcoidosis with high sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Pooled estimates from a meta-analysis of seven studies (with 164 patients) comparing FDG PET to the 1993 MHLW guidelines included a sensitivity of 89 percent and specificity of 78 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/42\">",
"     42",
"    </a>",
"    ]. FDG PET is more sensitive than gallium-67 scintigraphy, thallium-201, or technicium-99m SPECT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/41,43,44\">",
"     41,43,44",
"    </a>",
"    ]. It can also be combined with myocardial perfusion imaging (MPI) to detect fibrogranulomatous replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/5,30\">",
"     5,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, PET is non-specific for sarcoidosis, and uptake of 18F-FDG is seen in other inflammatory myocardial diseases. The actual specificity of FDG PET with MPI is uncertain. Reported specificity has ranged from 38 to 90 percent, in which the lower range may be due to detection of early subclinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/30,43,45\">",
"     30,43,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4958094\">",
"    <span class=\"h2\">",
"     CMR versus PET",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR and PET are the two imaging modalities that appear to have the highest sensitivity for detection of cardiac sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/5,28,30,41\">",
"     5,28,30,41",
"    </a>",
"    ]. PET appears to be more sensitive than CMR, but CMR may have higher specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/13,45,46\">",
"     13,45,46",
"    </a>",
"    ]. While CMR imaging avoids use of ionizing radiation, it is contraindicated in patients with non-MRI compatible pacemakers and ICDs and gadolinium should be avoided in patients with renal failure due to the risk of nephrogenic systemic fibrosis. Perhaps a combination of the CMR and PET will provide the most optimal imaging method to detect and monitor cardiac sarcoidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19878868\">",
"    <span class=\"h2\">",
"     Radionuclide imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial imaging with thallium-201, technetium sestamibi (MIBI-Tc) single photon emission computed tomography (SPECT), or gallium-67 is used to detect cardiac sarcoidosis and to monitor response to treatment.",
"   </p>",
"   <p>",
"    With thallium-201, focal perfusion, deficits may be seen at rest (which may simulate the appearance of coronary artery disease, although deficits may be in a noncoronary distribution) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/47\">",
"     47",
"    </a>",
"    ]. With exercise, however, &ldquo;reverse redistribution&rdquo; is generally seen with the perfusion defects decreasing in size or disappearing, in contrast to the lack of change in size or increase in defect seen in patients with coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/48\">",
"     48",
"    </a>",
"    ]. Fixed perfusion defects with segmental areas of decreased thallium-201 uptake in the myocardium are highly non-specific, but are thought to correspond to areas of fibrogranulomatous replacement. Experience suggests that obtaining an initial thallium-201 imaging study at diagnosis and every three months in patients with myocardial sarcoidosis is appropriate. Once the myocardial lesion has stabilized or subsided and the glucocorticoid dose is discontinued, the study should be repeated annually because reactivation of the granulomatous process is not uncommon even after years of remission.",
"   </p>",
"   <p>",
"    Focal perfusion defects may also be detected by MIBI-Tc SPECT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/4,49\">",
"     4,49",
"    </a>",
"    ] and these defects may overlap with regions of gallium-67 uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gallium-67 indicates areas of active disease, accumulating in areas of acute inflammation. It has therefore been used not only to differentiate between active and inactive disease, but also to assess response to treatment and progression of disease and may therefore complement thalium-201 imaging. The combined use of thallium-201 and gallium-67 may improve the detection of cardiac sarcoidosis. In addition, small series suggest that the presence of gallium-avid lesions may predict a greater response to glucocorticoid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radionuclide studies may be useful in patients in whom cardiac sarcoidosis is suspected because of clinical or electrocardiographic findings or in those who cannot undergo magnetic resonance imaging. These tests are not, however, recommended as screening tests in individuals with sarcoidosis involving other organs because of the associated radiation dose, their poor spatial resolution and prevalence of imaging artifacts that may produce nonspecific results [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14070738\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of exercise testing in evaluation of cardiac sarcoidosis is not established. Preliminary studies have found abnormal responses to exercise in patients with sarcoidosis although the clinical significance of these findings is unclear. Exercise echocardiography was performed in 21 patients with sarcoidosis and in 24 normal control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/55\">",
"     55",
"    </a>",
"    ]. In 10 of the sarcoidosis patients there was an abnormal fall in left ventricular ejection fraction with exercise without clinical or ECG evidence of myocardial ischemia. Moreover, a significantly impaired heart rate recovery index was observed in patients with sarcoidosis compared to healthy control subjects, suggesting that exercise testing may be useful not only to detect cardiorespiratory physiology and reserve but may, in the future, aid symptom-prognosis correlation and risk stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/56\">",
"     56",
"    </a>",
"    ]. Further follow-up is needed to determine the clinical significance of these observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14070711\">",
"    <span class=\"h1\">",
"     INVASIVE TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14070885\">",
"    <span class=\"h2\">",
"     Coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac catheterization with coronary angiography is useful in excluding the diagnosis of atherosclerotic coronary artery disease when other testing reveals regional myocardial abnormalities that could be caused by coronary disease or sarcoidosis. As noted above, sarcoid granulomas can cause myocardial perfusion defects, wall motion abnormalities, and contrast enhanced lesions on CMR. Primary sarcoidosis rarely involves the coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/57\">",
"     57",
"    </a>",
"    ]. Although granulomatous vasculitis may cause partial or complete narrowing of the epicardial coronary arteries, thrombosis and aneurysm formation are rare. Perfusion defects on thallium-201 imaging in patients with known systemic sarcoidosis strongly suggest cardiac involvement if coronary angiography has excluded significant atherosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4958181\">",
"    <span class=\"h2\">",
"     Endomyocardial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detecting non-caseating granulomas is the &ldquo;gold standard&rdquo; for diagnosis of cardiac sarcoidosis (",
"    <a class=\"graphic graphic_picture graphicRef63327 \" href=\"UTD.htm?5/6/5226\">",
"     picture 1",
"    </a>",
"    ). An endomyocardial biopsy is recommended if the patient lacks histological confirmation of non-caseating granulomas from any other source. However, the procedure has a low sensitivity, approaching 20 percent in one series of 26 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/58\">",
"     58",
"    </a>",
"    ]. Its use is limited by false negative results owing to sampling error that may occur due to the patchy distribution of disease. Furthermore, myocardial granulomas tend to affect the basal and lateral LV wall regions difficult to biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=see_link&amp;anchor=H7#H7\">",
"     \"Endomyocardial biopsy\", section on 'Late AV block, arrhythmias or refractory HF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4958216\">",
"    <span class=\"h2\">",
"     Electrophysiologic study",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with symptomatic bradycardia or heart block, EPS is not generally required to determine need for pacemaker placement. However, EPS may be helpful in selected patients for assessment of the sinus node or the conduction system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although data are limited, EPS may be helpful in selected patients as an aid in risk stratification of sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/59\">",
"     59",
"    </a>",
"    ]. The utility of EPS in this setting is supported by limited observational data [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series included 32 patients with cardiac sarcoidosis referred for evaluation of symptoms (palpitations, syncope, presyncope)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ventricular arrhythmia (including ventricular premature beats, nonsustained or sustained ventricular tachycardia (VT), or ventricular fibrillation [VF]) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/60\">",
"       60",
"      </a>",
"      ]. All 12 patients with spontaneous (six) or inducible (10; four with spontaneous) sustained VT or VF received an implantable cardioverter-defibrillator (ICD). At a mean 32 months follow-up, 9 of the 12 patients that had received an ICD had received an appropriate shock. In contrast, 2 of 20 patients without ICDs experienced SCD or sustained ventricular arrhythmias.",
"     </li>",
"     <li>",
"      In a series of 76 patients with cardiac sarcoidosis on PET or CMR and no cardiac symptoms, 11 percent had inducible sustained ventricular arrhythmias and received an ICD [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/61\">",
"       61",
"      </a>",
"      ]. Left ventricular ejection fraction was lower in patients with inducible ventricular arrhythmia (36.4 versus 55.8 percent). Over median five-year follow-up, six of eight patients in the group with inducible ventricular arrhythmias had appropriate ICD shocks or died compared with one death in the non-inducible group. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, some studies suggest that EP testing may help identify those patients with cardiac sarcoidosis who are likely to experience ventricular arrhythmias or SCD and that those with spontaneous or inducible arrhythmias should receive an ICD.",
"   </p>",
"   <p>",
"    Unfortunately, the true role of EP testing in risk stratification remains uncertain, since many patients with inducible ventricular arrhythmias meet criteria for ICD placement for primary prevention (heart failure plus a left ventricular ejection fraction [LVEF] &le;35 percent). In the earlier study cited above, the mean LVEF in the inducible VT group was 33 percent, and 40 percent of the inducible group had heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/60\">",
"     60",
"    </a>",
"    ]. Thus, many patients with inducible VT may meet criteria for ICD placement regardless of the EP study results or their sarcoid diagnosis. (See",
"    <a class=\"local\" href=\"#H22304146\">",
"     'Treatment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H16#H16\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Nonischemic cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, as noted in the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society device guidelines, EP testing may be helpful for risk stratification in selected patients with cardiac sarcoidosis who lack established indications for ICD placement, although the available evidence is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H16#H16\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Nonischemic cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4958298\">",
"    <span class=\"h2\">",
"     Right heart catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right heart catheterization is not used routinely in the diagnosis of cardiac sarcoid. It may provide prognostic information when pulmonary artery pressures and pulmonary capillary wedge pressure cannot be adequately estimated by echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/34\">",
"     34",
"    </a>",
"    ] but is an invasive technique with clinical risk. (See",
"    <a class=\"local\" href=\"#H22302770\">",
"     'Echocardiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22304146\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of cardiac sarcoidosis is aimed at controlling the inflammation, preventing fibrosis, and preventing compromise of cardiac structure or function. Corticosteroids are the cornerstone of treatment for cardiac sarcoidosis despite the lack of confirmatory randomized clinical trials.",
"   </p>",
"   <p>",
"    The role of glucocorticoids in treating extracardiac disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=see_link\">",
"     \"Neurologic sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link\">",
"     \"Renal disease in sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"     \"Hypercalcemia in granulomatous diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22304063\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of their ability to attenuate the inflammatory response, glucocorticoids are believed capable of halting or slowing the progression of inflammation and fibrosis in sarcoidosis. However, supportive data are largely anecdotal:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective, survey-based study of 104 cases of cardiac sarcoidosis, survival was better with glucocorticoids than with usual care (64 versus 40 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another observational study, 75 patients with cardiac sarcoidosis treated with glucocorticoids were compared to 20 patients not treated with glucocorticoids in whom the diagnosis of cardiac sarcoidosis was proven at autopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/63\">",
"       63",
"      </a>",
"      ]. Five-year survival was much higher in the steroid-treated patients (75 versus 10 percent). Among the treated patients, the outcome was best (89 percent five-year survival) when steroids were begun when the left ventricular ejection fraction was &ge;50 percent. This study suggests that early initiation of therapy is important.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A means to predict who may or may not be steroid-responsive remains unknown. The effect of steroid therapy on ventricular arrhythmias is even less certain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/64,65\">",
"     64,65",
"    </a>",
"    ] and some recommend an implantable cardioverter-defibrillator as primary therapy in some or all patients with cardiac sarcoidosis. (See",
"    <a class=\"local\" href=\"#H22304319\">",
"     'Pacing and ICD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Similarly, the optimal dose of glucocorticoids is not known, and choosing a dose requires balancing the risk of side effects with the likelihood of response [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/63,66\">",
"     63,66",
"    </a>",
"    ]. As noted above, there is lack of agreement among sarcoid experts on key aspects of management of cardiac sarcoidosis with differences in recommended glucocorticoid dose, use of steroid sparing agents, and duration of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/29\">",
"     29",
"    </a>",
"    ]. Doses of 60 to 80 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    daily are generally used initially, although an observational study from Japan found that there was no difference in outcome between patients treated with an initial high dose (&gt;40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of prednisone) compared with those treated with a low dose (&lt;30",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/63\">",
"     63",
"    </a>",
"    ]. It is unknown whether steroid dose should be adjusted for body surface area or whether the effective dose varies among patient populations.",
"   </p>",
"   <p>",
"    Until more data are available on dose adjustment, we suggest generally starting with a dose of 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and gradually reducing this dose to a maintenance level of 10 to 15",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    over one year. Glucocorticoid treatment should be continued for at least one to two years. If serial evaluations reveal that the disease is stable or dormant, glucocorticoids may be tapered and eventually discontinued. However, vigilance must continue for the rest of the patient's life, as relapses are common after tapering of steroid therapy. Any evidence of recurrence should be handled by reinstituting or increasing prednisone to 60",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    Alternative agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    may be given to patients who do not respond to glucocorticoids or who cannot tolerate their side effects. Their role remains anecdotal but they appear to be effective in selected cases. Their use depends on the type of the patient, severity of the disease, and experience of the clinician. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22304319\">",
"    <span class=\"h2\">",
"     Pacing and ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with cardiac sarcoidosis, sudden death due to ventricular tachyarrhythmias or conduction block accounts for 30 to 65 percent of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, there is a high rate of recurrence of ventricular tachycardia (VT) or sudden death with antiarrhythmic drug therapy, even when guided by electrophysiologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/65\">",
"     65",
"    </a>",
"    ]. These observations constitute the rationale for the use of pacemakers and implantable cardioverter-defibrillators (ICDs).",
"   </p>",
"   <p>",
"    A permanent pacemaker is indicated when there is evidence of complete AV block or other high grade conduction system disease is present even if the high grade conduction disease reverses transiently [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/59\">",
"     59",
"    </a>",
"    ]. Glucocorticoids or other forms of anti-inflammatory therapy should be continued on an individual basis (as tolerated and as needed clinically) in patients who have pacemakers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is limited experience with ICDs in patients with cardiac sarcoidosis. The frequency of ventricular tachyarrhythmias requiring ICD therapy was evaluated in a series of 45 patients with cardiac sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/68\">",
"     68",
"    </a>",
"    ]. Appropriate ICD therapies for VT or ventricular fibrillation (VF) were observed in 37.8 percent of patients during mean 2.6 year follow-up after implantation. Appropriate ICD therapy was associated with longer follow-up, lower LVEF, and complete heart block. There was a trend toward more ICD therapies in those receiving an ICD for secondary prevention as compared to those receiving an ICD for primary prevention (56.3 versus 27.6 percent). &nbsp;",
"   </p>",
"   <p>",
"    The 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society guidelines for device-based therapy offer clinical considerations for patients with cardiac sarcoidosis and indicate that cardiac sarcoidosis is a reasonable indication for ICD implantation, but do not offer more specific recommendations regarding ICD therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a minimum, ICD guidelines for patients with cardiomyopathy generally should be applied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ICD therapy is indicated for secondary prevention in patients with structural heart disease (including cardiac sarcoidosis) who have spontaneous sustained ventricular tachycardia or ventricular fibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/57,59,65,69,70\">",
"       57,59,65,69,70",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H5#H5\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Use of an ICD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ICD therapy is indicated for primary prevention in selected patients with NYHA class II to III heart failure with a left ventricular ejection fraction &le;35 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H16#H16\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Nonischemic cardiomyopathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential role of ICD therapy in patients with LVEF &gt;35 percent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    absence of heart failure is not well defined, although potential additional indications have been proposed in patients with cardiac sarcoidosis. We suggest ICD therapy in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest ICD therapy in patients with cardiac sarcoidosis with inducible ventricular arrhythmias at EP study performed for symptoms (palpitations, syncope, presyncope)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nonsustained ventricular arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/60\">",
"       60",
"      </a>",
"      ]. Further studies are needed to document the efficacy of such an approach. (See",
"      <a class=\"local\" href=\"#H4958216\">",
"       'Electrophysiologic study'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest ICD therapy in patients with an established diagnosis of sarcoidosis who have extensive cardiac magnetic resonance late gadolinium enhancement of the left ventricle or PET abnormalities, particularly in those requiring a permanent pacemaker [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/68\">",
"       68",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H22303008\">",
"       'Cardiovascular magnetic resonance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following potential approaches have been suggested by others:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some have suggested EP study to guide ICD placement in patients with CMR or PET evidence of late gadolinium enhancement of the left ventricle who lack other indications for ICD implantation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/61\">",
"       61",
"      </a>",
"      ]. Further study of this approach to guide ICD therapy is needed. (See",
"      <a class=\"local\" href=\"#H22303008\">",
"       'Cardiovascular magnetic resonance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some have advocated ICD placement in patients presenting with advanced conduction system disease (second or third degree AV block) although limited evidence is available to support this approach [",
"      <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22304911\">",
"    <span class=\"h2\">",
"     Ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter RF ablation may be effective in eliminating or reducing ventricular tachycardia in some patients with cardiac sarcoidosis with ventricular tachycardia not controlled by antiarrhythmic drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/59,71\">",
"     59,71",
"    </a>",
"    ], although results have been mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22304918\">",
"    <span class=\"h2\">",
"     Surgery and transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare cases, surgery is required to treat valvular disease (eg, mitral regurgitation) or to resect a ventricular aneurysm to abolish ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link\">",
"     \"Overview of the management of chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnosis of sarcoid should not bar consideration of potential transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. In the largest published retrospective review from the United Network for Organ Sharing (UNOS) database of 65 patients with sarcoidosis (mean age 46) who underwent cardiac transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/71\">",
"     71",
"    </a>",
"    ], one-year post-transplantation survival was better for sarcoid patients than for patients receiving transplantation for all other diagnoses (87.7 versus 84.5 percent). Furthermore, estimated post-transplant survival at five years was 80 percent for patients with sarcoidosis. Recurrent sarcoidosis can occur in the transplant, although the incidence is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25862?source=see_link&amp;anchor=H11#H11\">",
"     \"Left ventricular dysfunction after orthotopic cardiac transplantation\", section on 'Recurrent myocardial disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22305163\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of cardiac sarcoidosis is ill-defined. While prognostic predictors of mortality have been postulated, the best means of assessing disease prevalence and prognosis and choosing therapeutic interventions remains uncertain.",
"   </p>",
"   <p>",
"    Studies have suggested worse outcomes in those with symptomatic cardiac involvement. An early autopsy series of 113 patients concluded that survival in most patients was limited to approximately two years after the development of cardiac symptoms and signs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/67\">",
"     67",
"    </a>",
"    ]. However, substantially better outcomes were noted in two later reports where 44 percent (of 250 patients) and 75 percent (of 75 steroid-treated patients), respectively, survived for more than five years following their diagnosis of cardiac sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/12,66\">",
"     12,66",
"    </a>",
"    ]. Most patients in these series ultimately died from cardiac complications of sarcoidosis, including ventricular tachyarrhythmias, conduction disturbances, and progressive cardiac failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/63,67\">",
"     63,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with symptomatic cardiac sarcoidosis and coexisting pulmonary involvement account for approximately 5 percent of all cases of sarcoidosis, and experience decreased overall survival. In contrast, 30 to 50 percent of patients with pulmonary disease have structural but asymptomatic cardiac abnormalities that appear to have a less profound impact on survival [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These relationships were illustrated in a report cited above, in which 19 of 101 patients with biopsy proven cardiac sarcoidosis presented with cardiac symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/7\">",
"     7",
"    </a>",
"    ]. There were two major findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac sarcoidosis was diagnosed much more frequently in symptomatic patients (84 versus 4 percent).",
"     </li>",
"     <li>",
"      Symptomatic patients were at very high risk. At a mean follow-up of 1.7 years, 4 of the 19 patients died and nine received a pacemaker",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      implantable cardioverter-defibrillator. In contrast, there were no adverse cardiac events in the 82 asymptomatic patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While patients with asymptomatic cardiac sarcoidosis are thought to have a more benign course, sudden death can occur as an initial clinical manifestation of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/19/17722/abstract/11\">",
"     11",
"    </a>",
"    ]. Close monitoring of disease progression in known disease, along with heightened clinical suspicion of cardiac sarcoidosis are required. One hopes that screening for cardiac involvement enabling an early diagnosis of disease presence alongside close monitoring of disease progression will enable prompt management of disease complications. Moreover, with more detailed research into cardiac sarcoidosis, one predicts that in the future, a thorough clinical assessment utilizing tailored investigation modalities may predict and minimize cardiac risk and offer improved prognosis. (See",
"    <a class=\"local\" href=\"#H22303008\">",
"     'Cardiovascular magnetic resonance'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4958216\">",
"     'Electrophysiologic study'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=see_link\">",
"       \"Patient information: Sarcoidosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/35/5683?source=see_link\">",
"       \"Patient information: Sarcoidosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17483763\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac involvement may occur alone or alongside systemic sarcoidosis but is frequently clinically silent. Diagnosis and predicting disease progression given the highly variable clinical course present major clinical challenges. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of cardiac sarcoidosis include conduction disease, arrhythmias, sudden death, heart failure, cardiomyopathy, valvular heart disease, and simulated ischaemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various definitions and diagnostic approaches for cardiac sarcoidosis have been proposed, yet there remains no clear-cut consensus on which diagnostic methodologies are best to evaluate disease presence and progression. Furthermore, there are little data to guide risk stratification and therapeutic management (medical, device, or surgical), and thus to improve patient prognosis. (See",
"      <a class=\"local\" href=\"#H14070583\">",
"       'Diagnostic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should suspect cardiac sarcoidosis in young adults with unexplained cardiac clinical manifestations and in patients with a histologic (or clinical) diagnosis of extracardiac sarcoidosis, particularly in those who develop arrhythmias, conduction disease, or heart failure. (See",
"      <a class=\"local\" href=\"#H926160\">",
"       'Who to evaluate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A stepwise approach to diagnosis is suggested, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A full history and physical examination, electrocardiography, Holter monitoring, and echocardiography.",
"     </li>",
"     <li>",
"      In patients with abnormalities after the initial evaluation, we suggest noninvasive imaging, preferably with cardiovascular magnetic resonance imaging (CMR) and FDG PET to enhance disease detection and monitoring of treatment response. If neither CMR nor PET is available, we suggest a gallium, thallium, or technetium scan.",
"     </li>",
"     <li>",
"      Endomyocardial biopsy is indicated only if the patient lacks histologic confirmation from another source. A negative biopsy does",
"      <strong>",
"       not",
"      </strong>",
"      exclude the diagnosis of cardiac sarcoidosis.",
"     </li>",
"     <li>",
"      Coronary angiography is indicated if symptomatology and imaging results are unable to exclude ischemic heart disease as an alternate diagnosis.",
"     </li>",
"     <li>",
"      Electrophysiological testing is suggested to risk stratify selected high risk patients (eg, those with palpitations, syncope, presyncope,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nonsustained ventricular arrhythmias) who lack established indications for ICD implantation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H30#H30\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Nonischemic cardiomyopathy'",
"      </a>",
"      .). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indications for implantable cardioverter-defibrillator (ICD) therapy in patients with cardiac sarcoidosis are not well defined. At a minimum, ICD guidelines for secondary and primary prevention in patients with cardiomyopathy should be applied. (See",
"      <a class=\"local\" href=\"#H22304319\">",
"       'Pacing and ICD'",
"      </a>",
"      above.) ICD therapy is indicated for:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      ICD therapy is indicated for secondary prevention in patients with structural heart disease (including cardiac sarcoidosis) who have spontaneous sustained ventricular tachycardia or ventricular fibrillation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22304319\">",
"       'Pacing and ICD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H4#H4\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Secondary prevention of SCD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary prevention in selected patients with NYHA class II to III with a left ventricular ejection fraction &le;35 percent (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H13#H13\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Primary prevention of SCD'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to established indications for ICD therapy, we suggest ICD therapy in the following settings in patients with a left ventricular ejection fraction &gt;35 percent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lack of heart failure:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with cardiac sarcoidosis with an inducible ventricular arrhythmia at EP study performed for symptoms (palpitations, syncope, presyncope)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nonsustained ventricular arrhythmias (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4958216\">",
"       'Electrophysiologic study'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with an established diagnosis of sarcoidosis who have extensive cardiac magnetic resonance late gadolinium enhancement of the left ventricle or PET abnormalities, particularly in those requiring a permanent pacemaker (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22304319\">",
"       'Pacing and ICD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of cardiac sarcoidosis comprises steroid therapy and other immunomodulating (steroid-sparing) agents. The presence of cardiac or systemic sarcoid should not bar consideration for cardiac transplantation if otherwise indicated. (See",
"      <a class=\"local\" href=\"#H22304063\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22304918\">",
"       'Surgery and transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis of cardiac sarcoidosis is not well defined. Outcomes appear to be worse in those with symptomatic cardiac involvement. Further research is required to fully elucidate the pathophysiology, progression, and optimal management of this disease. (See",
"      <a class=\"local\" href=\"#H22305163\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3639535\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Om Sharma, MD, who passed away in August 2012. UpToDate wishes to acknowledge Dr. Sharma's past work as an author for this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/1\">",
"      Yigla M, Badarna-Abu-Ria N, Tov N, et al. Sarcoidosis in northern Israel; clinical characteristics of 120 patients. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/2\">",
"      Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/3\">",
"      Schulte W, Kirsten D, Drent M, Costabel U. Cardiac involvement in sarcoidosis. Eur Respir Mon 2005; 32:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/4\">",
"      Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) 2004; 83:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/5\">",
"      Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009; 157:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/6\">",
"      Thomsen TK, Eriksson T. Myocardial sarcoidosis in forensic medicine. Am J Forensic Med Pathol 1999; 20:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/7\">",
"      Smedema JP, Snoep G, van Kroonenburgh MP, et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest 2005; 128:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/8\">",
"      Yoshida Y, Morimoto S, Hiramitsu S, et al. Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J 1997; 134:382.",
"     </a>",
"    </li>",
"    <li>",
"     Fleming H. Cardiac Sarcoidosis. In: Sarcoidosis and Other Granulomatous Disorders, James DG.  (Ed), Dekker, New York 1994. p.323.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/10\">",
"      Sekiguchi M, Numao Y, Imai M, et al. Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis. Concepts through a study employing endomyocardial biopsy. I. Sarcoidosis. Jpn Circ J 1980; 44:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/11\">",
"      Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009; 120:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/12\">",
"      Schaedel H, Kirsten D, Schmidt A, et al. Sarcoid heart disease--results of follow-up investigations. Eur Heart J 1991; 12 Suppl D:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/13\">",
"      Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008; 133:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/14\">",
"      Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/15\">",
"      Yazaki Y, Isobe M, Hiramitsu S, et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol 1998; 82:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/16\">",
"      Ayyala US, Nair AP, Padilla ML. Cardiac sarcoidosis. Clin Chest Med 2008; 29:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/17\">",
"      Iwai K, Sekiguti M, Hosoda Y, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 1994; 11:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/18\">",
"      Goyal SB, Aragam JR. Cardiac sarcoidosis with primary involvement of the tricuspid valve. Cardiol Rev 2006; 14:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/19\">",
"      Gasparovic H, Bueno R, Rybicki FJ, et al. Sarcoidosis of the aortic root. J Thorac Cardiovasc Surg 2004; 128:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/20\">",
"      Weiler V, Redtenbacher S, Bancher C, et al. Concurrence of sarcoidosis and aortitis: case report and review of the literature. Ann Rheum Dis 2000; 59:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/21\">",
"      Gedalia A, Shetty AK, Ward K, et al. Abdominal aortic aneurysm associated with childhood sarcoidosis. J Rheumatol 1996; 23:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/22\">",
"      Shimada T, Shimada K, Sakane T, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001; 110:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/23\">",
"      Smedema JP, Snoep G, van Kroonenburgh MP, et al. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest 2005; 128:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/24\">",
"      Currie GP, Kerr K, Buchan K, Garg D. A rare cause of recurrent massive pericardial and pleural effusions. QJM 2008; 101:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/25\">",
"      Kinney E, Murthy R, Ascunce G, et al. Pericardial effusions in sarcoidosis. Chest 1979; 76:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/26\">",
"      Abrishami B, O'Connel C, Sharma O. Cardiac sarcoidosis with presentation of large left atrial mass. Curr Opin Pulm Med 2004; 10:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/27\">",
"      Uchida M, Shinohara T, Takahashi N, Saikawa T. Interventricular septal mass in a patient with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2012; 23:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/28\">",
"      Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009; 20:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/29\">",
"      Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest 2012; 141:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/30\">",
"      Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart 2011; 97:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/31\">",
"      Yeboah J, Lee C, Sharma OP. Cardiac sarcoidosis: a review 2011. Curr Opin Pulm Med 2011; 17:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/32\">",
"      Nery PB, Leung E, Birnie DH. Arrhythmias in cardiac sarcoidosis: diagnosis and treatment. Curr Opin Cardiol 2012; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/33\">",
"      Suzuki T, Kanda T, Kubota S, et al. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest 1994; 106:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/34\">",
"      Fahy GJ, Marwick T, McCreery CJ, et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 1996; 109:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/35\">",
"      Sun BJ, Lee PH, Choi HO, et al. Prevalence of echocardiographic features suggesting cardiac sarcoidosis in patients with pacemaker or implantable cardiac defibrillator. Korean Circ J 2011; 41:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/36\">",
"      Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther 1996; 10:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/37\">",
"      Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/38\">",
"      Tadamura E, Yamamuro M, Kubo S, et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR Am J Roentgenol 2005; 185:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/39\">",
"      Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest 2002; 122:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/40\">",
"      Sharma S. Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies. Curr Opin Pulm Med 2009; 15:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/41\">",
"      Ishimaru S, Tsujino I, Sakaue S, et al. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/42\">",
"      Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/43\">",
"      Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009; 16:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/44\">",
"      Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004; 45:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/45\">",
"      Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008; 35:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/46\">",
"      Tadamura E, Yamamuro M, Kubo S, et al. Images in cardiovascular medicine. Multimodality imaging of cardiac sarcoidosis before and after steroid therapy. Circulation 2006; 113:e771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/47\">",
"      Sato Y, Matsumoto N, Kunimasa T, et al. Multiple involvements of cardiac sarcoidosis in both left and right ventricles and papillary muscles detected by delayed-enhanced magnetic resonance imaging. Int J Cardiol 2008; 130:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/48\">",
"      Haywood LJ, Sharma OP, Siegel ME, et al. Detection of myocardial sarcoidosis by thallium 201 imaging. J Natl Med Assoc 1982; 74:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/49\">",
"      Eguchi M, Tsuchihashi K, Hotta D, et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology 2000; 94:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/50\">",
"      Nakazawa A, Ikeda K, Ito Y, et al. Usefulness of dual 67Ga and 99mTc-sestamibi single-photon-emission CT scanning in the diagnosis of cardiac sarcoidosis. Chest 2004; 126:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/51\">",
"      Okayama K, Kurata C, Tawarahara K, et al. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 1995; 107:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/52\">",
"      Pandya C, Brunken RC, Tchou P, et al. Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques. Eur Respir J 2007; 29:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/53\">",
"      Smedema JP, White L, Klopper AJ. FDG-PET and MIBI-Tc SPECT as follow-up tools in a patient with cardiac sarcoidosis requiring a pacemaker. Cardiovasc J Afr 2008; 19:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/54\">",
"      Wait JL, Movahed A. Anginal chest pain in sarcoidosis. Thorax 1989; 44:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/55\">",
"      Rubinstein I, Fisman EZ, Rosenblum Y, et al. Left-ventricular exercise echocardiographic abnormalities in patients with sarcoidosis without ischemic heart disease. Isr J Med Sci 1986; 22:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/56\">",
"      Ardic I, Kaya MG, Yarlioglues M, et al. Impaired heart rate recovery index in patients with sarcoidosis. Chest 2011; 139:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/57\">",
"      Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/58\">",
"      Uemura A, Morimoto S, Hiramitsu S, et al. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 1999; 138:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/59\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 51:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/60\">",
"      Aizer A, Stern EH, Gomes JA, et al. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol 2005; 96:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/61\">",
"      Mehta D, Mori N, Goldbarg SH, et al. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 2011; 4:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/62\">",
"      Takada K, Ina Y, Yamamoto M, et al. Prognosis after pacemaker implantation in cardiac sarcoidosis in Japan. Clinical evaluation of corticosteroid therapy. Sarcoidosis 1994; 11:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/63\">",
"      Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/64\">",
"      Belhassen B, Pines A, Laniado S. Failure of corticosteroid therapy to prevent induction of ventricular tachycardia in sarcoidosis. Chest 1989; 95:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/65\">",
"      Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol 1991; 18:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/66\">",
"      Reuhl J, Schneider M, Sievert H, et al. Myocardial sarcoidosis as a rare cause of sudden cardiac death. Forensic Sci Int 1997; 89:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/67\">",
"      Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 1977; 63:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/68\">",
"      Betensky BP, Tschabrunn CM, Zado ES, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012; 9:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/69\">",
"      Bajaj AK, Kopelman HA, Echt DS. Cardiac sarcoidosis with sudden death: treatment with the automatic implantable cardioverter defibrillator. Am Heart J 1988; 116:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/70\">",
"      Paz HL, McCormick DJ, Kutalek SP, Patchefsky A. The automated implantable cardiac defibrillator. Prophylaxis in cardiac sarcoidosis. Chest 1994; 106:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/71\">",
"      Jefic D, Joel B, Good E, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm 2009; 6:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/72\">",
"      Koplan BA, Soejima K, Baughman K, et al. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm 2006; 3:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/73\">",
"      Valantine HA, Tazelaar HD, Macoviak J, et al. Cardiac sarcoidosis: response to steroids and transplantation. J Heart Transplant 1987; 6:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/19/17722/abstract/74\">",
"      Oni AA, Hershberger RE, Norman DJ, et al. Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids. J Heart Lung Transplant 1992; 11:367.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4922 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17722=[""].join("\n");
var outline_f17_19_17722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17483763\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4957536\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17482569\">",
"      Heart block and arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17482576\">",
"      - Sudden death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17483512\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17483519\">",
"      Valvular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17483526\">",
"      Simulated infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17483533\">",
"      Pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17483540\">",
"      Cor pulmonale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12703616\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14070583\">",
"      DIAGNOSTIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17483101\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H925865\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H926160\">",
"      Who to evaluate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14070497\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17483816\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19878770\">",
"      INITIAL NONINVASIVE TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22302703\">",
"      Holter monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22302770\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19878795\">",
"      ADDITIONAL NONINVASIVE TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22303008\">",
"      Cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19879043\">",
"      PET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4958094\">",
"      CMR versus PET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19878868\">",
"      Radionuclide imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14070738\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14070711\">",
"      INVASIVE TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14070885\">",
"      Coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4958181\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4958216\">",
"      Electrophysiologic study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4958298\">",
"      Right heart catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22304146\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22304063\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22304319\">",
"      Pacing and ICD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22304911\">",
"      Ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22304918\">",
"      Surgery and transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22305163\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17483763\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3639535\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4922\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4922|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/6/5226\" title=\"picture 1\">",
"      Myocardial sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4922|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/56/35723\" title=\"table 1\">",
"      Diagnosis cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/39/34428\" title=\"table 2\">",
"      Stepwise diagnostic evaluation for cardiac sarcoidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14378?source=related_link\">",
"      Echocardiographic evaluation of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=related_link\">",
"      Heart rate variability: Uses other than after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25862?source=related_link\">",
"      Left ventricular dysfunction after orthotopic cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/0/36868?source=related_link\">",
"      Pathogenesis and diagnosis of Q waves on the electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=related_link\">",
"      Pathogenesis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/35/5683?source=related_link\">",
"      Patient information: Sarcoidosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=related_link\">",
"      Patient information: Sarcoidosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_19_17723="Antitrypanosomal drugs dosing";
var content_f17_19_17723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antitrypanosomal drugs for treatment of Chagas disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Benznidazole",
"       </td>",
"       <td>",
"        &le;12 years",
"       </td>",
"       <td>",
"        10 mg/kg per day orally in two divided doses for 60 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12 years or older",
"       </td>",
"       <td>",
"        5 to 7 mg/kg per day orally in two divided doses for 60 days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Nifurtimox",
"       </td>",
"       <td>",
"        &le;10 years",
"       </td>",
"       <td>",
"        15 to 20 mg/kg per day orally in three or four divided doses for 90 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11 to 16 years",
"       </td>",
"       <td>",
"        12.5 to 15 mg/kg per day orally in three or four divided doses for 90 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17 years or older",
"       </td>",
"       <td>",
"        8 to 10 mg/kg per day orally in three or four divided doses for 90 to 120 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Please see text for additional notes regarding use, adverse effects, and availability.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17723=[""].join("\n");
var outline_f17_19_17723=null;
var title_f17_19_17724="Complications of bronchoscopy";
var content_f17_19_17724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of bronchoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pre-medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tachycardia/arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Agitation (paradoxical, especially in the elderly)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allergy/anaphylactoid reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea and vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Topical anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngospasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchospasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmias/arrest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea and vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methemoglobinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bronchoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epistaxis (with nasal approach)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngeal spasm/edema/injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever (approximately 16 percent, 6 percent with infiltrates)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteremia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dissemination of endogenous infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection (bacterial, mycobacterial, fungal, HIV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Biopsy or other procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Broken equipment - foreign body in airway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rigid bronchoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complications of general anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Damage to teeth/oral mucosa/pharynx/glottis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perforation of airway/esophagus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tracheal fire (with laser)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17724=[""].join("\n");
var outline_f17_19_17724=null;
var title_f17_19_17725="Safety resources CSHCN";
var content_f17_19_17725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resources for the promotion of safety of children with disabilities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Transportation safety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         The Indiana University School of Medicine Automotive Safety Program provides a state-by-state listing of child safety passenger technicians",
"        </p>",
"        <p>",
"         &nbsp;",
"         <a href=\"file://www.preventinjury.org/specNeeds.asp\" target=\"_blank\">",
"          www.preventinjury.org/specNeeds.asp",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         The AAP policy statement on school bus transportation of children with special needs",
"        </p>",
"        <p>",
"         <a href=\"file://pediatrics.aappublications.org/content/108/2/516.full\" target=\"_blank\">",
"          pediatrics.aappublications.org/content/108/2/516.full",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         The National Highway Traffic Safety Administration provides information on child safety seats and federal motor vehicle safety standards and regulations",
"        </p>",
"        <p>",
"         <a href=\"file://www.nhtsa.dot.gov\" target=\"_blank\">",
"          www.nhtsa.dot.gov",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Wheelchair transportation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         The University of Pittsburgh's School of Health and Rehabilitation Science, the Rehabilitation Engineering Research Center on Wheeled Mobility, and the National Institute on Disability and Rehabilitation Research provides information about wheelchair transportation",
"        </p>",
"        <p>",
"         <a href=\"file://www.wheelchairnet.org\" target=\"_blank\">",
"          www.wheelchairnet.org",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Home safety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Easter Seals provides information about home safety for individuals with disabilities",
"        </p>",
"        <p>",
"         <a href=\"file://www.easterseals.com/site/PageServer?pagename=ntl_resource_room&amp;s_esLocation=res\" target=\"_blank\">",
"          www.easterseals.com/site/PageServer?pagename=ntl_resource_room&amp;s_esLocation=res",
"         </a>",
"         _",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fire safety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Centers for Disease Control and Prevention",
"        </p>",
"        <p>",
"         <a href=\"file://www.cdc.gov/homeandrecreationalsafety/fire-prevention/tools.html\" target=\"_blank\">",
"          www.cdc.gov/homeandrecreationalsafety/fire-prevention/tools.html",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         The US Fire Administration provides information on fire safety for people with disabilities",
"        </p>",
"        <p>",
"         <a href=\"file://www.usfa.dhs.gov/citizens/disability\" target=\"_blank\">",
"          www.usfa.dhs.gov/citizens/disability",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Respite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         The National Respite Network helps caregivers find respite services in their local area",
"        </p>",
"        <p>",
"         <a href=\"file://www.respitelocator.org\" target=\"_blank\">",
"          www.respitelocator.org",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prevention of maltreatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         The AAP provides a listing of state child abuse programs (which can provide additional evaluation and management or help with decisions about reporting)",
"        </p>",
"        <p>",
"         <a href=\"file://www.aap.org/sections/childabuseneglect/MedicalDiagnostic.cfm\" target=\"_blank\">",
"          www.aap.org/sections/childabuseneglect/MedicalDiagnostic.cfm",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         The AAP clinical report on maltreatment of children with disabilities",
"        </p>",
"        <p>",
"         <a href=\"file://pediatrics.aappublications.org/content/119/5/1018.full\" target=\"_blank\">",
"          pediatrics.aappublications.org/content/119/5/1018.full",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         The state of Florida Agency for Persons with Disabilities provides information on prevention of abuse, neglect, and exploitation of individuals with disabilities",
"        </p>",
"        <p>",
"         <a href=\"file://apd.myflorida.com/zero-tolerance/\" target=\"_blank\">",
"          apd.myflorida.com/zero-tolerance/",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         The Child Abuse and Neglect Disability Outreach Project (CAN Do!) provides a list of resources on abuse and disabilities",
"        </p>",
"        <p>",
"         <a href=\"file://www.disability-abuse.com/cando\" target=\"_blank\">",
"          www.disability-abuse.com/cando",
"         </a>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17725=[""].join("\n");
var outline_f17_19_17725=null;
var title_f17_19_17726="Contents: Infections and infestations";
var content_f17_19_17726=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Infections and infestations",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Infections and infestations",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Bacterial infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/37/33365\">",
"           Botryomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12825\">",
"           Cellulitis and erysipelas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/38/29286\">",
"           Cutaneous manifestations of gonorrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/34/21034\">",
"           Cutaneous manifestations of tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/43/11959\">",
"           Erythrasma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21846\">",
"           Impetigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/22/362\">",
"           Necrotizing soft tissue infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/8/43142\">",
"           Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43831\">",
"           Skin abscesses, furuncles, and carbuncles",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bites/Stings/Infestations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/23/39286\">",
"           Bedbugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/34/43556\">",
"           Chigger bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/0/43016\">",
"           Jellyfish stings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/15/25849\">",
"           Pediculosis capitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/49/24339\">",
"           Pediculosis corporis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/30/1511\">",
"           Pediculosis pubis and pediculosis ciliaris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/2/28712\">",
"           Scabies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fungal infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30648\">",
"           Candidal intertrigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7082\">",
"           Dermatophyte (tinea) infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5258\">",
"           Onychomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/47/31481\">",
"           Overview of Candida infections in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/15/3320\">",
"           Tinea versicolor",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/33/538\">",
"           Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29098\">",
"           Fever and rash in the immunocompetent patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/35/23097\">",
"           Gianotti-Crosti syndrome (papular acrodermatitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20152\">",
"           Skin lesions in the returning traveler",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31687\">",
"           Soft tissue infections following water exposure",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Viral infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/20/2378\">",
"           Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/38/23144\">",
"           Condylomata acuminata (anogenital warts)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/7/8312\">",
"           Condylomata acuminata (anogenital warts) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/40/26249\">",
"           Cutaneous warts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/10/9386\">",
"           Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/50/24359\">",
"           HIV-associated eosinophilic folliculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/43/6842\">",
"           Molluscum contagiosum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21751\">",
"           Prevention of genital herpes virus infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/32/7690\">",
"           Treatment of genital herpes simplex virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36488\">",
"           Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/20/33096\">",
"           Treatment of herpes zoster in the immunocompetent host",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-1D0808831D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f17_19_17726=[""].join("\n");
var outline_f17_19_17726=null;
var title_f17_19_17727="Shape of thoracostomy tube";
var content_f17_19_17727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Straight and angled thoracostomy tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Friedberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_19_17727=[""].join("\n");
var outline_f17_19_17727=null;
